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Elimination of the malaria parasite from endemic areas requires a multi-faceted 
approach, including development of novel antimalarial drugs and a deeper understanding 
of parasite-host interactions. Here we describe functional characterization of a 
Plasmodium hemolysin III (PfHlyIII) along with various approaches to determine 
whether hemolysin is a virulence factor in malaria, contributing to severe malaria anemia. 
In addition we also describe two antimalarial drug discovery projects including 
characterization of novel quinine and quinidine derivatives as efficacious, non-toxic 
antimalarials, as well as the development of a robust high throughput assay to screen for 
gametocytocidal compounds. 
Regarding characterization of Plasmodium hemolysin III, we have evidence for 
heterologous pore formation of recombinant PfHlyIII in Xenopus and also show 
expression of soluble native PfHlyIII in asexual blood stage parasites. Together these 
data support our hypothesis that PfHlyIII may be available upon schizont egress as a 
cytolytic protein that could damage and increase clearance of bystander erythrocytes. 
Unexpectedly, genetic disruption of P. berghei HlyIII (PbHlyIII KO) resulted in greater 
virulence in Balb/c mice leading to an early death phenotype and altered parasitophorous 
vacuole morphology in the asexual blood stages. We hypothesize that early death in mice 
infected with the PbHlyIII KO parasite may be a result of altered deformability of 
infected erythrocytes and increased sequestration leading to brainstem hemorrhage. 
Though we did not prove or disprove our hypothesis that PfHlyIII may damage 
uninfected erythrocytes and contribute to severe malaria anemia, our knockout phenotype 
of severe membrane defects suggests PfHlyIII may play a role in membrane homeostasis 
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or remodeling, either directly or indirectly through functioning as a receptor, similar to 
yeast homolog Izh2p.  
Synthesis and characterization of hydroxyethylapoquinine and derivatives 
involved revisiting an old quinine derivative with promising historical data supporting 
greatly reduced toxicity in humans and comparable efficacy against bird malaria 
compared to quinine. The modifications to quinine included hydroxyethylation at the 
methoxy side chain and isomerization of a vinyl group. Our studies included a novel 
synthetic approach to hydroxyethylapoquinine in addition to synthesis of three novel 
compounds: hydroxyethylapoquinidine and quinine and quinidine derivatives with only 
the hydroxyethyl substitution. We demonstrate antimalarial efficacy of all four 
derivatives against three strains of P. falciparum in vitro, with nanomolar IC50s against a 
quinine-sensitive strain 3D7, and elevated IC50s against quinine tolerant strains INDO 
and Dd2. In a murine malaria model the quinidine intermediate, hydroxyethylquinidine 
(HEQD) showed the greatest potency, similar to quinine and also performed the best in 
the in vitro assays. Furthermore the hydroxyethyl modifications greatly reduced the 
hERG channel inhibitory properties of all derivatives compared to the parent drugs, and 
further derivation of HEQD may yield a safer alternative to quinine or quinidine and be a 
potential long-half life partner drug in artemisinin-based combination therapies. 
SYBR Green I and a green fluorescence background suppressor from CyQUANT 
were used in conjunction with exflagellation media to develop a novel transmission 
blocking assay that can be used to screen for gametocytocidal compounds. Following 
optimization of the assay, we screened the Johns Hopkins Clinical Compound Library 
version 1.3 as well as the Medicines for Malaria Venture malaria box, a total of over 
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2,000 compounds, resulting in 43 hits with good efficacy against late stage gametocytes. 
Quaternary ammonium compounds and acridine-like compounds were novel drug classes 
revealed in our screen. Transmission blocking activity of top hits was confirmed using 
membrane feeding assays and correlation with other assays strengthened the validity of 
our assay. Overall our data supports use of the SYBR Green assay to screen for novel 
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Malaria: Etiology and Epidemiology 
Malaria is a protozoan parasitic disease, with historical references from as early as 
2700 BC China to 400 BC Greece that described periodic fevers and enlarged spleens (1). 
While there are over one hundred twenty Plasmodium species, only five currently infect 
humans and result in human malaria: Plasmodium falciparum, P. vivax, P. malaria, 
P.ovale, and P. knowlesi. That malaria fevers were the result of parasite reproduction was 
first suggested by Rasori in 1816, but Laveran was the first to identify the Plasmodium 
parasite in the blood of malaria patients, observing the sexual gametocyte stages of the 
parasite in 1880 and later convincing the leading malariologists in Italy that the cause of 
malaria was a protozoan, not a bacterium (2). Ross and Grassi are together attributed with 
linking the Anopheline mosquito vector to malaria transmission. Ross successfully 
identified Plasmodium oocysts in the mosquito in 1897 and further elucidated the 
Plasmodium life cycle in the mosquito (1). Grassi and his colleague Bignami fed 
mosquitoes on infected travelers and then transmitted the disease to uninfected 
individuals by mosquito bite, observing that only female Anopheline mosquitoes could 
successfully transmit malaria in 1898 (2).  
Since the initial discovery of Plasmodium as the causative agent of malaria and 
requirement for transmission by female Anopheline mosquitoes, many other scientists 
have worked to gain a deeper understanding of the parasite biology and have more finely 
tuned our understanding of the parasite life cycle in both the mammalian hosts and 
mosquito vectors. Of particular importance was the observation of a liver stage 
development by Shortt and Garnham in 1947 that preceded the blood stages responsible 
for clinical disease (1). The dormant hypnozoite stages of the parasite in the liver that 
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later develop and result in relapse of the disease were finally identified in 1982 by 
Krotoski, who was working with Garnham’s team (1). Overall, the entirety of the parasite 
life cycle was gradually revealed over a period of seventy plus years of diligent and 
rigorous research. Our current understanding of the human malaria life cycle is 
represented in Figure 1.1. 
 
Figure 1.1 Plasmodium life cycle in the Anopheline mosquito and human host. 
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 In brief, an infected female Anopheline mosquito takes a bloodmeal from a 
human host, and inoculates approximately 100 Plasmodium sporozoites into the dermis 
and bloodstream. The sporozoites travel through the dermis until they reach a blood 
vessel, after which they migrate to the liver and invade, traverse and develop in 
hepatocytes. After a seven to ten day development and schizogeny, mature liver schizonts 
rupture and release merozoites into the bloodstream, beginning the erythrocytic cycle of 
maturation from a ring trophozoite to a metabolically active, hemoglobin degrading 
trophozoite, followed by DNA replication and segmentation into a mature schizont, ready 
for egress and release of new merozoites for reinvasion of erythrocytes. Some early 
erythrocytic stages undergo a different route of development into the sexual gametocyte 
stages of the parasite, and in P. falciparum in particular, there are five morphologically 
distinct stages of gametocyte development. Mature gametocytes are taken up in a 
bloodmeal by Anopheline vectors where male and female gametes mature and undergo 
fertilization in the midgut to form a zygote. These zygotes elongate and become motile, 
developing into ookinetes that invade the mosquito midgut wall and develop into oocysts. 
The oocysts then mature and produce sporozoites, which upon oocyte rupture, migrate 
through the hemocoel and invade the salivary glands of the mosquito, where they are 
poised for inoculation into a new host. 
Humans and the malaria parasite have a unique relationship that has undergone 
evolutionary changes over the past 10,000 years, due to each organism exerting selective 
pressure on the other. As a result, Plasmodium became distributed geographically over 
larger areas and multiple continents as humans dispersed across the globe. Interestingly, 
the map of global malaria distribution as estimated from around the year 1900 has shrunk 
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geographically over the years as a result of different factors, including human 
antimalarial interventions and development of infrastructure, but also aided by temperate 
climates being less amenable to sustaining endemic malaria, making it easier to eliminate 
malaria in these areas (3,4).  
Overall the geographical area at risk for human malaria has been halved, from 
around 53% of the total earth land area to 27% (4). In addition, malaria deaths have also 
seen a decline over the past two decades, with a 31.5% decline in malaria-attributed child 
mortality in sub-Saharan Africa from 2004 (5,6) and a continual decline in global malaria 
deaths outside of Africa since 1990 (6). Nevertheless, malaria continues to pose a public 
health threat with 3.3 billion people at risk for malaria infection every year, and an 
estimated 200 million cases in 2013, resulting in approximately 584,000 deaths (7). 
Africa, southern Asia, and Central and South America all continue to have malaria 
transmission, with most of the deadly malaria outbreaks occurring in Sub-Saharan Africa 
due to P. falciparum (7). While great strides have been made to reduce mortality and 
morbidity over the past decade, ultimately control alone will not be sufficient as malaria 
control has no definitive end point beyond reducing morbidity and mortality. Elimination 
is defined as interrupting transmission until no parasites remain in a given geographical 
area and should be the ultimate goal for each country. Eradication takes the concept of 
elimination further, applying it on a global scale, describing a time point when no 
Plasmodium parasites are left in the human population or to be transmitted by 
mosquitoes. All countries with varying levels of malaria transmission have been 
classified according to stage of elimination from initial stages of control to prevention of 
re-introduction (Figure 1.2). As each country moves toward elimination they must be 
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evaluated on several levels of feasibility, including technical, operational, and financial 
feasibility, as done for Zanzibar in 2009 (8). Most scientists agree that while the available 
antimalarial interventions are effective and should be used to control malaria (curb 
disease, prevent death and interrupt transmission), improving upon the current 
interventions is vital in order to achieve elimination in some settings and ultimately 
eradication. Funding for control strategies and continued pressure on the vector and 




Figure 1.2 Global map of countries with endemic malaria classified according to stage of 
elimination: Control (red), Elimination (green), Pre-elimination (yellow), and Prevention 






Disease and Pathology of Plasmodium Infection 
 Malaria disease can manifest with a variety of symptoms including fever, chills, 
sweating, headache, nausea and body aches (9). Patients with uncomplicated malaria may 
present with fever, enlarged liver or spleen, and mild jaundice or anemia, whereas more 
severe disease occurs when malaria infection is complicated by organ failures or blood or 
metabolic abnormalities. Manifestations of severe malaria include cerebral malaria, 
severe malaria anemia, hemoglobinuria, and acute respiratory distress syndrome (9).  
Symptoms such as fever and anemia of malaria are the result of asexual stage 
parasites undergoing their replication cycle and the resulting inflammatory response 
initiated by the host, in addition to the destruction and clearance of erythrocytes. More 
severe symptoms are often the result of parasite sequestration, often seen with late 
asexual stages of P. falciparum, which bind to endothelial surfaces in capillaries and 
small blood vessels via a surface protein PfEMP1, resulting in restricting blood flow and 
oxygen deprivation in tissues. Dormant liver stage hypnozoite forms of the parasite are 
found in P. vivax and P. ovale infections and can reactivate, resulting in relapse after 
patients have recovered from the illness months or years after the original infection.  
Older children and adults in endemic countries who have prolonged exposure to 
the parasite develop clinical immunity where they no longer exhibit classic symptoms of 
malaria, such as fever or malaise. However these infected individuals continue to act as 
reservoirs for the parasite, perpetuating the transmission cycle and resulting in continued 
infection and disease for the more vulnerable populations including infants, pregnant 




Treatment: An Overview of Antimalarial Drug Classes 
 
Currently antimalarial drugs are available to treat liver stages, asexual and sexual 
erythrocytic stages of the Plasmodium parasite in the human host. However the efficacy 
and safety of some of these compounds is limited, with many no longer useful due to the 
development of drug resistance. There are five well-described classes of antimalarial 
compounds with historical success, as well as several new classes of antimalarial 
compounds in the process of development, and all target various stages of the malaria 
parasite. The most well-studied and commonly used classes of malaria drugs include the 
quinolines, antifolates, antibacterials, atovaquone and the endoperoxides (Figure 1.3). 
Emerging novel drug classes currently listed in the global antimalarial portfolio 
development stage include aminopyridines (MMV390048) imidazolopiperazine 
(KAF156) , spiroindolones (KAE609), triazolpyrimidines (DSM265) and ozonides 









Figure 1.4 Novel antimalarial drugs in development phase in the global portfolio of 











Quinolines have been derivatized such that we have several different classes of 
these compounds including the original cinchona-derived alkaloids quinine and quinidine 
and modified amino-alcohols like mefloquine, as well as the 4-aminoquinolines such as 
chloroquine and amodiaquine, and the 8-aminoquinolines such as primaquine. Quinolines 
are commonly thought to inhibit hemozoin formation in the parasite and chloroquine in 
particular has been shown to bind to the growing face of the heme crystal through atomic 
force microscopy, and accumulates to high levels in the digestive vacuole of the parasite 
(12–14). 
 However, not all quinolines may accumulate to sufficient concentrations in the 
food vacuole to inhibit hemozoin crystallization, and compounds such as quinine and 
mefloquine are likely to have other antimalarial targets in addition to their inhibitory 
action against hemozoin (15–17). Primaquine has a unique and somewhat unclear 
mechanism of action, but is thought to inhibit Plasmodium mitochondrial function and 
selectively generate oxidative stress through reactive intermediates, but shows little 
activity against heme crystallization, and thus little inhibition against asexual stages 
(18,19). Importantly, primaquine is currently the only licensed antimalarial that can kill 
liver stage parasites, including the dormant hypnozoite stages, and also has cidal activity 
against P. falciparum gametocytes (20,21). Unfortunately primaquine also has safety 
issues for patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and 
requires metabolism by CYP 2D6 in order to be active against parasites, making it 
challenging to treat infected individuals with deficiencies in either G6PD or CYP 2D6 
(22,23).Tafenoqine, a primaquine derivative, is currently under clinical trial investigation, 
and hopefully will prove equally effective and less toxic than its counterpart (10,11,19).  
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Resistance against the quinolines has developed at various levels, with 
chloroquine no longer effective in many parts of the world, and increasing levels of 
resistance emerging against partner drugs such as mefloquine and amodiaquine.  
Quinoline resistance is likely due to alterations in the transporters which control drug flux 
as a result of mutations in pfcrt, pfmdr1, and pfnhe (24). Nevertheless, quinolines 
continue to be important as partner drugs in artemisinin-based combination therapies as 
well as malaria prophylaxis, and primaquine in particular is important in malaria 
elimination strategies to kill both hypnozoites as well as deplete the asymptomatic 
reservoir of gametocytes. 
The artemisinin-based endoperoxides were first isolated from the Chinese 
medicinal plant sweet wormwood, Artemisia annua, which had been historically used to 
treat fevers, much like the cinchona bark used in South America from which the 
quinolines were isolated (25). As a response to the failure of chloroquine and the spread 
of resistance during the 1950’s and 1960’s, the Vietnamese turned to China for help in 
finding a replacement antimalarial drug. The result was the launch of the 523 research 
program in 1967 and the eventual isolation of the active component artemisinin in the 
1970’s, which was later derivatized into a methyl-ether, artemether, in addition to a water 
soluble artesunate. It was eventually found that these compounds required metabolism 
into an active form, dihydroartemisinin, which was responsible for their antimalarial 
action (25). The mechanism of action of the artemisinins is thought to be damage to 
biomolecules including bystander proteins and perhaps membrane potential 
depolarization as a result of reaction oxygen species (ROS) production after iron-
dependent bioactivation of the endoperoxide bridge (26). The artemisinins are active 
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against the late ring to mature schizont asexual blood stages and also show activity 
against early and late stage gametocytes (27).  
The discovery of K13 loci mutations conferring artemisinin ‘resistance’, better 
described as a delayed parasite clearance phenotype, support ROS-mediated parasite 
killing as a mechanism for the endoperoxides as the kelch superfamily of proteins 
mediate responses to oxidative stress and ubiquitin-regulated protein degradation (28–
30). While no significant or sustained increase in IC50 has been recorded for the termed 
‘artemisinin resistant’ parasites, multiple accounts of delayed parasite clearance and 
treatment failure with ACTs have been reported in South East Asia, and this delayed 
clearance remains an indirect measure of drug efficacy (29,31,32).The pfkelch mutation 
linked with artemisinin ‘resistance’ results in increased levels of P. falciparum 
phosphatidylinositol-3-kinase (PfPI3K) expression in ring stage parasites which may be 
important for the altered stress response and survival of these stages, pointing to PfPI3K 
as a selectively inhibited target of the artemisinins in the early ring stages (33). 
 It has been proposed that extending the ACT dosing time from three to four days, 
including at least two parasite life cycles, will prevent treatment failure and allow 
clearance of the ‘resistant’ or slow-clearing parasites (28). Currently the artemisinin-
based combination therapies are the most effective and safe antimalarial drug regimens 
available, and until compounds are discovered that are equally rapid in their killing 
ability, the artemisinins and ACTs will continue to be the gold standard for antimalarial 
treatment. Altering the dosing strategies and improving the partner drugs in ACTs may 
protect this vital class of antimalarials from being lost to drug resistance. 
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The three other main classes of antimalarial compounds are termed ‘magic bullet’ 
type compounds (27) as they target a single enzyme or process, and include the 
antibacterials, antifolates, and atovaquone. Antibacterials with activity against 
Plasmodium typically inhibit the apicoplast ribosomes, resulting in inhibition of protein 
biosynthesis, or inhibit DNA gyrases (34). The tetracycline derivatives like doxycycline 
bind to the 30S subunit, whereas the macrolide reagents azithromycin target the 50S 
subunit, both classes causing a delayed death phenotype (35). The fluoroquinolones such 
as ciprofloxacin are DNA gyrase inhibitors but may also have additional targets and also 
result in a delayed death for asexual blood stage parasites (36).  
Drugs targeting the folate pathway can be divided into two groups based on their 
specific targets, one group inhibiting dihydrofolate reductase (DHFR) and the other 
inhibiting dihydropteroate synthase (DHPS). Drugs targeting DHFR include proguanil, 
pyrimethamine, and dapsone which bind to DHFR and inhibit folic acid metabolism and 
downstream nucleic acid biosynthesis. DHPS is an enzyme upstream of DHFR, and 
sulfonamides such as sulfadoxine that act as para-aminobenzoic acid analogs 
competitively inhibit DHPS, resulting in formation of dead end metabolites.  
Atovaquone is a unique antimalarial that acts as an analog of coenzyme Q, 
targeting the cytochrome bc1 complex of the mitochondrial electron transport chain, 
targets asexual blood stages and has some activity against liver stages (37,38). Because 
each of these drugs (antibacterials, antifolates, atovaquone) inhibits a specific enzyme or 
protein, target site mutations in these proteins can confer resistance, making it less 
difficult for the parasite to quickly evolve resistance (38,39). Nevertheless, many of these 
compounds are used alone for malaria prophylaxis like doxycycline, or in combination as 
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in the case of sulfadoxine-pyrimethamine (SP) or Malarone, a formulation of atovaquone 
and proguanil. 
As antimalarial drug resistance continues to pose a challenge for treatment and 
elimination of malaria, novel classes and derivations of currently effective 
pharmacophores are being pursued at multiple levels in the drug development phase. 
Some of the more promising leads that have made it to the later stages of development 
are pictured in Figure 1.4. The artemisinins are a highly successful group of compounds 
and derivations of this class have resulted in novel synthetic endoperoxides such as 
OZ439, also known artefenomel, which is currently being tested in combination with 
piperaquine (40). Artemisone and a tetraoxane TDD E209 are also in late stage 
development. DSM265 is a novel compound with a novel target, Plasmodium 
dihydroorotate dehydrogenase and is currently being tested in phase IIa monotherapy 
trials (40,41). 
 In a collaborative approach between Novartis Institute for Tropical Diseases in 
Singapore and the Swiss Tropical and Public Health Institute the spiroindolone class was 
found to have activity against P. falciparum, and subsequent improvements resulted in 
the compound KAE609, which was found to target the Plasmodium Na
+
 -ATPase 4 ion 
channel (PfATP4) (42). KAF156 is another new compound with a novel mechanism of 
action, targeting the cyclic amine resistance locus, and is also in phase II clinical trials 
(40,41). In addition this compound has been shown to have activity against multiple 
stages of the parasite in the mouse model, including protecting mice against sporozoite 
challenge, killing asexual stages and preventing transmission (43). Finally, MMV390048 
is part of a novel class of compounds, the aminopyridines and is an inhibitor of 
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phosphatidylinositol-4-kinase and is currently in clinical trials (10,40). Considering the 
paucity of novel targets and classes of antimalarial compounds discovered in the past 
century, these emerging new compounds discovered within the past decade are an 
exciting step forward for the malaria community and promise to provide alternatives and 


































Elimination of Malaria: Challenges for Transmission Control and Diagnosis 
 
 Ultimately the goal for the global malaria community is elimination and 
eventually eradication. However antimalarial drugs alone will not be sufficient to 
accomplish this task, in part due to drug resistance, but also due to the complexity of the 
vector, the poverty, poor infrastructure and conflict in many endemic areas, as well as the 
large asymptomatic population. Vector control, diagnostics and vaccines are all tools that 
will be necessary components in any elimination strategy, in addition to antimalarial drug 
administration. In order to eliminate malaria, transmission of the parasite must be 
interrupted, which can be accomplished by preventing mosquito-human interactions, 
making mosquitoes no longer infectious to humans, or making humans no longer 
infectious to mosquitoes.  
The first strategy involves vector control measures such as long lasting insecticide 
treated nets (LLINs), indoor residual spraying (IRS), or larviciding to reduce vector 
populations as well as create a physical barrier between humans and mosquitoes in the 
case of LLINs (44). LLINs are a popular intervention strategy due to their low cost and 
ease of distribution, but insecticide resistance and improper use have resulted in LLINs 
being less effective than expected. Indeed insecticide resistance and behavorial changes 
in Anopheles mosquitoes will continue to challenge control efforts and novel insecticides 
are vital for future success (45). 
There are also efforts to make mosquitoes less competent vectors of  
Plasmodium through genetic modifications or introduction of bacteria to mosquito 
microbiota which inhibit Plasmodium development in the mosquito. Some approaches 
involve genetically modifying the mosquito itself to express anti-Plasmodium genes such 
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as immune factors that play a role in anti-Plasmodium defense in the mosquito (46,47). 
Other strategies involve paratransgenesis, or modifying symbiotic bacteria to deliver anti-
pathogen factors and reduce vector competence (46,47). The challenge for these models 
is stably introducing them into the population and ensuring that the mosquitoes or 
bacteria will spread throughout a population. 
Finally, a largely untouched strategy involves breaking the transmission cycle by 
making humans no longer infectious to mosquitoes. The obvious solution is to kill 
parasites in every infected individual, but doing so may prove very challenging. First 
infected individuals must be identified, and as mentioned earlier, there is a large 
asymptomatic population, particularly in endemic areas, that do not present with clinical 
illness and remain untreated (48). Active case detection of these individuals and 
treatment is one solution; another would involve mass drug administration of a safe and 
effective drug that would kill all parasite stages, including gametocytes and active or 
dormant liver stages. Primaquine in combination with an ACT would accomplish killing 
of all stages, but MDA of primaquine is ethically questionable as it can cause hemolysis 
in individuals with G6PD deficiency and is not really appropriate for mass administration 
to all of a population. Furthermore, MDA efforts would need to be combined with vector 
control to prevent new infections from occurring.  
Ultimately a vaccine that could prevent infection and also block transmission 
would be ideal, to simultaneously drain the gametocyte reservoir and also prevent 
transmission of Plasmodium to mosquitoes. The only vaccine that is currently in phase III 
trials is the RTS,S/AS01 which targets P. falciparum sporozoites, aimed at preventing 
infection. Phase III trials of this vaccine resulted in only partial efficacy, with 50% 
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protection in older children, and only 30% efficacy in the target population, infants 
(49,50). For elimination purposes, development of a vaccine to prevent transmission 
would be a means of eliminating access for mosquitoes to the gametocyte reservoir in 
even asymptomatic individuals and is worth pursuing along with a more effective vaccine 
to prevent infection (51). Finally, diagnosis of low parasitemia individuals is also crucial 
to identify and eliminate every last case of malaria and warrants further research in the 
development of high sensitivity diagnostic tools (52). 
All available tools including antimalarial drugs, vaccines, vector control strategies 
and diagnostics will be required to achieve the goal of elimination and eventually 
eradication. Each tool requires innovative strategies for improved design and 
implementation. My dissertation work has involved studying drug design and 
development for improved antimalarials, designing an assay to identify transmission 
blocking compounds, and finally understanding basic parasite biology and pathogenesis 
of the malaria parasite in the human host through the characterization of a Plasmodium 
hemolysin III. While varied in their scope, all three projects have one end goal in mind: 
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CHAPTER 2:  
PLASMODIUM HEMOLYSIN III: A ROLE IN THE PARASITE AND IN 


















Xenopus and native PfHlyIII expression data previously published, adapted from 
following manuscript (remaining data unpublished): 
Moonah S, Sanders NG, Persichetti, JK, Sullivan, DJ. Erythrocyte lysis and Xenopus 
laevis oocyte rupture by recombinant Plasmodium falciparum hemolysin III. Eukaryot 





 Severe anemia is a hallmark of malaria pathogenesis and contributes significantly 
to the morbidity and mortality seen in children, but also in pregnant women infected with 
malaria. Together, clearance of infected and uninfected erythrocytes in conjunction with 
inhibition of erythropoiesis is thought to be responsible for the dramatic decline in 
hemoglobin levels to less than 5 g/dL that defines severe malaria anemia. However the 
host and parasite factors that mediate the processes of uninfected erythrocyte clearance 
are still under investigation. We hypothesized that a cytolytic protein produced by the 
Plasmodium parasite, such as a hemolysin, might act as a virulence factor and damage 
uninfected host erythrocytes, contributing to severe malaria anemia.  
 Initial characterization of PfHlyIII in our lab had demonstrated that recombinant 
Plasmodium hemolysin III (recPfHlyIII) expressed in E. coli was capable of binding to 
erythrocytes and lysing them in a time and temperature dependent manner. Size 
dependent inhibition of recPfHlyIII-associated hemolysis by osmotic protectants of 
increasing hydrodynamic radii supported a pore-forming mechanism with recPfHlyIII 
pores approximated to be 3-3.5 nm in diameter. Furthermore, transfection and integration 
of a C-terminally GFP-tagged recPfHlyIII into the Dd2attB P. falciparum strain resulted 
in localization of the recPfHlyIII protein to the digestive vacuole of the parasite. Based 
on these previous findings, we modified our hypothesis to suggest that soluble PfHlyIII in 
the digestive vacuole of Plasmodium could be released upon parasite egress in infected 
individuals, resulting in damage to bystander erythrocytes, facilitating uninfected 




For my thesis, I developed the following aims to test our new hypothesis:  
(1) Demonstrate PfHlyIII forms a functional pore in a heterologous Xenopus oocyte 
expression system, (2) Determine whether soluble PfHlyIII is expressed and present in 
late asexual blood stages, and (3) Characterize host effects of a Plasmodium berghei 
hemolysin knock-out on severe malaria anemia. 
 Demonstration of functional pore formation in a eukaryotic system was 
accomplished by expressing recPfHlyIII in Xenopus laevis oocytes, and observing that 
recPfHlyIII expressing oocytes were sensitive to hypotonic lysis, similar to oocytes 
expressing human aquaporin 1, a well-described water channel. Furthermore, oocyte 
rupture was inhibited by the addition of an osmotic protectant, similar to what was seen 
in previous studies with inhibition of erythrocyte lysis by recPfHlyIII. 
 We generated and affinity purified rabbit polyclonal antiserum against the eighty-
amino acid N-terminal tail of PfHlyIII in order to study native protein expression in the 
parasite. Using our PfHlyIII-specific antibody to probe parasite lysates, we found that 
PfHlyIII was expressed in all asexual blood stages as both a soluble and integral 
membrane protein, with increased expression of the protein throughout the infected 
erythrocyte maturation. In addition we also found evidence that PfHlyIII may be 
expressed in gametocyte stages, but is not detectable by immunoblot in the sporozoite 
stages. Our evidence for native expression in asexual blood stages supports our 
hypothesis that soluble PfHlyIII could be released upon parasite egress and come into 
contact with bystander erythrocytes in patient plasma.  
 We next used two separate approaches to test whether Plasmodium hemolysin III 
contributes to severe anemia, utilizing the murine malaria model. The first approach 
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involved construction and characterization of a genetic knockout of PbHlyIII (PbHlyIII 
KO), in order to determine whether PbHlyIII KO parasites lacking hemolysin would be 
less virulent and result in less anemia compared to WT P. berghei infected mice. To test 
our hypothesis that knocking out PbHlyIII would result in decreased virulence and 
anemia, we infected Balb/c mice with either WT or PbHlyIII KO P. berghei ANKA and 
monitored the mice for parasitemia, survival and hemoglobin levels to follow the 
progression of anemia as the disease progressed. To our surprise, the PbHlyIII KO 
infected mice died 8-15 days earlier than WT infected mice, with no significant 
difference in parasite growth rate between the groups. To confirm this phenotype we 
generated a separate PbHlyIII KO parasite in the GFP-Luc P. berghei ANKA strain and 
showed that both knockout parasites resulted in earlier death compared to the wild type. 
However, because the mice infected with the knockout parasite died so early, we were 
unable to determine whether these mice would be protected from anemia, thus preventing 
us from using this model to determine whether PbHlyIII plays a role a severe malaria 
anemia.  
The second approach involved immunizing mice against PbHlyIII using a GST-
fusion peptide followed by parasite challenge and observing whether mice with 
antibodies against PbHlyIII would be protected against severe anemia. With the 
immunization approach we found that mice with the strongest antisera reactivity after 
PbHlyIII immunization died very quickly, albeit with low parasitemia, and that those 
with weak sera reactivity were not protected from parasitemia or severe anemia compared 
to non-immune or the GST-immunized controls. Based on the pathology of the mice, we 
suspect that the method of immunization and challenge may have resulted in the 
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development of severe fibrosis and an adverse immunization reaction that resulted in 
early death. We were unable to measure anemia in these mice due to their early death and 
thus were unable to resolve the question regarding the role of PbHlyIII in severe anemia 
using this approach. 
While we were unable to provide sufficient evidence to support or reject a role for 
the Plasmodium protein in severe murine malaria anemia, we were intrigued by the fact 
that knocking out the P. berghei hemolysin resulted in increased virulence of the parasite. 
We decided to further characterize the knockout parasite in order to determine the 
functional role of hemolysin III for Plasmodium. First pursuing the lethality phenotype, 
we found that the PbHlyIII KO infected mice had slightly higher parasite loads and also 
hemorrhages in the spleen, as well as some hemorrhages in the brain, which may have 
contributed to their early death. Furthermore, transmission electron microscopy images of 
the PbHlyIII KO asexual stage parasites show striking morphological differences, with 
undulating membranes and extra vacuolar spaces compared to the WT parasites. Further 
investigation of these alterations may lead to a clearer understanding of the function of 
hemolysin in the parasite, perhaps as a receptor or transporter. Finally, by following the 
PbHlyIII KO parasite through the mosquito life cycle we observed a growth defect in the 
parasite resulting in decreased oocyte number in the mosquito midgut and a large 
reduction in sporozoite load in the salivary glands. Further investigation of these 
mosquito stages to determine where the hemolysin protein is required for normal 




Future directions for this project include further study of the mosquito stages of 
the PbHlyIII KO parasite to determine which step(s) of development between gamete 
fusion and sporozoite invasion of the salivary glands require PbHlyIII for normal 
maturation. In addition the hemolysin gene in P. falciparum should also be knocked out 
and the knockout parasite characterized to confirm what we have found in P. berghei to 
also hold true in the human malaria parasite. While we have confirmed by PCR and 
Southern Blot that we have successfully disrupted the pbhlyiii loci in two separate strains, 
we have not done whole genome sequencing to rule out other genetic changes that may 
have occurred as a consequence of knocking out the gene encoding hemolysin III in P. 
berghei. Finally, a different immunization approach should be developed to try and 
answer our initial question of whether Plasmodium hemolysin III contributes to severe 












The Complex Etiology and Pathophysiology of Severe Malaria Anemia 
As described earlier, malaria infection can result in either uncomplicated or severe 
disease. Severe malaria can present with a variety of manifestations, including cerebral 
malaria (convulsions, impaired consciousness), pulmonary edema, jaundice, abnormal 
bleeding, and severe anemia (1). The WHO defines severe malaria anemia (SMA) as a 
hematocrit less than 15% or hemoglobin less than 5 g/dL along with a parasite positive 
bloodfilm, though patients can present with anemia even with low or undetectable 
parasitemia (1,2). While P. falciparum is often associated with the most severe disease, 
P. vivax can also cause severe anemia and results in the removal of a large quantity of 
uninfected cells despite often low parasitemia (3).  
The etiology of SMA is complicated, with additional factors beyond Plasmodium 
infection that can influence anemia status, including infection with other pathogens 
(helminths or bacteria), vitamin deficiencies (iron or Vitamin D) and genetic disorders 
(G6PD deficiency,beta or alpha thalassemias) (4–7). Broadly, anemia as a result of 
malaria infection is due to the removal of infected and uninfected erythrocytes combined 
with the decrease or inhibition of erythropoiesis preventing red blood cell replenishment. 
Influencing each of these mechanisms is a complex dynamic of immune pathways and 
host defense mechanisms which ultimately may protect the host from high parasitemia, 
but often result in severe symptoms of anemia. 
On the one hand, removal of parasitized erythrocytes is anticipated through the 
destruction of the red cell upon egress of the parasite during the asexual cycle. In addition 
infected cells may be targeted for antibody-mediated clearance through recognition of 
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surface proteins or complement deposition, as well as splenic removal of immature ring 
stages due to reduced deformability (8–11). Some immature ring infected erythrocytes 
may undergo a process called ‘pitting’ whereby the parasite is removed in the spleen and 
the red cell is returned to circulation, though these erythrocytes experience reduced 
survival because of parasite antigens retained on the surface (11,12). P. falciparum 
mature blood stage parasites express PfEMP1 concentrated on knobs on the surface of the 
erythrocyte , resulting in cytoadhesion and sequestration of these later stages, essentially 
protecting them from removal by the spleen, whereas P. vivax mature stages are more 
deformable and can be seen in circulation (11) . Eventually the infected red blood cells 
are destroyed upon egress of the parasite.  
The contribution of uninfected red blood cell (uRBC) clearance to anemia is 
surprisingly high, with approximately 10 or 34 uninfected erythrocytes removed for every 
P. falciparum or P. vivax infected red cell, respectively(13,14). Similar to the removal of 
parasitized erythrocytes, uninfected cell removal is largely attributed to 
erythrophagocytosis through a combination of mechanisms including antibody-mediated 
clearance, complement activation, oxidation and parasite-related senescence (8,9,15–17). 
Rhoptry-associated proteins from infected erythrocytes have been shown to recognize the 
surface of uRBCs in a parasitemia-dependent manner which can result in opsonisization 
followed by phagocytosis or complement activation (9). Other data suggests that the loss 
of CR1 and CD55 from the surface of uRBCs due to parasite product derived immune 
complex formation and removal may result in increased complement component C3b 
deposition and increased removal of uRBCs (18–22). One murine malaria study suggests 
a factor extrinsic to either erythrocytes or antibodies is responsible for uRBC clearance.  
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SCID mice, devoid of T or B cells, developed less anemia than wild type Balb/c or nude 
mice (lacking T cells only), but transferring serum from infected Balb/c mice to infected 
SCID mice did not result in increased clearance rates, signifying an antibody-independent 
clearance mechanism (23). In a separate study, red blood cells transferred from mice 
experiencing severe malaria anemia into healthy animals did not undergo similar 
clearance, suggesting that these cells were not permanently or sufficiently changed to 
warrant their removal. In the same study, depletion of macrophages and CD4+ T cells 
reduced anemia in semi-immune mice, supporting the idea that a hyperphagocytic 
response might be responsible for enhanced clearance of uRBCs, though the trigger for 
this response is still not well-defined (24). A very recent study confirms the role of 
activated CD8+ T cells in the splenic clearance of parasitized erythrocytes related to an 
increase in the removal of uRBCs (25). Finally, deformability may also play a role in 
uRBC clearance, as uRBCs have been shown to have reduced deformability in patients 
with SMA (26). Overall, there is evidence for increased erythrophagocytosis in hosts 
experiencing SMA, but the triggers for this response remain undefined and appear to be 
antibody-independent.  
In the face of such aggressive removal of both infected and uninfected 
erythrocytes, one would expect the replacement mechanisms to be equally vigorous. 
However erythropoiesis has been shown to be disrupted in SMA patients, preventing the 
production and development of new erythrocytes to replace those which have been 
removed through the afore-mentioned processes. In a murine malaria model, impaired 
responses to erythropoietin during reticulocytosis (27) and decreased expression of the 
transferrin receptor CD71on red blood cells (28) were demonstrated to prevent 
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maturation of erythroid precursors, suggesting potential downstream effects of 
Plasmodium infection on erythropoiesis. Interestingly, the parasite product hemozoin has 
been shown to affect erythropoiesis on multiple levels including: inhibiting macrophage 
activation which could disrupt erythroblastic islands, preventing production of 
reticulocytes (29,30),stimulating the production of endoperoxides by macrophages which 
may affect growth of erythrocytes (30–34), and finally suppressing erythropoietin 
induced proliferation of erythroblasts (35). Parasites may also contribute directly to 
dyserythropoeisis by infecting and destroying erythroblasts, as has been shown in the 
case of P. vivax (36). 
 Strongly correlated with the inhibition of erythropoiesis in SMA is immune 
dysfunction and imbalance, often skewed toward inflammation and Th-1 type 
mechanisms. For example, multiple studies have shown relationships between high tumor 
necrosis factor alpha (TNF-α) to interleukin ten (IL-10) ratios and SMA (37–40). Other 
research suggests cerebral malaria and SMA are influenced by separate TNF-α promoter 
alleles (41), while one study points toward uniquely programmed monocytes and T cells 
as the source of the skewed TNFα:IL-10 ratio (39). The origins of imbalanced 
inflammatory responses may return full circle to parasite-produced hemozoin which can 
be phagocytosed and influence macrophage activation and production of downstream 
inflammatory mediators (42,43). Other immune mediators such as migration inhibitory 
factor (MIF) and stem cell growth factor (SCGF) have also been suggested as 
contributors to severe anemia and malaria pathogenesis through suppression of 
erythropoiesis, though the MIF studies have been done in mice and not proven in humans 
(44–47). While inhibition of erythropoiesis is obviously detrimental for the host, one 
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modeling study suggests that decreasing production of new red blood cells may prevent 
even more severe anemia in the host by reducing the number of cells the parasite can 
invade and destroy (48).  
Unfortunately current treatment options for SMA are limited to antimalarial drugs 
and transfusion for very severe cases. However transfusions may not be beneficial and 
also carry the risk of HIV transmission. Furthermore, drug treatment of uncomplicated 
malaria in endemic areas does not have a significant impact on hemoglobin levels, and 
prevention of infection or prophylaxis is really the only way to prevent severe malaria 
anemia and other acute pathologies of the disease (49).  
It is evident from the complexity of SMA and the paucity of treatment options 
available that further study of SMA is urgently needed in order to better understand the 
mechanisms and identify and test potential interventions. Animal models of severe 
malaria and specifically severe malaria anemia have their own limitations. The severe 
malaria mouse model of P. berghei ANKA infected C57Bl/6J mice is often used to 
mimic cerebral malaria (CM), but is not a good model for SMA as the mice progress 
quickly to CM and develop acute rather than chronic anemia, due more to parasite 
destruction of infected cells than loss of uRBCs (30,50). Balb/c mice infected with the 
same strain of parasite can develop anemia over a longer period of time, but development 
of high parasitemia may make it difficult to differentiate between anemia due to parasite 
egress and anemia due to uRBC clearance. However, it has been shown that anemia is not 
always correlated with the peak parasitemia in both mouse and Aotus monkey malaria 
models (30,51), which is in agreement with a human study with evidence for a higher 
correlation with anemia and 90-day parasitemia history, rather than current parasite 
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burden (2). Specifically a study of P. chabaudi infection in Balb/c mice demonstrates that 
the percentage of infected erythrocytes rather than total parasite number correlated more 
strongly with a decrease in total circulating erythrocytes, suggesting that available 
uninfected erythrocytes are the limiting factor in these infections (52). Semi-immune 
animal models may the best way to study the contribution of uRBC removal in human 
SMA, where animals have similarly low levels of parasitemia but continued clearance of 
uninfected red blood cells and development of severe anemia (30,51,53).  
Overall it appears that severe malaria anemia is a complex pathology of 
Plasmodium infection, and that the immune response to parasite infection and products 
may result in downstream effects on erythropoiesis as well as enhanced 
erythrophagocytosis of infected and uninfected erythrocytes. The exact parasite-related 















Pore-forming Toxins and Hemolysins 
Cytolytic proteins have been described for many pathogenic microorganisms and 
are often responsible for invasion and egress of the pathogen into and out of the host cell, 
or are classified as toxins or virulence factors with pathogenic effects for the host. 
Bacterial cytolysins in particular make up a diverse class of proteins, differing by size, 
secondary structure, target cell, pore diameter, and mechanism of pore-formation/lysis.  
In general bacterial cytolysins can be divided into either alpha-helical or beta-barrel pore-
forming toxins resulting in the formation of homogenous (consistently the same 
composition) or heterogenous (range in number of monomer components) pores, or in 
some cases disruption of the membrane without formation of a discrete lesion. The size 
of pores formed by many of the cytolysins ranges from small (0.5-5 nm) such as the pore 
formed by E. coli hemolysin A, to the much larger pores (20-100 nm) like those formed 
by the cholesterol dependent cytolysins like perfringolysin O (54). Beta-barrel toxins 
make up the majority of bacterial cytolysins and tend to form larger pores, while the 
alpha-helical toxins tend to form smaller pores.  
Mechanism of pore-formation and/or membrane disruption has been postulated 
and in some cases confirmed for different classes of bacterial cytolysins, and can depend 
on the target cell and availability of certain ligands, such as cholesterol, glycans, lipids, 
membrane proteins, or GPI-anchored proteins. For many cytolysins the general 
mechanism of action includes binding to a target ligand or receptor followed by 
oligimerization and insertion into the membrane to form an aqueous pore (55). Thiol-
activated cytolysins such as streptolysin O depend on cholesterol for the initial binding to 
target membranes, and some studies suggest that binding to cholesterol triggers a 
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conformational change followed by self-association between monomers, resulting in a 
oligomeric transmembrane pore (56). Staphylococcus aureus alpha-toxin is known to 
form homogenous hexameric small pores 2-3 nm in diameter and does not require a 
specific ligand to bind cells, though the toxin does show preferential binding to rabbit 
erythrocytes compared to human erythrocytes (54). Clostridium perfringens produces a 
cholesterol-dependent cytolysin, perfringolysin O which upon binding to the membrane, 
triggers formation of heterogenous oligomers containing 35-50 monomers which shift to 
reveal beta-hairpins, ultimately resulting in insertion of a 25-30 nm beta-barrel pore into 
the target membrane (57). Some cytolysins disrupt membranes without forming a discrete 
pore, as has been described for E. coli hemolysin A, an alpha-toxin which transiently 
disrupts membrane bilayers by inserting into the outer membrane monolayer and 
disrupting the bilateral tension of the lipid bilayer (58). 
Consequences of pore-formation in target cells aside from direct cytolysis, 
include efflux of potassium and influx of calcium which can trigger downstream events 
including inflammatory responses as well as apoptosis, leading to the destruction of 
tissue and loss of endothelial or epithelial barriers (55). Pore-forming toxin induced 
barrier disruption can be the result of direct damage to endothelial or epithelial layer 
integrity or a downstream consequence of increased inflammation as a result of a toxin-
induced pores (55). Ultimately barrier disruption can have lethal outcomes for an infected 
individual, as toxins like S. pneumoniae pneumolysin can destroy lung tissue with a 




Plasmodium falciparum Hemolysin III: A Pore-forming, Hemolytic Protein 
Localizing to the Digestive Vacuole 
While considering potential mediators of severe malaria anemia, our lab 
discovered that Plasmodium encodes a putative hemolysin III protein, with structural 
homology to hemolysin III proteins previously described in Bacillus cereus (59–61) and 
Vibrio vulnificus (62). Plasmodium hemolysin III is part of the hemolysin III superfamily 
of integral membrane proteins ranging from bacterial proteins with previously described 
hemolytic activity (59,60,62) to eukaryotic proteins with seven predicted transmembrane 
domains acting as functional receptors for ligands including progestin and adipo-Q 
(PAQR) (63). Phylogenetic analysis based on protein sequence data of representative 
proteins in the hemolysin III superfamily (Figure 2.1) suggests the Plasmodium 
hemolysin III proteins are more closely related to the bacterial hemolysins than the 
eukaryotic PAQR proteins. 
The Bacillus and Vibrio hemolysin III proteins with similar predicted secondary 
structure and topology to Plasmodium hemolyin III have been previously characterized. 
Expression of B. cereus hemolysin III in E. coli resulted in preparation of crude extracts 
with hemolytic activity but difficulty in attempts to further purify the protein. However 
hemolysis and osmotic protectant experiments using the crude extract supported a pore-
forming mechanism for B. cereus HlyIII with a temperature dependent binding and 3-3.5 
nm pore-formation step with temperature-independent lysis (59,60). The hemolysin III of 
V. vulfnificus shares 48% identity to B. cereus HlyIII, and expression of recombinant V. 
vulnificus HlyIII in E. coli also results in hemolytic activity, with insertional inactivation 




Figure 2.1 Hemolysin III Superfamily Phylogenetic Tree of Representative Proteins 
including Plasmodium hemolysins, apicomplexan homologs, bacterial hemolysins, and 
eukaryotic PAQR proteins. Alignments were made using Muscle and neighbor joining 
was used to construct the phylogenetic tree with bootstrapping; cutoff 70%. 
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Multiple sequence alignment of all of the above sequences used in the 
phylogenetic tree reveals conserved residues including a serine and histidine, as well as a 
conserved motif, DxxxIxxxIxG (Figure 2.2). These residues were conserved across all 
species with the exception of one bacteria protein and one yeast protein, suggesting that 
they are important for protein structure/function. In addition all of the HlyIII superfamily 
of proteins have seven predicted transmembrane domains with similarly predicted 
topology as represented in Figure 2.3. 
 
Figure 2.2 Protein sequence alignment of HlyIII superfamily proteins reveals conserved 
residues and motif across eukaryotes and prokaryote sequences. Arrows point to 
conserved residues including a serine and histidine, as well as a conserved motif aspartic 




Figure 2.3 Transmembrane domain predictions generated by TMpred for various HlyIII 
superfamily proteins including Plasmodium, Toxoplasma, Vibrio, and Bacillus 
hemolysins and eukaryotic homologs including a yeast protein and human PAQR. 
Predicted hydrophobic regions have positive hydropathy scores (>0). 
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 Of note, all the representative eukaryotic proteins in the HlyIII superfamily, 
regardless of function, have an additional N-terminal domain not found in the bacterial 
hemolysins. Thus, even though the overall sequences of Plasmodium hemolysins are 
more similar to the bacterial hemolysins, structurally, Plasmodium hemolysins share 
conserved N-terminal domains with the other eukaryotic members of the family that may 
be important for function. 
The eukaryotic proteins such as S. cerevisiae Izh2p and various PAQR proteins 
all share homology and unique motifs and are classified as part of the PAQR protein 
family. Several studies have suggested three subclasses within this family based on 
differing motifs and physical characterisitics: Class I, Class II, and Class III (64,65).  
Class I proteins are restricted to eukaryotes and include yeast proteins such as 
Izh2p as well as the human adiponectin receptors (PAQR1 and 2). Yeast Izh2p, a 
homolog to human adiponectin receptors, is an important mediator in cellular 
metabolism, and has been recently shown to play a role in iron, phosphate and zinc 
homeostasis, with downstream implications for lipid metabolism (66). In humans, 
adiponectin is a polypeptide hormone that regulates metabolism, and deficiencies in 
adiponectin can result in insulin resistance and type 2 diabetes (67). Izh2p has been 
shown to respond to progesterone in a G-coupled protein receptor (GCPR) independent 
manner, confirming a functional role as a membrane progesterone receptor that does not 
rely on GCPRs for function (64), and other studies suggest a role for sphingolipids as 
downstream effectors of Izh2p (65).  
Class II proteins are also progesterone receptors but have a unique eighth 
transmembrane domain that is C-terminal to the last PAQR domain. Recent studies 
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confirm the PAQR proteins as functional hormone or steroid membrane receptors, 
including demonstration of progestin receptors in zebrafish and adiponectin receptors in 
yeast (68,69), suggesting these proteins are important for downstream signaling after 
interaction with a hormone or steroid.  
Class III proteins include the eukaryotic and prokaryotic proteins with homology 
to hemolysins which may or may not predict hemolytic functions for these proteins (65). 
Plasmodium hemolysin III falls into the class III protein category and phylogenetically 
appears more similar to the bacterial hemolysins, despite having the additional N-
terminal tail reminiscent of the class I and class II proteins.  
Initial work in our lab was done to characterize a putative Plasmodium falciparum 
hemolysin III by expressing a recombinant, his-tagged PfHlyIII in E. coli followed by 
characterization of pore-forming activity of the purified lysate in hemolytic assays as well 
as immunofluorescent microscopy demonstrating binding of the protein to the surface of 
erythrocytes in the presence of an osmotic protectant, polyethylene glycol. From this 
studies we concluded recombinant PfHlyIII was a pore-forming protein that could bind to 
and lyse erythrocytes in a time and temperature dependent manner, forming pores of 
approximately 3.5 nm in diameter. Temperature studies suggested a multi-step 
mechanism of binding followed by insertion into the membrane, similar to what has been 
described for other hemolytic proteins. Furthermore, glibenclamide, a channel inhibitor, 
was also able to partially inhibit hemolysis of erythrocytes when incubated in addition to 
recPfHlyIII lysate. In a separate approach, C-terminal GFP-tagged PfHlyIII was 
overexpressed in the Dd2attB strain of P. falciparum and the PfHlyIII-GFP was localized 
to the digestive vacuole of the parasite. Interestingly parasites overexpressing PfHlyIII-
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GFP were observed to exhibit a swollen food vacuole phenotype. Work from these 
studies was previously published (70). 
While we had demonstrated that recombinant Plasmodium hemolysins were 
functional cytolytic proteins, we were ultimately interested in whether or not they could 
be virulence factors in malaria, contributing to severe malaria anemia. Specifically we 
hypothesized that Plasmodium falciparum hemolysin III might contribute to damage and 
destruction of bystander erythrocytes if the protein was released in soluble form upon 
egress of the parasite from the erythrocyte and subsequent rupture of the digestive 
vacuole (Figure 2.4). 
 Thus the aims of my thesis project were the following: (1) heterologous 
expression of recombinant PfHlyIII in Xenopus oocytes followed by confirmation of 
pore-formation in eukaryotes, (2) determining whether soluble PfHlyIII is expressed and 
present in late asexual blood stages, and (3) determining the virulence of Plasmodium 
hemolysin III in a mouse model of malaria. 
 
Figure 2.4 Hypothesis: soluble PfHlyIII may damage bystander red blood cells upon 






MATERIALS AND METHODS 
Phylogenetic Tree Construction 
The evolutionary history was inferred using the Neighbor-Joining method (71). 
The optimal tree with the sum of branch length = 10.66815406 is shown. The percentage 
of replicate trees in which the associated taxa clustered together in the bootstrap test (500 
replicates) are shown next to the branches (72). The evolutionary distances were 
computed using the Poisson correction method (73) and are in the units of the number of 
amino acid substitutions per site. The analysis involved 60 amino acid sequences. All 
positions containing gaps and missing data were eliminated. There were a total of 142 
positions in the final dataset. Evolutionary analyses were conducted in MEGA6 (74). 
Xenopus Expression 
Plasmid construction: pGS21a_PfHly3-flag with an Nhe site was constructed 
using the QuikChange Lightning site-directed mutagenesis kit (Agilent Stratagene 
#210518-5), digested with EcoRI and NheI and ligated into pXβG-ev1-myc to produce 
pXβG-ev1-myc-PfHly3-flag. We received pXβG-ev1-myc and pXβG-ev1-hAQP1 cDNA 
as a generous gift from Dr. P. Agre. 
Expression in Oocytes: Capped cRNA was produced using in vitro transcription 
from either the pXβG-ev1-myc-PfHly3-flag or pXβG-ev1-hAQP1 plasmid templates, 
linearized with XbaI, using T3 RNA polymerase and the RNeasy minikit (Qiagen 
#74104). Xenopus laevis oocytes generously donated by Dr. C. Montell were 
defolliculated and injected with 25-44 ng of cRNA or 50 nl of DEPC-treated water 
(diethyl pyrocarbonate), followed by incubation at 16 °C for 3-5 days in OR3 medium. 
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Oocytes were collected 72, 96 and 120h post-injection for Western Blot analysis and 
swelling assays, described below.  
Western Blot analysis: 10 oocytes per treatment were pooled into 200 µl of ice 
cold lysis buffer (20 mM Tris-HCl, pH 7.5, 140 mM NaCl, 2% Triton X-100, 1x Protease 
Inhibitors- Sigma Fast Protease Inhibitor Cocktail Tablet EDTA free) and incubated on 
ice for 30 minutes. Oocytes were homogenized by pipetting samples repeatedly and 
centrifuged at 4500 x g for 15 minutes at 4°C to removed yolk and cellular debris. The 
supernatant was transferred to a new tube and incubated on ice for 30 minutes, with 
occasional vortex. The sample was spun at 15,000 x g to remove insoluble materials and 
the supernatant was stored in SDS loading buffer at -80°C. Samples were heated for 10 
minutes at 95°C and cooled on ice, then run on an SDS-PAGE gel (BioRad Mini-
PROTEAN 4-20% TGX Gel, # 456-1093) at 100V for 2 hours. Proteins were then 
transferred to a nitrocellulose membrane and probed with 10 µg/ml anti-Flag M2 
produced in mouse (Sigma F3165) in 5% milk in TBS-T, 1:5,000 anti-myc-HRP 
produced in mouse (Invitrogen R951-25), anti-AQP1 B-11 produced in mouse (Santa 
Cruz sc-25287), or anti-beta actin produced in mouse (AbCam 8224). HRP-conjugated 
anti-mouse antibodies produced in goat (IgG+IgM (H+L) Jackson Lab 115-035-068) 
were used for myc, hAQP1, and beta actin blots, followed by ECL. 
Swelling Assays: Method modified from Preston, G. M., Carroll, T. P., Guggino, 
W. B. & Agre, P. (1992) Science 256 , 385-387. Briefly, 5-6 oocytes per group were 
transferred to a small petri dish of water (hypotonic) and monitored with 
videomicroscopy at room temperature for swelling and rupture over a time course of 0-60 
minutes. Still pictures were taken at 0, 1, 5, 10, 15, 30, 45, and 60 minutes and the 
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number of intact oocytes was determined based on the number of oocytes which did not 
rupture in water after each time point.               
Recombinant GST and MBP Fusion Protein Expression and Purification, anti-
PfHly III antibody production and affinity purification, and Western Blot assays 
with GSTF80AA competition. 
Plasmid construction and GST fusion protein expression and purification: The 
first 80 amino acids of PfHly III were expressed as a glutathione S-transferase (GST) 
fusion protein (GSTF80AA) by cloning a 240-bp insert encoding the codon-optimized N-
terminal 80 amino acids into the pGEXT vector (parent pGEX-4T-3 with inserted Tev 
protease sequence, gift of Prigge lab, Supplementary Figure 1). Primers for expression 
from optimized genomic template were as follows:  
forward, 5’- GAATTCAATGGAATTTTACAAAAACTTC-3’ 
reverse, 5’- GAATTCCTAAGCTTGCCGCGAAACAGGGTTTTG-3’. Expression of the 
GST fusion protein was conducted in BL21*RIL cells in LB broth plus ampicillin and 
chloramphenicol induced with 1 mM isopropyl-D-thiogalactopyranoside (IPTG) at an 
optical density at 600 nm (OD600) of 0.6 and incubated for 10 h at 20°C. The 
GSTF80AA fusion protein was purified after high-pressure cell homogenization 
(EmulsiFlex C5 cell disruptor; Avestin; 100 MPa) in lysis buffer (50mM Tris, pH 8.0, 
1% Triton X 100, 150mM NaCl, 10mM DTT, DNAseI 10 µg/µL, MgCl2 5 mM, Sigma 
Protease Inhibitor 1X), followed by centrifugation, and incubation of supernatant with 
glutathione-Sepharose 4B resin (GE Healthcare), followed by elution with 10 mM 
glutathione. Similar conditions were used the express and purify recombinant GST fused 
to the P. berghei and P. chabaudi hemolysin N-termini. 
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Primers for these constructing the respective expression constructs were as follows: 
Pb80AA forward: 5’ – GAATTCAATGGGGAGGTATTATGAATGC – 3’ 
Pb80AA reverse: 5’-GAATTCCTAAGCTTTCCTCTCAGCAGCGTTTTTTCATG - 3’ 
Pc80AA forward: 5’- GAATTCAATGATAGGATATTATGAAACC– 3’ 
Pc80AA reverse: 5’- GAATTCCTAAGCTTTCCTCTCAATAATGTCGCTTC – 3’ 
Plasmid construction and MBP fusion protein expression and purification: 
Separately, a maltose binding protein (MBP) construct was also made using a new PCR 
insert: forward 5’- CGCCATGGAAATGGAATTTTAC – 3’ and reverse 5’ AGCGGAT 
CCTCAGCCGCGAAACAG -3’ cloned into the NcoI and BamHI sites of the MBP-tev-
pRSF plasmid (gift from Bosch lab, Supplementary Figure 2), producing a plasmid 
encoding MBP-F80AA. The MBP-F80AA fusion protein was expressed in LB plus 
kanamycin and 0.2% glucose, induced as described above for the GST fusion protein, and 
purified using amylose resin (NEB catalog no. E8021L), eluted with 10 mM maltose.  
Anti-PfHlyIII antibody production, purification and verification: Purified 
GSTF80AA was used to immunize a rabbit at Cocalico Biologicals, and preimmune 
serum, test bleeds, and the final bleed were received and tested by Western Blotting. The 
MBPF80AA protein was used for testing of anti-PfHly III antibodies as well as for 
affinity purification involving coupling the MBPF80AA fusion protein to an N-hydroxy-
succinimide (NHS)-activated HiTrap column (GE Healthcare), running the antiserum 
over the column for 1 h, washing with binding buffer (0.05 M NaH2PO4, 0.15 NaCl, 
0.01MEDTA), and eluting with 0.1Mglycine, 0.15 M NaCl, pH 2.6. Antibody responses 
were determined by Western Blot analysis as described above with antiserum 
concentrations at 1:10,000 and affinity-purified test bleed 2 (APTB2) at 1:1,000. The 
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GSTF80AA fusion protein was used in competition for native or recombinant PfHly III 
antigen by preincubating APTB2 anti-PfHly III antiserum (20 _l, 0.34 mg/ml with 
majority of protein present as bovine serum albumin [BSA] from purification) with 100_l 
of GSTF80AA fusion protein (0.35 mg/ml), at an approximately 1:50 ratio in 1 ml of 
blocking buffer (5% milk in PBS-Tween 0.1%) for 1 h, followed by dilution to 20 ml for 
Western Blot analysis. 
PfHlyIII knockout (KO) and single crossover disruption (SXO) constructs 
The pfhly3 (PF3D7_1455400) targeting plasmid designed for double homologous 
recombination was constructed by cloning regions -1615bp to -811bp (5’ arm) and 
+1104bp to +1952bp (3’ arm) with respect to the pfhly3 initiation codon into SpeI/AflII 
and EcoRI/AvrII sites respectively in the pCC1D plasmid (gift from Jacobs-Lorena lab, 
Supplementary Figure 3), modified from the pHHT-FCU plasmid (75).  
PCR primers were:  
5’ arm forward: 5’- actagtCATGTCCTCTTTTTGATTCACAT – 3’ 
5’ arm reverse: 5’- cttaagTTGGTAAA ATATAAATTGTCCTCATTT – 3’ 
3’arm forward: 5’- gaattcCGTGGGAATCCCT GAATAAA – 3’ 
3’ arm reverse: 5’- cctaggATGCAATGTTTG AGTAAAAGAAAA – 3’.  
Sequencing primers were:  
5’arm forward: 5’- CTATGGAATACTAAATATATAT CCAATGGCCCC – 3’ 
5’arm reverse: 5’- CAAAATGcttaagTTGGTA AAATATAAA TTGTCCTC – 3’ 
3’arm forward: 5’ – CAGAATACCCAGGTGTTCTCTCTGATG – 3’ 
3’arm reverse: 5’- CGGTGTGAAATACCGCACAGATGCG – 3’ 
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The pfhly3 (PF3D7_1455400) targeting plasmid for single crossover (SXO) disruption 
was constructed by cloning region +71bp to +740bp with respect to the pfhly3 initiation 
codon into the AflII site in the pCC1S plasmid (gift from Prigge lab, Supplementary 
Figure 4).  
Primers for homology region were:  
SXO forward:  
5’-GCCGGGcttaagGGGTAGTACAAAAATTGATGATAATGAAATTGCG -3’  
SXO reverse: 5’- GAGCTCcttaagGGCTTTTTCACAGAATATATA ACTGCTCC – 3’ 
Sequencing primers were:  
pCC1S forward: 5’- CGAACATTAAGCT GCCATATCCttaattaaGTCG – 3’ 
SXO insert reverse: 5’- GGCTTTTTCACAGAAT ATATAACTGCTCC – 3’ 
PbHlyIII genetic knockout construct  
The pbhly3 (PBANKA_131910) targeting plasmid designed for double 
homologous recombination was constructed by cloning regions -834bp to -283bp and 
+973bp to +1487bp with respect to the pbhly3 initiation codon into the ClaI/SbfI and 
EcoRI/XbaI sites respectively in the pL0001 plasmid (gift from Jacobs-Lorena lab, 
originally obtained through the MR4 as part of the BEI Resources Repository, NIAID, 
NIH: Plasmodium berghei pL0001, MRA-770, deposited by AP Waters, Supplementary 
Figure 5).  
Parasite strains and transfection 
The P. falciparum 3D7, P. berghei ANKA, and P. berghei GFP-Luc strains were 
used for gene targeting and were obtained through the MR4 as part of the BEI Resources 
Repository, NIAID, NIH: Plasmodium falciparum 3D7, MRA-102, deposited by DJ 
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Carucci; Plasmodium berghei ANKA, MRA-311, deposited by TF McCutchan; 
Plasmodium berghei (ANKA) 676m1cl1, depositied by CJ Janse and AP Waters: 
Genetically modified parasite of clone cl15cy1 of the ANKA strain; expresses GFP-
luciferase fusion. This line has been selected by flow (FACS) sorting, based on GFP 
fluorescence. Stable transfectant with pL1063 (MRA-852); this line does not contain a 
drug-selectable marker. The transgene is integrated into the genome by double cross-over 
integration and therefore parasites should not lose the transgene and will remain 
fluorescent throughout life cycle. Gametocyte, ookinete, oocysts, sporozoite and liver 
development is comparable to wildtype P. berghei (ANKA) (76).  
For P. falciparum transfection, 400 microL of 50% hematocrit uninfected 
erythrocytes were suspended in 5 ml of cold Cytomix (120 mM KCl, 0.15 mM CaCl2, 2 
mM EGTA, 5 mM MgCl2, 10 mM K2HPO4/KH2PO4, 25 mM HEPES) and centrifuged 
at 500 x g for 5 min. The 200 microL RBC pellet was resuspended in 400 microL of 
targeting construct (65 µg DNA) suspended in cold Cytomix, and transferred to a 0.2 cm 
BioRad Gene Pulser cuvette for electroporation at 0.31 kV, 950 µF, infinity resistance, 
with time constants of 14.2 (KO) and 14.5 (SXO) and voltage of 307 mV. Electroporated 
RBCs were placed immediately on ice and washed with cold RPMI and then added to 2 
ml of 10% synchronized trophozoites at 1% hematocrit and 10 ml of complete media 
(RPMI 1640, 10% human serum, .005% hypoxanthine, 25 mM HEPES, 0.26% 
NaHCO3). Cultures were maintained at 5% CO2, 5% O2, 90% N2 at 37 °C. Drug selection 
with WR92100 began 1 day post transfection and was maintained with media changes 




For P. berghei transfection, one donor mouse was injected with frozen stock of 
desired parasite culture and parasites were harvested by cardiac puncture at 5-10% and 
used to infect 5 donor mice per transfection with 10
6
 iRBCs. When donor mouse 
parasitemia reached 0.5-3%, parasites were harvested by cardiac puncture, washed and 
cultured overnight in 150 ml RPMI supplemented with 20% fetal calf serum and 0.36 
mg/ml gentamcyin at 36.5°C with gently shaking (50 rpm). Mature schizonts were 
purified using a Nycodenz gradient (Histodenz, Sigma D2158) with 10ml of 55% 
nycodenz PBS dispensed beneath culture suspension followed by centrifugation at 450 x 
g, no brake for 25 min. Schizonts were collected from the interface, pelleted and washed 





 schizonts per transfection. Schizonts were resuspended in 100 µL 
nucleofector solution (Mouse T Cell Nucleofector Solution and Supplement, Lonza VPA-
1006) with 20 µg of linear dna targeting construct and electroporated in an Amaxa 
Nucleofector using program U-033, followed by immediate addition of 100 µL of culture 
media and injection into the tail vein of a per-warmed Swiss Webster mouse. Drug 
selection with .07 mg/ml pyrimethamine was started one day post transfection and was 
maintained 4-7 days until positively selected parasites reached 5% parasitemia. Drug-
selected parasites were genotyped by PCR and knockouts were confirmed by Southern 
Blot. 
PCR Analysis 
Primers for confirming integration and genetic knockout were: 
5’ Integration forward: 5’ – CCCTTATGGTATTCCCCTATCC – 3’ 
5’ Integration reverse: 5’ – GCTTTCCTCTTAATTCACTTGG – 3’ 
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3’ Integration forward: 5’ – AGATGGCTGTCTAGCGGAAA – 3’ 
3’ Integration reverse: 5’ – ATAGCACCACGGAAAGTGCT – 3’ 
Phusion High Fidelity DNA polymerase (NEB M0530S) was used for genotyping using 
1-2 µL whole blood from the tail vein of infected mice as the DNA template. The 50 µL 
reaction contained 1X buffer, 0.2 mM dNTPs, 0.5 µM primers, 3% DMSO and 1U of 
Phusion Taq Polymerase. Cycling parameters were 98°C (0:30), 35 cycles of 98°C 
(0:10), 55°C (0:30), 68°C (1:30), followed by 68°C (6:00). 
Southern Blot Analysis 
A digoxigenin (DIG) labeled probe specific to the 3’ homology region used for 
targeting the genome, +973bp to +1487bp with respect to the pbhly3 initiation codon, 
was synthesized by PCR, using DIG-11-dUTP (Roche Applied Science 11209256910) 
and 3’ homology arm primers (see above). Next, genomic DNA from WT and HlyIIIKO 
P. berghei ANKA was isolated and subjected to restriction enzyme digest with HindIII 
overnight (10 µg DNA with 5U of enzyme/µg DNA). The genomic DNA digest was then 
run on a 0.8% TAE agarose gel at 65 mV for 6 hours. The DNA was transferred to a 
nitrocellulose membrane using downward transfer overnight followed by crosslinking the 
DNA to the membrane. Following incubation of the membrane in hybridization buffer for 
1 hr at 42°C, the DIG-labeled probe was denatured (95°C 5min) and added (300 ng in 25 
µL PBS) to the membrane and hybridized for overnight at 42°C. The membrane was 
washed 2x for 5min with low astringency buffer at room temperature followed by two 20 
minute high astringency washes at 65°C. The DIG nucleic acid kit was used for detection 
(Roche Applied Science 11175041910). Briefly, the membrane was washed in maleic 
acid buffer and blocked at room temperature for 1 hour with blocking reagent and probed 
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with anti-digoxigenin 1:10,000 for 30 min, room temperature followed by 3 washes for 
15 min and addition of CSPD for detection. 
Immunization studies 
Recombinant glutathione-S-transferase (GST) or GST fused to the P. berghei 
hemolysin III N-terminus (GSTB80AA) was expressed and purified from E. coli as 
described above. Mice (6 week old, female, Balb/c) mice were prebled (100 µL) and 
serum was collected (37°C 1hr, 4°C O/N, centrifuge 13,000 rpm 15min 4°C to collect 
supernatant) and stored at -20°C for baseline serum reactivity analysis. The following day 
mice were divided into four groups: a non-immunized control group (n=10), GST alone, 
25 µg (n=10), GSTB80AA, native, 50 µg (n=10) and GSTB80AA, denatured, 50 µg 
(n=5) and immunized according to their group with antigen emulsified in 200 µL 
complete Freund’s adjuvant (CFA). Each group received three boost immunizations of 
the same antigen in incomplete Freund’s adjuvant (IFA) on days 18, 32, and 54 post 
priming.* The non-immunized control group did not receive adjuvant or antigen at any 
point. Animals underwent a test bleed (100 µL) on day 45 and day 74 and serum 
reactivity was assessed by Western Blot of whole cell P. berghei ANKA parasite lysate 
run on an SDS-PAGE gel and transferred to a nitrocellulose membrane, probed with 
1:1000 antiserum in blocking buffer. Based on serum reactivity, mice were divided into 7 







Cage # mice Immunization Status Challenge 
A 5 Non-immune WT 
B 5 GST alone control WT 
C 5 GSTB80AA – strong responder WT 
D 4 GSTB80AA – weak responder WT 
E 5 Non-immune HlyIII KO 
F 5 GST alone control HlyIII KO 
G 3 GSTB80AA – weak responder HlyIII KO 
 
 Following challenge, mice were monitored for survival, parasitemia and 
hemoglobin levels using either complete blood count analysis of 50 µL tail blood or 2 µL 
blood into 0.5 mL Drabkin’s reagent dispensed in triplicate and absorbance read at 405 
nm. 
*Note: All emulsions except the final boost were made by vortexing the antigen and 
adjuvant, while the final emulsion was made using the syringe emulsifying technique 
which gave a more stable emulsion. 
Histology 
Mice were sacrificed and perfused with 25 mL PBS and organs were subsequently 
removed, rinsed in PBS and fixed in Z-fix (Anatech LTD, #174) and submitted for 
paraffin processing and staining of sections with Giemsa or H&E to Johns Hopkins 
Medical Laboratories Reference Histology.  
RNA isolation, cDNA preparation and qPCR analysis 
Tissues were snap-frozen and stored at -80°C until time for processing. 1mL of 
Trizol was added to each sample and then samples were placed on ice to thaw briefly. 
Samples were then transferred to homogenizing tubes and homogenized for 20-30 
seconds until frothy and homogenous. The samples were then incubated at room 
temperature for 5 min followed by addition of 200 µL chloroform and shaking to mix 
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thoroughly. Samples were centrifuged at 12,000 x g for 15 min at 4°C, the upper phase 
was transferred to a fresh Eppendorf tube and an equivalent volume of 70% ethanol was 
added to each tube. Samples were further purified using a PureLink RNA minikit (Life 
Technologies 12183018A). 
Reverse transcription was performed using 1 µg RNA as template with DNAse 
treatment for 15min followed by addition of 50 µM random hexamers and 0.8 mM 
dNTPs, 5 min incubation at 65°C. After being chilled on ice, a reverse transcription mix 
(1X RT buffer with MgCl2, 10 mM DTT, 40U RNAsin (Promega N2611)) was added 
along with 1 µL MuLV reverse transcriptase (Life Technologies N8080018) and samples 
were incubated at room temperature for 10 min, 42°C for 50 min, 70°C for 15 min, 
chilled on ice for 1 min and stored at -80°C. 
Multiplex qPCR with primers specific for P. berghei ANKA 18s rRNA were used 
to quantify parasite load in the following mouse tissues: brain, lung, liver, heart, kidney 
and spleen. Mouse hypoxanthine guanine phosphoribosyl transferase (hprt) functioned as 
the housekeeping gene. Primers were as follows: 
18s forward: 5’- GGAGATTGGTTTTGACGTTTATGCG-3’ 
18s reverse: 5’- AAGCATTAAATAAAGCGAATACATCCTTA-3’ 
HPRT forward: 5’- TCCCAGCGTCGTGATTAGC-3’ 
HPRT reverse: 5’- CGGCATAATGATTAGGTATACAAAACA-3’ 
Taqman probes (Integrated DNA Technologies, Coralville, IO): 
18s: 5’ 6-FAM/ZEN-CAATTGGTTTACCTTTTGCTCTTT-3’IBFC 
HPRT: 5’ Cy5-TGATGAACCAGGTTATGACC-3’BHQ-2 
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Reaction conditions for qPCR (384 well plate, 10 µL reaction): 1X IQ Multiplex Power 
Mix (BioRad, Hercules, CA), 0.2 µM 18s primers, 0.5 µM HPRT primers, 0.2 µM 
Taqman probes, and 3 µL cDNA.  
Mosquito Infections and Analysis 
Anopheles stephensi mosquitoes were maintained on a 10% sucrose solution at 
27C and kept on a 12 hour light/dark schedule. Day 3-5 old mosquitoes were fed on two 
subsequent days for 7-10 minutes per day on P. berghei ANKA WT or P. berghei ANKA 
HlyIIIKO infected mice with 5-10% parasitemia and 1-2% gametocytemia. Ten days post 
feeding mosquito midguts were dissected and stained with 0.1% mercurochrome and 
oocysts were counted. Eighteen days post feeding mosquito salivary glands were 
removed and sporozoites isolated and counted. In two experiments, naïve mice were 
exposed to infected mosquito bite prior to salivary gland dissection. Inoculated mice were 














Recombinant PfHlyIII Expression and Hypotonic Lysis in Xenopus Oocytes 
 While recombinant PfHlyIII had been previously expressed and partially purified 
as a bacterial lysate and shown to have hemolytic properties (70), we were interested in 
expressing a recombinant Plasmodium hemolysin protein in Xenopus laevis oocytes in 
order to confirm heterologous protein expression and pore-formation in a eukaryotic 
system.  
 We produced an RNA transcript encoding a myc and flag-tagged recombinant 
PfHlyIII (myc-PfHlyIII-flag, Figure 2.5A and B) and then injected the RNA into Xenopus 
oocytes along with water injection control and human aquaporin 1(hAQP1) RNA as a 
positive control for pore formation. Protein expression was monitored by Western Blot 
from 72 to 120 hours post-injection and myc-PfHlyIII-flag and hAQP1were expressed at 
all time points (Figure 2.5C). 
 Next we conducted swelling assays based on those previously described (77) by 
placing oocytes in a hypotonic solution and monitoring oocyte swelling and lysis using 
videomicroscopy. Oocytes expressing myc-PfHlyIII-flag swelled and ruptured in a 
similar manner to hAQP1-expressing oocytes compared to little or no rupture by water-
injected controls (Figure 2.6 A and B), suggesting the recombinant hemolysin was able to 
form pores and disrupt the membrane of the oocyte, making them susceptible to 
hypotonic lysis. Polyethylene glycol (PEG) can function as an osmotic protectant and has 
been used to determine pore-size of other hemolysins and pore-forming proteins in other 
studies (60). Addition of PEG of increasing molecular weight or hydrodynamic radii 
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resulted in decreased hypotonic lysis of myc-PfHlyIII-flag expressing oocytes (Figure 




Figure 2.5 In vitro transcription of recombinant P. falciparum hemolysin III (rPfHlyIII) 
RNA and expression of recombinant PfHlyIII protein in Xenopus oocytes. (A) DNA 
template for in vitro transcription of myc-PfHlyIII-flag RNA. (B) myc-PfHlyIII-flag 
transcription product on 1% agarose, 6.6% formaldehyde denaturing gel. (C) Protein 
expression of 10 pooled Xenopus laevis oocytes per injection treatment (DEPC H2O, 




Figure 2.6 Hypotonic lysis of rPfHlyIII expressing oocytes compared to hAQP1 and 
water injected controls upon incubation in water. (A) Quantification of intact oocytes 
over time, expressed as mean percent intact oocytes with SEM, average of three 
independent experiments using 5-10 oocytes per group in each experiment. (B) Time 




Figure 2.7 Addition of osmotic protectants prevents hypotonic lysis. Polyethylene glycol 
of increasing hydrodynamic radii protected rPfHlyIII expressing oocytes from hypotonic 
lysis in a buffer dependent manner: (water, 30 mM PEG1500, PEG3350, or PEG6000). 
Results are expressed as mean percentage of intact oocytes with SEM, from three 
independent experiments.  
Native HlyIII Expression Studies in P.falciparum 
 
 According to data from various studies in the PlasmoDB genome database, the 
transcriptome of P. falciparum strains including 3D7 show a cyclical expression of 
PfHlyIII mRNA, with peak mRNA levels at late trophozoite stages (78). We wanted to 
characterize the PfHlyIII protein expression pattern in asexual blood stages to determine 
whether soluble PfHlyIII could be present in the clinically relevant stages of Plasmodium 
infection and potentially be released upon parasite egress. Furthermore we hoped 
understanding protein expression of PfHlyIII would help us further elucidate the function 
of the protein in the parasite.  
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 In order to look at protein expression, we chose the first eighty amino acids of the 
PfHlyIII N-terminus as an epitope (Figure 2.8) as this region lacks any predicted 
transmembrane domains and is sufficient in length to be antigenic, whereas the remaining 
 peptide is predicted to have seven transmembrane domains and is not targetable.  
 
 
Figure 2.8 TMpred-generated prediction of transmembrane regions I to VII in PfHly III, 
N-terminal 80 amino acids indicated with no transmembrane domains. 
 
Next we designed constructs with glutathione-S-transferase (GST) or maltose 
binding protein (MBP) fused to the codon-optimized 80 amino acid N-terminus of 
PfHlyIII (Figure 2.9A, 2.10A), and also produced GST constructs using the P. berghei 
and P. chabaudi HlyIII homologous N-terminal regions (Figure 2.9 B,C). Using these 
constructs we expressed and GST and MBP fusion peptides in E. coli and purified them 




Figure 2.9 Plasmid construction and expression of GST- hemolysin III 80 amino acid N-
terminus fusion proteins for P. falciparum, P. berghei, and P. chabaudi. (A) GST-
expression construct for P. falciparum codon-optimized 80 amino acid N-terminus. (B) 
Expression constructs for P. berghei (B80AA) and P. chabaudi (C80AA). (C) SDS-
PAGE analysis of GSTF80AA expression and purification using Glutathione Sepharose 
4B beads, resulting in the purified 36 kDa fusion protein and free GST (25 kDa). Gel 
stained with Coomassie Brilliant Blue. (D) Western Blot of purification fractions using 




Figure 2.10 Plasmid construction and expression of MBP-tagged hemolysin III 80 amino 
acid N-terminus fusion protein for P. falciparum. (A) MBP-expression construct for P. 
falciparum codon-optimized 80 amino acid N-terminus. (B) SDS-PAGE analysis of 
MBPF80AA expression and purification using Amylose Resin, Eluting with 10 mM 
Maltose, resulting in the purified 53 kDa fusion protein and free MBP (43 kDa). Gel 













Having generated a P. falciparum HlyIII antigen, we immunized a rabbit (through 
Cocalico Biologicals), generating rabbit polyclonal antiserum, followed by verification 
and affinity purification using the MBPF80AA fusion peptide. Affinity purification of 
test bleed two (APTB2) using the MBPF80AA increased the specificity of the antiserum, 
resulting in clear detection of the recombinant MBPF80AA peptide (Figure 2.11A) and 
also detection of a unique band in P. falciparum asexual blood stages (25 kDa, Figure 
2.11B). The 25 kDa band was no longer recognized after competition with the 
GSTF80AA antigen, confirming specificity for PfHlyIII (Figure 2.11B, last panel). 
 
Figure 2.11 Generation of rabbit polyclonal antiserum against the 80 amino acid N-
terminus of PfHlyIII, affinity purification and detection of PfHlyIII in asexual blood 
stages. (A) Test bleed antiserum recognizes recombinant MBP-tagged PfHly III N-
terminal 80-amino-acid peptide (MBPF80AA, 53 kDa) compared to the preimmune 
serum. (B) Affinity-purified test bleed 2 (APTB2) recognizes a unique band of less than 
30 kDa in three strains of P. falciparum: 3D7, Dd2attB, and Dd2attB transfected with 
PfHly III-GFP; anti-GFP and APTB2 both recognize a unique higher-molecular-weight 
product in the PfHly III-GFP transfected strain. Competition with antigen ablates the 
unique band.  
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With the appropriate tool in hand, we used the affinity purified antiserum to 
determine stage specific expression of native PfHlyIII in asexual blood stages. Using 
synchronized parasite lysates at different time points (Figure 2.12A), we found that 
PfHlyIII was expressed in increasing amounts throughout the life cycle, with peak levels 
of expression at late trophozoite and schizont stages (Figure 2.12B). Furthermore, 
PfHlyIII was detected in both pellet and supernatant fractions (Figure 2.12C, Figure 
2.13A), suggesting the protein is present in both membrane bound and soluble forms in 
all asexual blood stages. 
 
Figure 2.12 Asexual Stage Specific Expression of Native PfHlyIII. (A) Light microscopy 
images of synchronized asexual blood stages of P. falciparum, 3D7 strain, Giemsa stain: 
Ring (R), early trophozoite (ET), late trophozoite/early schizont (T/S) and late schizont 
(LS). Whole cell parasite lysates from these cultures were used for the detection of native 
parasite PfHlyIII by Western Blot using rabbit polyclonal antiserum (APTB2), with 2.5 
µg of total protein loaded per well. (B) Native PfHlyIII (25 kDa) was detected in all 
asexual blood stages.(C) Native PfHlyIII was present in pellet (P) and supernatant (S) 
fractions in all stages. 
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Treatment of the P. falciparum pellet fraction with a variety of solvents (Figure 
2.13B) resulted in complete breakdown of the peptide in strong base (100 mM NaOH), 
very little release of the membrane bound form in a weak base (100 mM Na2HCO3), a 
moderate amount of solubilized protein with non-ionic detergent (1% Triton-X) and 
complete solubilization of the membrane bound protein with an ionic detergent (1% 
sodium dodecyl sulfate). These results confirm native PfHlyIII is present as both a 
soluble and integral membrane protein in all asexual blood stages, including mature 
schizonts. 
 
Figure 2.13 Native PfHlyIII is expressed in asexual stages in soluble form and also 
integrally associated with the membrane. (A) Whole cell lysate (WC), pellet or 
membrane fraction (P) and supernatant or cytosolic fraction (S) were run on an SDS-
PAGE denaturing gel and either stained with Coomassie Brilliant Blue (left panel) or 
probed for native PfHlyIII expression by Western Blot (right panel). (B) Pellet fractions 
were treated with different solvents to test association of protein with the membrane, 
including 100 mM NaOH, 100 mM Na2CO3, 1% Triton-X, and 1% SDS.  
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 In addition to looking PfHlyIII expression in asexual blood stages, we were also 
interested in determining expression levels of PfHlyIII in gametocytes and mosquito 
stages, specifically sporozoites to determine whether this protein was important for 
transmission stages of the parasite. In gametocyte cultures collected days 11, 14, and 17 
post initiation of gametocytogenesis (days 4, 9, and 12 post treatment with N-
acetylglucosamine), PfHlyIII was found to be expressed in early stages as a 25 kDa and 
36 kDa protein (Figure 2.14, first panel). However the asexual stage specific merozoite 
surface protein was also present in the earlier gametocyte preparations, despite 
purification attempts (Figure 2.14, second panel), suggesting that there was some asexual 
stage protein carried over in the gametocyte lysate, which may indicate that the 25 kDa 
band in the APTB2 probed blot may be from asexual stages. Nevertheless, there is a 
unique 36 kDa band present in the gametocyte prep that was not observed in blots from 
asexual stages, suggesting PfHlyIII may be expressed in gametocytes in a longer form 
(closer to the predicted molecular weight of 33 kDa). 
 In a separate experiment, P. falciparum sporozoites were purified from salivary 
glands and probed for PfHlyIII expression. Even at the highest concentration of 
sporozoite whole cell lysate (100,000 sporozoites), PfHlyIII was not detected, compared 
to a high abundance circumsporozoite protein (CSP) that was detected at even very low 






Figure 2.14 Expression of PfHlyIII in early, middle and late stage P. falciparum 
gametocytes. Gametocytes were harvested at day 11, day 14, and day 18 post-
gametocytogenesis. 
 
Figure 2.15 Circumsporozoite (CSP) and PfHlyIII expression in P. falciparum 
sporozoites whole cell lysates diluted serially from 100,000 to 100 sporozoites. 
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In order to address the question of whether Plasmodium hemolysin III is a 
virulence factor in the parasite that can contribute to pathogenesis in the host, we turned 
to a murine malaria model, Balb/c mice infected with P. berghei ANKA. We chose this 
model due to the chronic nature of the disease and the ability to measure the progression 
of anemia in these mice. We wanted to determine whether the P. berghei homolog of 
PfHlyIII, PbHlyIII, was influential in the development of anemia in this mouse model. 
 We took two approaches to address the question of hemolysin associated 
virulence. The first involved knocking out the PbHlyIII gene and comparing the virulence 
and development of anemia in mice infected with either wild type or PbHlyIII KO P. 
berghei. We predicted that parasites lacking hemolysin III would be less virulent and 
cause less anemia in mice. Our second approach involved immunizing mice against 
PbHlyIII and then challenging them with parasites to determine whether antibodies 













Genetic knockout studies in P. berghei and attempts in P. falciparum 
For genetic knockout of pbhlyiii, we modified the pL0001 plasmid containing the 
TgDHFR selection cassette by adding two homology arms, one including part of the 5’ 
UTR of pbhlyiii and the other the end of the gene and part of the 3’ UTR. These 
homology regions were chosen in order to completely disrupt the gene, essentially 
knocking it out upon successful homologous recombination (Figure 2.16A and B). We 
were successful in obtaining pbhlyiii knockouts in two different parasite strains. We 
originally knocked out PbHlyIII in the WT P. berghei ANKA parasite (PbHlyIII KO1), 
and later repeated the knockout using the P. berghei ANKA GFP-Luc parasite (PbHlyIII 
KO2) in order to strengthen the case for our knockout phenotype. Upon clonal dilution 
we obtained at least one clone from each knockout transfection. The modified loci were 
verified for positive integration by PCR (Figure 2.17) and Southern blotting (Figure 
2.18). 
 





Figure 2.17 PCR verification of drug cassette insertion and disruption of PbHlyIII locus 
from genomic DNA isolated from wild type (WT), PbHlyIII KO1 (KO1), GFP-luciferase 
(GL), or PbHlyIII KO2 (KO2) P. berghei parasites. 
 
Figure 2.18 Southern Blot verification of drug cassette insertion and disruption of 
PbHlyIII locus using hindIII digest of genomic DNA from wild type (WT), PbHlyIII 
KO1 (KO1), GFP-luciferase (GL), or PbHlyIII KO2 (KO2)P. berghei parasites and a 
digoxigenin labeled probe (3’ homology arm used in the targeting construct). 
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In order to gain a deeper understanding of the functional role of the Plasmodium 
falciparum HlyIII protein and compare it to the P. berghei HlyIII knockouts, we also 
designed plasmids for genetic knockout or disruption of the hemolysin III gene in P. 
falciparum (Figure 2.19). Unfortunately our attempts to disrupt or knockout the 
hemolysin-coding gene in P. falciparum were unsuccessful, with no parasites detected up 
to 60 days post drug-selection. Due to the low efficiency and long schedule of P. 
falciparum knockout strategies at the time, we decided to focus on characterization of the 
PbHlyIII KO parasites. 
 
 
Figure 2.19 Genetic knockout (A) and single crossover disruption plasmid designs for P. 




Virulence and Anemia in PbHlyIII KO vs WT P. berghei infected mice 
 In our first experiment comparing PbHlyIII KO1 versus WT P. berghei infected 
Balb/c mice we were surprised to find that the knockout parasite was more virulent than 
the wild type, killing mice between 7-15 days post infection compared to 22-25 days for 
the wild type infected mice (Figure 2.20A). We did not find a difference in parasite 
growth rate as both parasitemia and parasite densities were comparable between both WT 
and PbHlyIII KO1 infected groups (Figure 2.20B and C). Finally, because all but one 
KO1 infected mouse died before the mice developed anemia (day 14), we were unable to 
measure a significant difference in anemia between the two groups. For the single KO1 
infected mouse that survived until day 30, we noticed a slightly higher hemoglobin level, 
but were unable to find a statistically significant difference (Figure 2.20D). 
 We were interested in determining whether this virulence phenotype would be 
repeated in other mouse backgrounds, so we also compared the WT and PbHlyIII KO1 
parasite infections in C57/Bl6 mice. In two separate experiments we found no difference 
in survival in these mice (Figure 2.21A and C), but did notice a significant difference in 
parasite growth rate, with PbHlyIII KO1 parasites multiplying more quickly than WT P. 
berghei (Figure 2.21B and D). 
 While the virulence phenotype was intriguing and suggestive of further study, due 
to the early death of PbHlyIII KO1 infected mice, we were unable to compare significant 
differences in anemia in Balb/c mice, and thus turned to an alternative approach, 





Figure 2.20 Survival, parasitemia and hemoglobin levels in 16 week female Balb/c mice 
infected i.p. with 1x10
5 
WT or PbHlyIII KO1 P. berghei infected erythrocytes. (A) 
Survival of mice up to day 30 post infection. (B) Parasitemia counted by Giemsa stained 
bloodfilm beginning day 3 post infection and continuing every other day until day 27. (C) 
Hemoglobin levels obtained from complete blood count analysis on days 5, 10, 15, and 
20 post infection. (D) Parasite densities, calculated as a function of total parasites per 
microliter, estimated from parasitemia multiplied by the total red blood cell count for 




Figure 2.21 Survival and parasitemia of C57/Bl6 mice infected i.p. with 1x10
5 
WT or 
PbHlyIII KO1 P. berghei infected erythrocytes: two independent experiments. 
(Experiment 1: A and C) (A) 12-week old C57/Bl6 mice die on day 7 in both WT and 
KO1 infected groups (C) KO1 parasites multiply faster than WT. (Experiment 2: B and 
D) (B) 9-week old C57/Bl6 mice die between day 6-9 post infection in both WT and KO1 







Immunization against PbHlyIII followed by parasite challenge 
 Our second approach to determine the contribution of Plasmodium hemolysin to 
anemia in the mammalian host involved immunization of mice against the P. berghei 
hemolysin III homology to determine whether antibodies against HlyIII could protect 
mice from developing severe anemia. We chose to express and purify a GST-tagged 80 
amino acid N-terminus of PbHlyIII (Figure 2.9B) as our hemolysin-specific antigen as 
we had successfully used the P. falciparum construct for our earlier antibody studies. We 
adapted a prime-boost strategy from the Thermoscientific Pierce Antibodies online 
protocol for mouse immunization (79) using 50 µg of our GSTB80AA fusion peptide or 
GST alone as a control emulsified with Complete Freund’s adjuvant (CFA) for the 
priming and Incomplete Freund’s adjuvant for the subsequent boosts (Figure 2.22A).  
We tested the sera reactivity of the immunization groups by Western Blotting 
whole cell P. berghei parasite lysate and found that there was very little reactivity after 
the first two boosts (test bleed 1, data not shown). Thus we boosted a third time, using a 
syringe method rather than vortexing for forming the emulsion, and found that test bleed 
2 showed reactivity in all immunized groups (Figure 2.22B). Specifically the non-
immunized groups showed no distinct bands, whereas the GST-immunized group had a 
25 kDa band and the GSTB80AA-immunized group had two bands, one 25 kDa band 
likely associated with GST, and another slightly smaller band that was likely specific to 
the hemolysin peptide. We observed that there was some variability in sera reactivity, 
especially within the hemolysin III-immunized group, with some mice showing much 
stronger sera reactivity than others.  
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Based on the sera reactivity in the different groups, we divided the non-
immunized and GST-control groups into 2 groups of 5 mice each for WT or PbHlyIII 
KO1 P. berghei ANKA challenge (Figure 2.22C first and second panels), and we divided 
the GSTB80AA immunized group into three separate groups for challenge: one ‘strong’ 
responder group for WT challenge and two ‘weak’ responder groups for WT or HlyIII 
KO1 P. berghei challenge (Figure 2.22C third panel). We used the PbHlyIII KO1 parasite 
challenge as a control, hypothesizing that PbHlyIII immunization would have no effect 
on survival or disease in the PbHlyIII KO1 challenged mice. Following challenge on day 
97 we monitored the mice daily for survival and parasitemia by bloodfilm. Hemoglobin 
levels were monitored daily in Drabkin’s reagent and complete blood count analysis was 






Figure 2.22 Immunization schedule, sera reactivity and experimental groups for HlyIII 
immunization and parasite challenge. (A) Immunization schedule with priming in 
Complete Freund’s Adjuvant (CFA) followed by three boosts in Incomplete Freund’s 
Adjuvant (IFA), test bleed and challenge. (B) Serum from each mouse was tested for 
reactivity against WT P. berghei whole cell parasite lysate after test bleed: non-
immunized (10 mice, no distinct bands), GST control group (10 mice, 25 kDa band), 
GSTB80AA group (12 mice*, 25 kDa band and one distinctly lower than the GST 
associated band). (C) Based on sera reactivity, mice were split into 2 groups per 
immunization group for WT or HlyIII KO P. berghei challenge, with the exception of the 
GSTB80AA immunized mice which were divided into three groups, a strong responder 
group for WT challenge and two weak responder groups for WT or HlyIII KO challenge. 
*Three mice died in GSTB80AA group after the third boost, cause of death unknown. 
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Figure 2.23 summarizes the parasitemia, hemoglobin levels and survival of both 
WT and KO1 challenged groups. Overall we found that the immunization had no 
significant effect on parasite growth, hemoglobin levels, or survival, with the exception 
of the GSTHlyIII immunized, strong responder group, which overall suppressed 
parasitemia (Figure 2.23A) but also resulted in shorter time to death post-challenge 
(Figure 2.23E). Because the GSTHly strong responder mice died so quickly, we were 
unable to calculate a significant difference in parasitemia or anemia, though the single 
mouse that survived past day 15 did have much lower parasitemia and less anemia than 
the control groups and ‘weak’ responders (Figure 2.23A and C).  
Severe weight loss was noted for these mice as early as three days post challenge 
and post-mortem necropsy of the strong responder mice revealed the development of 
severe fibrosis in the abdominal cavity, suggesting an adverse reaction to the 
immunizations and subsequent challenge that may have contributed to their early death. 
We hypothesized that using the same intraperitoneal route of immunization and challenge 
may have contributed to inflammation and the aforementioned fibrosis.  
Due to the complicated results of immunization we were unable to conclude 
whether antibody strong response to PbHlyIII was protective for these mice and able to 
suppress parasitemia and protect against the development of anemia. Neither GST alone 
nor GSTHly weak responders were able to suppress parasitemia and both developed 
similar levels of anemia and died at similar rates to non-immunized mice after challenge 
with WT P. berghei. We did note that a majority of the KO1 P. berghei challenged mice 
died between day 8 and 15 regardless of immunization status (Figure 2.23F), again 
confirming our early death KO phenotype. 
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              WT Challenge             HlyIII KO1 Challenge 
 
Figure 2.23 Parasitemia, hemoglobin levels, and survival of WT or PbHlyIII 
KO1 challenged mice after no immunization (NI), immunization with GST alone 
(GST), or GSTB80AA fusion peptide , strong or weak responders (GSTHly strong or 
GSTHly weak). (Left panel: A, C, E) Parasitemia, hemoglobin levels and survival of WT  
P. berghei challenged mice. (Right panel: B, D, F) Parasitemia, hemoglobin levels and  
survival of PbHlyIII KO1 P. berghei challenged mice. 
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 As neither the WT vs KO approach, nor the immunization approach were 
successful in answering our virulence question, we decided to focus on the early death 
phenotype of the knockout parasite in hopes of uncovering the functional role of 
hemolysin III in the parasite itself and understanding why lacking hemolysin resulted in a 
more virulent parasite. 
Essentiality of PbHlyIII in the malaria life cycle 
First, we wanted to determine whether the gene was essential for all stages of the 
murine parasite, thinking that if the HlyIII KO parasite was unable to complete any 
particular stage of its life cycle, we might have a further clue to the functional role of this 
protein in the parasite. To that end, we had confirmation that the hemolysin gene was 
inessential for asexual blood stages due to the positive transfection results and 
observations of asexual blood stage parasites by Giemsa stained blood film (Figure 2.24). 
We also observed that the HlyIII KO1 and HlyIIIKO2 parasites could both form male and 
female gametocytes (Figure 2.24, right panel). Of note, we did observe that the HlyIIII 
KO parasites tended to have larger vacuoles in the asexual blood stages (Figure 2.24, left 





Figure 2.24 Wild type or HlyIII KO P. berghei ANKA blood stage parasites appear 
morphologically comparable by Giemsa stained bloodfilms, with an observation of more 
vacuoles present in the knockout asexual parasites compared to WT. Asexual blood 
stages with ring, trophozoite, and erythrocyte multiply-infected with trophozoites (left 
panel) and sexual blood stages, male and female (right panel). 
 
Once we confirmed that the knockout parasites could form gametocytes, we then 
needed to ascertain whether these HlyIII KO gametocytes were infectious to mosquitoes 
and could continue the parasite progression through the mosquito stages, resulting in 
infectious sporozoites. We therefore fed Day 5 Anopheles stephensi mosquitoes on either 
WT or HlyIII KO1 P. berghei ANKA infected Balb/cJ mice with at least one gametocyte 
per field (~150-200 red blood cells) confirmed by bloodfilm and monitored the 
mosquitoes for oocyst development and sporozoite production (Figure 2.25A). 
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 In three independent experiments, we observed that the HlyIII KO1 parasite 
made consistently fewer and smaller oocysts per mosquito midgut (Figure 2.25 B-D) and 
that the sporozoite yield from salivary glands was at least ten-fold less compared to the 
WT P. berghei ANKA strain (Figure 2.25B). Furthermore, the WT and KO1 infected 
mosquitoes were allowed to feed on naïve mice in at least two independent experiments, 
with only the WT inoculated mice developing patency between day 4 and day 7 post feed 
(Figure 2.25B).  
In the third experiment, we significantly increased the number of salivary glands 
dissected in order to obtain sufficient WT and HlyIII KO1 sporozoites to infect mice 
directly intravenously and check for patency, but were still unable to obtain sufficient 
sporozoites in the knockout group for injection (<2000 total estimated, only a single 
sporozoite counted out of multiple dilutions and more than fifty fields).  
Thus we found that the HlyIII KO1 parasite was not essential for mosquito stage 
development but did have a significant growth defect, resulting in fewer oocysts and less 
sporozoites in the salivary glands. We were unable to determine essentiality in the liver 
stage due to insufficient sporozoite recovery from the salivary glands. We did observe 
that the male to female gametocyte ratio was higher in the KO1 parasite group compared 




Figure 2.25 PbHlyIII KO1 P. berghei oocyst and sporozoite counts from mosquitoes 
compared to WT P. berghei following bloodfeeding on infected mice in three 
independent experiments. (A) Experimental strategy for infecting mosquitoes with P. 
berghei WT or HlyIII KO1 parasites and assessment of oocyst and sporozoite 
development. (B) Quantitative results for oocysts and sporozoites determined from 
midgut and salivary gland dissections. (C and D) Number of oocysts per midgut 




Dissecting the Lethality Phenotype 
We were still curious to understand why the PbHlyIII KO parasites were more 
lethal and to confirm that our virulence phenotype was real and related to disruption of P. 
berghei HlyIII. In order to confirm our phenotype we chose to knockout the same gene in 
a separate P. berghei strain expressing GFP-luciferase, confirming the separate knockout 
by both PCR and Southern blot as mentioned above (Figure 2.17, 2.18). When we 
repeated the previous experiment with infection of Balb/c mice with 1x10
5
 P. berghei 
infected erythrocytes, we found that the second knockout parasite PbHlyIII KO2 was 
equally lethal to the first, killing Balb/c mice between day 8-12 compared to day 18-22 
for GFP-luc WT P. berghei (Figure 2.26B). 
 Increased passaging of the original PbHlyIII KO1 parasite through mice seemed 
to slightly decrease the virulence, with some mice surviving closer to the WT (Figure 
2.26A), but as we were unable to successfully passage the PbHlyIII KO parasite through 
the mosquito, we were unable to confirm this observation. We did note a slight decrease 
in parasitemia for the PbHlyIII KO1 infected mice that survived past day 10 (Figure 
2.26C) that might have played a role in their survival, but the parasitemia quickly rose to 
match the WT parasitemia by day 15 and the two mice went on to die several days earlier 
than the WT infected mice. Regardless, infection with either PbHlyIII knockout parasite 
resulted in significantly earlier death than infection with either the WT or GFP-luc P. 
berghei ANKA strains (Figure 2.26A, B). We did not find a significant difference in 
parasite growth rate or weight loss between the wild type and knockout groups (Figure 
2.26C, D). However, HlyIII KO infected mice had slightly but not significantly higher 




Figure 2.26 Survival, parasitemia and weights of 19 week old Balb/c mice infected with 
1x10
5
 P. berghei infected erythrocytes (WT, PbHlyIII KO1, GFP-luc, or PbHlyIII KO2). 
Left panel: Balb/c mice infected with WT compared to PbHlyIII KO1 P. berghei ANKA 
(A, C, E) Survival, parasitemia and weights monitored between day 3 and day 30 post 
infection. Right panel: Balb/c mice infected with GFP-luciferase compared to PbHlyIII 
KO2 P. berghei ANKA (B, D, F) Survival, parasitemia, and weights monitored between 
day 3 and day 30 post infection. The Log-Rank test showed significant differences in 
survival between the WT and KO1 groups and the GFP-luc and KO2 groups with p-
values <.05. An unpaired t-test showed a significant difference between WT and KO1 
parasitemia on day 13 post infection, p-value <.05. 
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Once the increased lethality phenotype of our PbHlyIII KO was confirmed, we 
then turned to histology and qPCR methods in order to determine cause of death. We had 
observed that our PbHlyIII KO infected Balb/c mice looked similar to the experimental 
cerebral malaria (ECM) model of P. berghei ANKA infected C57/Bl6 mice in that the 
mice experienced seizures. As ECM is thought to be the result of parasite sequestration 
and vessel occlusion, we hypothesized knocking out a pore-forming protein like 
hemolysin III might result in altered deformability and increased sequestration of the 
parasitized erythrocytes, which might cause increased vascular occlusion and 
hemorrhage. We decided to infect mice with WT or PbHlyIII KO parasites and harvest 
organs for histology to look for parasite sequestration and hemorrhage, and concurrently 
measure parasite load with qPCR to quantitatively determine whether HlyIII KO 
parasites were sequestering in particular organs.  
We infected Balb/c mice with either WT or PbHlyIII KO1 P. berghei parasites 
and sacrificed the mice on D7 post infection, the day that PbHlyIII KO infected mice had 
begun to die in our earlier experiments. The day of sacrifice we immediately harvested 
blood as well organs including heart, lung, kidney, liver, spleen, and brain for formalin 
fixation or RNA isolation. Three independent experiments were completed, one with 
perfusion to determine sequestered parasite load. qPCR of 18s copy number in the 
perfused organs showed significantly increased parasite load in both the spleen and the 
heart in the KO infected mice compared to WT (Figure 2.27) suggestive that there was 
increased parasite clearance or sequestration in these organs. While no other organs had 
significant differences in parasite load between the WT and PbHlyIII KO groups, all 




Figure 2.27 Parasite load in Balb/c mouse brain, lung, liver, spleen, kidney and heart on 
Day 7 post infection with WT or PbHlyIII KO1 P. berghei, based on 18s copy number 
measured by qPCR.. Mouse tissues were perfused with PBS followed by RNA isolation 
and cDNA synthesis. Equivalent RNA concentrations from both WT and KO1 tissues 
were used to ensure equivalent comparisons. An unpaired t-test was used to analyze each 
organ group and only spleen and heart were found to have significant differences 
between WT and KO1 groups, p-values <.05, n=3 mice per group. 
 Histology of the different organs revealed evidence of brain hemorrhage (Figure 
2.28), edema, fibrosis and immune cell infiltration in the lung, and increased parasitized 
and uninfected erythrocytes as well as hemorrhage and fibrosis in the spleen (Figure 
2.29) in the PbHlyIII KO compared to the WT P. berghei ANKA infected mice. 
Histology of other tissues including heart, liver and kidney were comparable between 
both WT and KO groups (Figure 2.30). These general trends were seen for both perfused 
and non-perfused tissues in all three experiments. However, blinded scoring of brain 
sections in the third experiment without perfusion suggested some mixed results, with 




Figure 2.28 H&E stained brain sagittal sections from PbHlyIII KO P. berghei ANKA 
infected Balb/c mice. Brain sections from PbHlyIII KO infected mice had varying levels 
of peri-mortem hemorrhage in the cerebral cortex, brainstem and cerebellum. (A and B) 
10x and 20x views of a peripheral brainstem hemorrhage. (C and D) 10x and 20x views 
of a central hindbrain hemorrhage. (E) 20x view of a small cerebral cortex hemorrhage. 
(F) 10x view of a small cerebellum hemorrhage. Representative images from two 




Table 2.1 Scoring of WT or PbHlyIII KO Mouse Brain Hemorrhage 
   # hemorrhages in four brain sagittal sections 
WT 4 8 13 3 
PbHlyIII 
KO1 
10 10 4 - 
GFP Luc 20 10 15 - 
PbHlyIII 
KO2 
3 10 7 - 
mouse 1 2 3 4 
 
 Specifically brain hemorrhage was noted in the brainstem and cerebellum (Figure 
2.28), with a few hemorrhages also seen in the cerebral cortex. Though the final histology 
experiment suggested the GFP-Luc and to some extent the WT P. berghei infected mice 
had several brain hemorrhages, overall our observations over the course of three 
experiments were that the PbHlyIII KO infected mice had increased levels of brain 
hemorrhage compared to the WT strains. In particular, we suspected that brainstem 
hemorrhage might be a cause of death but this hypothesis requires further investigation. 
 Other striking findings included increased edema and fibrosis in the lungs seen in 
one of the two non-perfused biologic replicates (Figure 2.29D) as well as fibrosis and 
hemorrhage in the spleen (Figure 2.29B) in the PbHlyIII KO groups compared to the WT. 
Other tissues including kidney, liver and heart showed no evidence of increased parasite 






Figure 2.29 H&E stained spleen and lung sections from WT or PbHlyIII KO P. 
berghei ANKA infected Balb/c mice. (Top panel) PbHlyIII KO infected mouse spleens 
(B) have increased amounts of fibrosis, hemorrhage and both infected and uninfected 
erythrocytes compared to WT infected mice (A). (Bottom panel) Lung sections from 
PbHlyIII KO (D) infected mice showed increased levels of fibrosis, edema and immune 
cell infiltration compared to WT infected mice (C) Representative images from two 








Figure 2.30 H&E stained heart, liver and kidney sections from WT or PbHlyIII KO 
P. berghei ANKA infected Balb/c mice. Heart sections (top panel), liver sections 
(middle panel) and kidney sections (bottom panel) showed no striking differences in 
pathology between WT and PbHlyIII KO P. berghei infected mice. All tissues contained 





Following up on our earlier observation of an increasing number of vacuoles seen 
in the PbHlyIII KO parasites compared to the WT on Giemsa stained bloodfilms (Figure 
2.24), we next pursued higher resolution visualization of these parasites using 
transmission electron microscopy (TEM). Both WT and PbHlyIII KO1 parasitized red 
blood cells were harvested by cardiac puncture, washed and immediately fixed for TEM. 
Using this technique we observed some striking phenotypic differences between the WT 
and KO parasites. WT P. berghei asexual stage parasites are depicted in Figure 2.31.  
 
 
Figure 2.31 Transmission electron microscopy images of wild type P. berghei ANKA 
parasites, asexual blood stages. (A-C) Three individual wild type (WT) asexual stage 
parasites exhibit varying amounts of hemoglobin digestion and variations of normal 
parasite morphology. Nucleus (n) and hemoglobin (Hb) digestion as indicated. 
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 First we observed that the PbHlyIII KO asexual stage parasites had clear 
aberrations in membrane structure and vacuole formation. While some of the phenotypes 
were minor with some undulating membranes and small vacuolar formations on the 
periphery of the parasite (Figure 2.32A), other parasites possessed large extra vacuoles 
either on the periphery (Figure 2.32C) or closer to the nucleus (Figure 2.32B and D). In 
some cases these vacuoles were seen at the juncture between two parasites (Figure 
2.32E), while others completely contained the parasites (Figure 2.32F). Overall the 
knockouts seemed to have a loss of membrane integrity with accumulation of vacuoles 
and empty space in the parasite and in some cases the parasitophorous vacuole. 
 Our second observation was that many of the parasitized erythrocytes had 
drastically altered shapes resulting from either self-closure or some other mechanism, 
deformed by extracellular medium (Figure 2.33).  
 Finally we also noted that in many cases the parasitophorous vacuole seemed to 
be attached to the host plasma membrane and deform the erythrocyte surface along the 
surface of the parasite (Figure 2.34). We also found that in some cases we observed 
budding occurring at the erythrocyte plasma membrane surface (Figure 2.34 C and D). 
 Despite all of these major disturbances in parasite morphology, the PbHlyIII KO 
asexual blood stage parasites were successful at replicating and as stated earlier did not 
seem to have a defect in parasite growth rate in vivo. Furthermore the knockout parasites 
also seemed to be able to take up and degrade hemoglobin as evidenced by the presence 




Figure 2.32 Transmission electron microscopy images of PbHlyIII KO P. berghei 
ANKA parasites depicting membrane disturbances and vacuolar aberrations (black 
arrows) (A) minor membrane disturbance (B) severe vacuolar aberration (C) Peripheral 
vacuole (D) Perinuclear vacuole (E) Vacuole between two parasites (F) Two parasites 




Figure 2.33 Transmission electron microscopy images of PbHlyIII KO P. berghei 
ANKA asexual blood stages depicting change in shape of erythrocyte with uptake of 
extracellular medium (asterix). (A and B) Serial sections of the same parasitized 
erythrocyte displaced by extracellular medium. (C and D) Different parasitized 






Figure 2.34 Transmission electron microscopy images of PbHlyIII KO P. berghei 
ANKA asexual blood stages with erythrocyte membrane deformed by parasitophorous 
vacuole or parasite and budding from the host plasma membrane. (A and B) Asexual 
blood stage parasites with parasitophorous vacuoles attached to and deforming the 
erythrocyte surface (arrows). (C and D) Asexual blood stage parasites, each clearly 
deforming the erythrocyte membrane with budding from the erythrocyte plasma 




DISCUSSION AND CONCLUSIONS 
The presence of a hemolysin like gene in Plasmodium was an intriguing find for 
our lab as we were curious why a parasite with an erythrocytic stage would encode a 
cytolytic protein that is similar to hemolytic proteins found in bacteria. Initial work done 
to characterize a recombinant Plasmodium hemolysin III (recPfHlyIII) in our lab revealed 
that recPfHlyIII was a pore-forming protein with hemolytic activity. Inhibition of 
recPfHlyIII was accomplished partially with a potassium channel inhibitor glibenclamide, 
whereas addition of sufficient size polyethylene glycol was able to completely inhibit 
hemolysis, while still allowing the protein to bind to the surface of erythrocytes. In a 
separate study a recombinant GFP tagged PfHlyIII was overexpressed in a P. falciparum 
strain, and live fluorescence microscopy supported a digestive vacuole localization for 
recPfHlyIII-GFP. This evidence supported our hypothesis that PfHlyIII was a functional 
cytolytic protein and could be a potential virulence factor in the mammalian host by 
damaging host erythrocytes and contributing to severe malaria anemia.  
We further modified our hypothesis based on the localization results to state that 
soluble hemolysin in the food vacuole could be released upon parasite egress and damage 
bystander erythrocytes. In order to test our new hypothesis we developed the following 
aims: (1) confirm heterologous pore-formation in Xenopus oocytes, (2) characterize 
native hemolysin III protein expression in Plasmodium falciparum, and (3) determine 
whether the P. berghei HlyIII homolog can act as a virulence factor, contributing to 
severe malaria anemia in a mouse model of malaria. 
We successfully expressed recPfHlyIII in Xenopus oocytes and demonstrated 
sensitivity of recPfHlyIII expressing oocytes to hypotonic lysis similar to those 
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expressing human aquaporin 1 (hAQP1), a well described water channel (77). The water 
injected controls were stable up to one hour, whereas hAQP1 and recPfHlyIII expressing 
oocytes ruptured within the first 1-15 minutes in hypotonic solution suggestive of 
disruption in the surface membrane resulting in sensitivity to hypotonic lysis. As further 
evidence for pore formation we repeated the experiment in the presence of varying sizes 
of the osmotic protectant polyethylene glycol and found that larger PEG molecules were 
able to protect the oocytes from hypotonic lysis, similar to what was found with 
recPfHlyIII expressed and enriched from E. coli (70). Based on this heterologous 
expression of recPfHlyIII in eukaryotic Xenopus oocytes, we predict that Plasmodium 
hemolysins are expressed natively as pore-forming proteins, similarly to what has been 
shown for bacterial hemolysins.  
In order to characterize native protein expression of PfHlyIII, we expressed and 
purified a GST-fusion peptide with the 80 amino acid N-terminus of PfHlyIII and used 
this antigen to generate rabbit polyclonal antisera to PfHlyIII. Affinity purified antisera 
was used to probe parasite lysate and demonstrated soluble, native PfHlyIII protein 
expression in all asexual blood stages of P. falciparum. Using synchronized parasite 
lysates, we also demonstrated increased expression of PfHlyIII as parasites matured from 
ring to schizont stages. Early and middle gametocyte stages showed evidence of PfHlyIII 
expression, whereas later gametocyte stages did not have PfHlyIII specific bands by 
Western Blot. P. falciparum sporozoites also lacked PfHlyIII expression by Western Blot 
even at very high numbers. Overall we have evidence for native PfHlyIII expression in 
all blood stages except late stage gametocytes, suggesting an important functional role for 
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PfHlyIII in these stages, particularly in later schizont stages when the protein is most 
abundant.  
Furthermore we found that PfHlyIII was not detectable in as many as 100,000 
sporozoites probed by Western Blot, although it is possible that PfHlyIII is a very low 
abundant protein in these stages and that we were unable to detect it with our antibody in 
this assay. Regarding the solubility of native PfHlyIII, we found that the protein was 
expressed in asexual blood stages of Plasmodium as both a soluble and integral 
membrane protein as evidenced by the detection of PfHlyIII in cytosolic and membrane 
fractions, with release from the membrane completed with ionic detergent. Thus we have 
evidence to support our hypothesis that soluble PfHlyIII is present in asexual blood 
stages and may be released upon schizont rupture and present in patient plasma. However 
we were unable to specifically test malaria patient plasma samples for presence of 
PfHlyIII antibodies due to the high background signal of patient plasma with our 
MBPF80AA antigen in ELISA studies (data not shown), and further work needs to be 
done to demonstrate that native PfHlyIII is present in malaria patient plasma and could be 
available to damage nearby erythrocytes. 
With evidence for soluble Plasmodium hemolysin expressed in asexual blood 
stages, we sought to find direct evidence for Plasmodium hemolysin contributing to 
severe malaria anemia through destruction of erythrocytes. Attempts to disrupt the 
hemolysin gene in P. falciparum were unsuccessful with no parasites present after fifty 
days of drug selection. In light of the time-consuming methods then available for gene 
disruption in P. falciparum, we turned to a mouse model of malaria P. berghei ANKA in 
Balb/c mice to try to answer our virulence question, using two separate approaches: one 
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involving knocking out the hemolysin homolog in P. berghei (PbHlyIII), and the other 
immunization against PbHlyIII. 
Immunization of mice with a GST-tagged PbHlyIII N-terminus fusion peptide 
resulted in varying levels of sera response based on Western Blotting of parasite lysate 
with test bleed sera. In the end however, immunization against PbHlyIII resulted in little 
to no protection from parasitemia or anemia following challenge, with mice mounting the 
strongest immune response dying early with low parasitemia, likely due to sepsis or 
another complication resulting from the method of immunization and challenge. Weak 
responders survived to day 20 but developed similar anemia to GST immunized or non-
immunized controls. A different route of immunization and challenge may prevent early 
death by reducing intraperitoneal inflammation. Furthermore using syringe emulsion 
techniques may provide a more stable emulsion than the vortex technique which may also 
result in fewer boosts required for a good immune response and less predilection for 
intraperitoneal inflammation (80). Once repeated we may find that a strong immune 
response against PbHlyIII does protect from parasitemia and even severe anemia, but this 
hypothesis remains to be tested. 
Knocking out the P. berghei hemolysin homolog PbHlyIII yielded an unexpected 
phenotype. Rather than reducing the virulence of the parasite, PbHlyIII KO parasites 
were found to be more lethal than their WT counterparts, killing Balb/cmice 
approximately 10 days earlier than predicted, similar to what is usually seen in the 
experimental cerebral malaria model with C57/Bl6 mice (including some visible seizing 
of PbHlyIII KO P. berghei infected mice). While the early death phenotype precluded 
any anemia studies of the knockout group, the increased lethality of the parasite was 
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fascinating and proved difficult to interpret. Parasite growth rates as measured by both 
parasitemia and parasite density were the same in both WT and PbHlyIII KO infected 
Balb/c mice, whereas in C57/Bl6 mice, we did note a slight but significant increase in 
parasite growth rate that may be a result of either differential sequestration of infected 
erythrocytes, increased rate of invasion or perhaps an increased number of singly-infected 
erythrocytes. In Balb/c mice however it was particularly noted while studying the TEM 
images that there were many multiply-infected erythrocytes in the PbHlyIII KO infected 
groups, suggesting the last supposition is unlikely. Lethality in the C57/Bl6 mice was 
unchanged with PbHlyIII KO compared to WT P. berghei infection, so the increased 
parasite growth rate in the KO did not result in earlier mortality in these mice. 
In order to determine the cause of early death in the PbHlyIII KO infected Balb/c 
mice, we sacrificed the mice shortly before onset of early death on day 7 post infection 
and processed several tissues including brain, liver, lung, spleen, heart and kidney for 
evidence of pathology and parasite sequestration. qPCR on these tissues supported an 
increased level of parasite sequestration in the spleen and in the heart (Figure 2.27), with 
H&E staining of spleen sections confirming the increased level of both infected and 
uninfected erythrocytes present in many PbHlyIII KO infected mice (Figure 2.29). We 
also noted severe edema, fibrosis and immune cellular infiltration in the lung in most 
PbHlyIII KO infected mice, but noted that many of these features were seen in the WT 
infected mice often as well, suggesting that lung pathology was unlikely the cause of the 
early death. Most interesting was the level of brain hemorrhage noted in initial studies 
with the PbHlyIII KO parasite, though as evidenced by Table 2.1, later studies suggested 
hemorrhages were not necessarily unique to the PbHlyIII KO infected mice. Furthermore 
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qPCR data does not support significantly increased parasite sequestration in the brain or 
small capillaries in the WT group, but there is evidence for some parasites sequestered in 
both groups, which might contribute to inflammation and hemorrhage. Regardless, the 
consistent findings of brainstem and cerebellum hemorrhage in the PbHlyIII KO groups 
warrant further study, and we hope that examining the brainstems of mice post-mortem 
will more clearly indicate why Balb/c mice infected with PbHlyIII KO P. berghei die so 
much earlier than those infected with WT. 
The increased erythrocyte clearance and spleen pathology in the PbHlyIII KO 
groups is suggestive of altered deformability of the parasitized erythrocytes in the 
PbHlyIII KO compared to the wild type. While our original observations of the WT and 
PbHlyIII KO asexual stages by Giemsa film suggested some slight alterations in the 
number of vacuoles present, the higher resolution images produced using transmission 
electron microscopy revealed even greater disparities between the WT and PbHlyIII KO 
strains. In particular the extra vacuoles we noted by Giemsa were quite varied in shape, 
size and location, present as multiple small vesicles or larger vacuoles either on the 
periphery of the parasite, between parasites or hugging the parasite nucleus. The vacuoles 
appeared to be empty, devoid of hemozoin suggesting they were distinct from digestive 
vacuoles. The presence of digestive vacuoles with hemozoin in conjunction with 
hemoglobin containing vesicles in the PbHlyIII KO parasite also suggests the membrane 
or vacuole aberration does not affect the hemoglobin digestion pathway. Overall the 
morphologic changes seem to be the result of altered membrane integrity and structure, as 




 Vesicle and membrane dynamics are quite complicated, so it is difficult to 
pinpoint the mediator of the membrane disruptions we see in the PbHlyIII KO parasites. 
However, as Plasmodium hemolysin is likely to function either as a pore or a receptor 
based on the evolutionary data available for the hemolysin III protein family, there are a 
few speculations we could make regarding the disruption of hemolysin being directly 
responsible for the morphology we see. One possibility is that hemolysin is a pore that is 
important for transport of some substrate involved either directly or downstream in 
membrane fusion or formation, perhaps directly after invasion and formation of the 
parasitophorous vacuole. Another possibility is that hemolysin is functioning as a 
receptor in the parasite and that the disruption has downstream effects on a signaling 
pathway such as the phosphoinositide 3-kinase pathway involved in intracellular 
trafficking. PAQR-2, a hemolysin III family member, is an adiponectin receptor homolog 
in C. elegans with downstream effectors involved in phosphatidylcholine biosynthesis 
and fatty acid elongation, suggesting PAQR-2 may play an important role in membrane 
fluidity. In the above model PAQR-2 appears to be important for cold adaptation, and the 
authors speculate PAQR-2 may function as a hydrolase (81). Yeast Izh2p is another 
example of a progestin receptor with regulatory roles in metabolic homeostasis, with 
deletion resulting in increased sensitivity to zinc levels and zinc homeostasis (66). 
FurthermoreIzh2p may regulate downstream pathways, perhaps through iron, zinc or 
phosphate homeostasis, including lipid metabolism and lipid remodeling (66).  
As Plasmodium hemolysin does have a conserved N-terminal domain similar to 
the PAQR family proteins, PfHlyIII may have a similar function to PAQR-2 or Izh2p as a 
hormone receptor, with disruption leading to downstream disruption of lipid metabolism 
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or remodeling. Despite the seemingly severe morphological changes in the knockout 
parasite, it does not appear that loss of hemolysin results in death for asexual parasites or 
even gametocytes, suggesting that there are other compensatory effectors or even 
mutations that can overcome hemolysin disruption. 
In a separate attempt to nail down the function of hemolysin and essentiality in 
the parasite, we attempted to follow the PbHlyIII KO through the mosquito stages and 
into the liver. However while we were able to observe oocyst formation in the midgut as 
well as minimal sporozoites in the salivary glands, there does seem to be a defect in the 
mosquito stage growth and development in the PbHlyIII KO parasite. Specifically the 
oocysts appear to be smaller and fewer in number compared to WT P. berghei, and the 
final sporozoite harvest from salivary glands is tenfold lower compared to WT. We did 
not rule out the possibility that sporozoites are formed but unable to invade the salivary 
glands efficiently. Due to the limited number of sporozoites harvested from the salivary 
glands, we were unable to test whether the PbHlyIII KO sporozoites were infectious to 
mice and could develop into liver stage and subsequent blood stage infections. Future 
directions will include dissecting this growth phenotype further and may help elucidate 
the requirement and function of Plasmodium berghei hemolysin III. 
In conclusion we were able to clearly define the cyclical native protein expression 
of PfHlyIII in asexual blood stages and demonstrate the functional pore formation of 
recombinant PfHlyIII in a eukaryotic system. While we did not find direct evidence for a 
virulent role of PfHlyIII in severe malaria anemia, our data still supports this possibility, 
as PfHlyIII is a soluble, pore-forming protein present in asexual blood stages of 
Plasmodium falciparum. Furthermore the disruption of the P. berghei homolog PbHlyIII 
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resulted in several distinct phenotypes: early lethality in Balb/c mice that may be a result 
of altered deformability, nonlethal but morphologically severe membrane and 
parasitophorous vacuolar aberrations, and a significant growth defect in the mosquito 
stages yielding low numbers of salivary gland sporozoites. Further exploration of these 
altered phenotypes should be provide new insights as to the role of Plasmodium 
hemolysin III proteins and may also provide new insights into the eukaryotic hemolysin 




















1.  Warrell D a. Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94:1–
90.  
2.  Mcelroy PD, Kuile FOTER, Lal AA, Bloland PB, Hawley WA, Oloo AJ, et al. 
Effect of Plasmodium Falciparum Parasitemia Density on Hemoglobin 
Concentrations Among Full-Term, Normal Birth Weight Children in Western 
Kenya, IV. The Asembo Bay Cohort Project. Am J Trop Med Hyg. 
2000;62(4):504–12.  
3.  Douglas NM, Anstey NM, Buffet PA, Poespoprodjo JR, Yeo TW, White NJ, et al. 
The anaemia of Plasmodium vivax malaria. Malar J. 2012 Jan 11:135. 
4.  Calis JCJ, Phiri KS, Faragher EB, Brabin BJ, Bates I, Cuevas LE, et al. Severe 
anemia in Malawian children. N Engl J Med. 2008 Feb 28;358(9):888–99.  
5.  Cusick SE, Opoka RO, Lund TC, John CC, Polgreen LE. Vitamin d insufficiency 
is common in ugandan children and is associated with severe malaria. Carvalho 
LH, editor. PLoS One. Public Library of Science; 2014 Jan;9(12):e113185. 
6.  Orimadegun AE, Sodeinde O. Glucose-6-phosphate dehydrogenase status and 
severity of malarial anaemia in Nigerian children. J Infect Dev Ctries. 2011 
Nov;5(11):792–8. 
7.  Foote EM, Sullivan KM, Ruth LJ, Oremo J, Sadumah I, Williams TN, et al. 
Determinants of anemia among preschool children in rural, western Kenya. Am J 
Trop Med Hyg. 2013 Apr;88(4):757–64.  
112 
 
8.  Awah NW, Troye-Blomberg M, Berzins K, Gysin J. Mechanisms of malarial 
anaemia: potential involvement of the Plasmodium falciparum low molecular 
weight rhoptry-associated proteins. Acta Trop. 2009 Dec;112(3):295–302.  
9.  Layez C, Nogueira P, Combes V, Costa FTM, Juhan-Vague I, da Silva LHP, et al. 
Plasmodium falciparum rhoptry protein RSP2 triggers destruction of the 
erythroid lineage. Blood. American Society of Hematology; 2005 Nov 
15;106(10):3632–8.  
10.  Buffet P a, Safeukui I, Milon G, Mercereau-Puijalon O, David PH. Retention of 
erythrocytes in the spleen: a double-edged process in human malaria. Curr Opin 
Hematol. 2009 May;16(3):157–64.  
11.  Buffet PA, Safeukui I, Deplaine G, Brousse V, Prendki V, Thellier M, et al. The 
pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic 
physiology. Blood. 2011 Jan 13;117(2):381–92. 
12.  Roberts DJ, Casals-Pascual C, Weatherall DJ. The clinical and 
pathophysiological features of malarial anaemia. Curr Top Microbiol Immunol. 
2005;295:137–67.  
13.  Jakeman GN, Saul A, Hogarth WL, Collins WE. Anaemia of acute malaria 
infections in non-immune patients primarily results from destruction of uninfected 
erythrocytes. Parasitology. 1999 Aug;119 Pt 2:127–33.  
14.  Collins We, Jeffery Gm, Roberts Jm. A retrospective examination of anemia 




15.  Foeller M, Bobbala D, Koka S. Suicide for survival-death of infected erythrocytes 
as a host mechanism to survive malaria. Cell Physiol. 2009;133–40. 
16.  Kiefer CR, Snyder LM. Oxidation and erythrocyte senescence. Curr Opin 
Hematol. 2000 Mar;7(2):113–6.  
17.  Mohan K, Dubey ML, Ganguly NK, Mahajan RC. Plasmodium falciparum: role 
of activated blood monocytes in erythrocyte membrane damage and red cell loss 
during malaria. Exp Parasitol. 1995 Feb;80(1):54–63.  
18.  Biryukov S, Stoute JA. Complement activation in malaria: friend or foe? Trends 
Mol Med. 2014 May;20(5):293–301.  
19.  Odhiambo CO, Otieno W, Adhiambo C, Odera MM, Stoute JA. Increased 
deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic 
region of western Kenya: implications for the development of severe anemia. 
BMC Med. 2008 Jan;6(1):23.  
20.  Stoute JA. Complement receptor 1 and malaria. Cell Microbiol. 2011 
Oct;13(10):1441–50.  
21.  Ekvall H, Arese P, Turrini F, Ayi K, Mannu F, Premji Z, et al. Acute haemolysis 
in childhood falciparum malaria. Trans R Soc Trop Med Hyg. 2001;95:611–7.  
22.  Gwamaka M, Fried M, Domingo G, Duffy PE. Early and extensive CD55 loss 
from red blood cells supports a causal role in malarial anaemia. Malar J. 2011 
Jan;10:386.  
23.  Salmon MG, De Souza JB, Butcher GA, Playfair JH. Premature removal of 
uninfected erythrocytes during malarial infection of normal and immunodeficient 
mice. Clin Exp Immunol. 1997 Jun;108(3):471–6.  
114 
 
24.  Evans KJ, Hansen DS, van Rooijen N, Buckingham LA, Schofield L. Severe 
malarial anemia of low parasite burden in rodent models results from accelerated 
clearance of uninfected erythrocytes. Blood. 2006 Feb 1;107(3):1192–9.  
25.  Safeukui I, Gomez ND, Adelani AA, Burte F, Afolabi NK, Akondy R, et al. 
Malaria Induces Anemia through CD8+ T Cell-Dependent Parasite Clearance 
and Erythrocyte Removal in the Spleen. MBio. 2015 Jan 27;6(1):e02493–14 – . 
26.  Dondorp AM, Angus BJ, Hardeman MR, Chotivanich KT, Kamdrat S, 
Ruangveerayuth R, et al. Prognostic significance of reduced red blood cell 
deformability in severe falciparum malaria. Am J Trop Med Hyg. 
1997;57(5):507–11.  
27.  Chang K-H, Tam M, Stevenson MM. Inappropriately low reticulocytosis in 
severe malarial anemia correlates with suppression in the development of late 
erythroid precursors. Blood. American Society of Hematology; 2004 May 
15;103(10):3727–35.  
28.  Chang K-H, Stevenson MM. Malarial anaemia: mechanisms and implications of 
insufficient erythropoiesis during blood-stage malaria. Int J Parasitol. 2004 
Dec;34(13-14):1501–16.  
29.  Chasis JA, Mohandas N. Erythroblastic islands: niches for erythropoiesis. Blood. 
2008 Aug 1;112(3):470–8.  
30.  Lamikanra AA, Brown D, Potocnik A, Casals-Pascual C, Langhorne J, Roberts 
DJ. Malarial anemia: of mice and men. Blood. American Society of Hematology; 
2007 Jul 1;110(1):18–28.  
115 
 
31.  Schwarzer E, Turrini F, Ulliers D, Giribaldi G, Ginsburg H, Arese P. Impairment 
of macrophage functions after ingestion of Plasmodium falciparum-infected 
erythrocytes or isolated malarial pigment. J Exp Med. 1992 Oct 1;176(4):1033–
41.  
32.  Schwarzer E, Ludwig P, Valente E, Arese P. 15(S)-hydroxyeicosatetraenoic acid 
(15-HETE), a product of arachidonic acid peroxidation, is an active component 
of hemozoin toxicity to monocytes. Parassitologia. 1999 Sep;41(1-3):199–202.  
33.  Skorokhod A, Schwarzer E, Gremo G, Arese P. HNE produced by the malaria 
parasite Plasmodium falciparum generates HNE-protein adducts and decreases 
erythrocyte deformability. Redox Rep . Maney Publishing; 2007 Jan 19;12(1):73–
5. 
34.  Skorokhod OA, Caione L, Marrocco T, Migliardi G, Barrera V, Arese P, et al. 
Inhibition of erythropoiesis in malaria anemia: role of hemozoin and hemozoin-
generated 4-hydroxynonenal. Blood. American Society of Hematology; 2010 Nov 
18;116(20):4328–37.  
35.  Thawani N, Tam M, Bellemare M-J, Bohle DS, Olivier M, de Souza JB, et al. 
Plasmodium products contribute to severe malarial anemia by inhibiting 
erythropoietin-induced proliferation of erythroid precursors. J Infect Dis. 2014 
Jan 1;209(1):140–9.  
36.  Ru Y-X, Mao B-Y, Zhang F, Pang T, Zhao S, Liu J, et al. Invasion of 
erythroblasts by Pasmodium vivax: A new mechanism contributing to malarial 
anemia. Ultrastruct Pathol. 2009 Oct;33(5):236–42.  
116 
 
37.  Othoro C, Lal AA, Nahlen B, Koech D, Orago AS, Udhayakumar V. A low 
interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria 
anemia in children residing in a holoendemic malaria region in western Kenya. J 
Infect Dis. 1999 Jan 1;179(1):279–82.  
38.  Kurtzhals J, Akanmori B. The cytokine balance in severe malarial anemia. J 
Infect. 1999;180:1997–8.  
39.  Boeuf PS, Loizon S, Awandare GA, Tetteh JKA, Addae MM, Adjei GO, et al. 
Insights into deregulated TNF and IL-10 production in malaria: implications for 
understanding severe malarial anaemia. Malar J. 2012 Jan;11:253. 
40.  Thuma PE, van Dijk J, Bucala R, Debebe Z, Nekhai S, Kuddo T, et al. Distinct 
clinical and immunologic profiles in severe malarial anemia and cerebral 
malaria in Zambia. J Infect Dis. 2011 Jan 15;203(2):211–9. 
41.  McGuire W, Knight JC, Hill a V, Allsopp CE, Greenwood BM, Kwiatkowski D. 
Severe malarial anemia and cerebral malaria are associated with different tumor 
necrosis factor promoter alleles. J Infect Dis. 1999 Jan;179(1):287–90. 
42.  Awandare G a, Kempaiah P, Ochiel DO, Piazza P, Keller CC, Perkins DJ. 
Mechanisms of erythropoiesis inhibition by malarial pigment and malaria-
induced proinflammatory mediators in an in vitro model. Am J Hematol. 2011 
Feb;86(2):155–62. 
43.  Perkins DJ, Were T, Davenport GC, Kempaiah P, Hittner JB, Ong’echa JM. 




44.  McDevitt MA, Xie J, Shanmugasundaram G, Griffith J, Liu A, McDonald C, et 
al. A critical role for the host mediator macrophage migration inhibitory factor in 
the pathogenesis of malarial anemia. J Exp Med. 2006 May 15;203(5):1185–96.  
45.  Haldar K, Mohandas N. Malaria, erythrocytic infection, and anemia. Hematology 
Am Soc Hematol Educ Program. 2009 Jan;87–93.  
46.  Awandare GA, Martinson JJ, Were T, Ouma C, Davenport GC, Ong’echa JM, et 
al. MIF (macrophage migration inhibitory factor) promoter polymorphisms and 
susceptibility to severe malarial anemia. J Infect Dis. 2009 Aug 15;200(4):629–
37.  
47.  Keller CC, Ouma C, Ouma Y, Awandare GA, Davenport GC, Were T, et al. 
Suppression of a novel hematopoietic mediator in children with severe malarial 
anemia. Infect Immun. 2009 Sep;77(9):3864–71.  
48.  Cromer D, Stark J, Davenport MP. Low red cell production may protect against 
severe anemia during a malaria infection--insights from modeling. J Theor Biol. 
2009 Apr 21;257(4):533–42.  
49.  Ekvall H. Malaria and anemia. Curr Opin Hematol. 2003 Mar;10(2):108–14.  
50.  De Oca MM, Engwerda C, Haque A. Plasmodium berghei ANKA (PbA) infection 
of C57BL/6J mice: a model of severe malaria. Methods Mol Biol. 2013 
Jan;1031:203–13.  
51.  Carvalho LJ de M, Alves FA, Oliveira SG de, Rio do Valle R del, Fernandes 
AAM, Muniz JAPC, et al. Severe anemia affects both splenectomized and non-
splenectomized Plasmodium falciparum-infected Aotus infulatus monkeys. Mem 
Inst Oswaldo Cruz. Fundação Oswaldo Cruz; 2003 Jul;98(5):679–86.  
118 
 
52.  Lamb TJ, Langhorne J. The severity of malarial anaemia in Plasmodium 
chabaudi infections of BALB/c mice is determined independently of the number of 
circulating parasites. Malar J. 2008 Jan;7:68.  
53.  Egan AF. Aotus New World monkeys: model for studying malaria-induced 
anemia. Blood. American Society of Hematology; 2002 May 15;99(10):3863–6.  
54.  Bhakdi S, Tranum-Jensen J. Membrane damage by pore-forming bacterial 
cytolysins. Microb Pathog. 1986;1(c):5–14.  
55.  Los FCO, Randis TM, Aroian R V, Ratner AJ. Role of pore-forming toxins in 
bacterial infectious diseases. Microbiol Mol Biol Rev. 2013 Jun;77(2):173–207.  
56.  Bernheimer AW, Rudy B. Interactions between membranes and cytolytic 
peptides. Biochim Biophys Acta - Rev Biomembr. 1986 Jun;864(1):123–41. 
57.  Johnson B, Heuck A. Perfringolysin O Structure and Mechanism of Pore 
Formation as a Paradigm for Cholesterol-Dependent Cytolysins. MACPF/CDC 
Proteins-Agents of Defence, Attack. 2014. p. 63–81.  
58.  Goñi FM, Ostolaza H. E. coli alpha-hemolysin: a membrane-active protein toxin. 
Braz J Med Biol Res. 1998 Aug;31(8):1019–34.  
59.  Baida G, Kuzmin N. Cloning and primary structure of a new hemolysin gene 
from Bacillus cereus. … Biophys Acta (BBA)-Gene Struct. 1995;1264:151–4.  
60.  Baida G, Kuzmin N. Mechanism of action of hemolysin III from Bacillus cereus. 
Biochim Biophys Acta (BBA). 1996;1284:122–4.  
61.  Ramarao N, Sanchis V. The pore-forming haemolysins of bacillus cereus: a 
review. Toxins (Basel). 2013 Jun;5(6):1119–39. 
119 
 
62.  Chen Y-C, Chang M-C, Chuang Y-C, Jeang C-L. Characterization and virulence 
of hemolysin III from Vibrio vulnificus. Curr Microbiol. 2004 Sep;49(3):175–9.  
63.  Tang YT, Hu T, Arterburn M, Boyle B, Bright JM, Emtage PC, et al. PAQR 
proteins: a novel membrane receptor family defined by an ancient 7-
transmembrane pass motif. J Mol Evol. 2005 Sep;61(3):372–80.  
64.  Smith JL, Kupchak BR, Garitaonandia I, Hoang LK, Maina AS, Regalla LM, et 
al. Heterologous expression of human mPRalpha, mPRbeta and mPRgamma in 
yeast confirms their ability to function as membrane progesterone receptors. 
Steroids. 2008 Oct;73(11):1160–73. 
65.  Villa NY, Moussatche P, Chamberlin SG, Kumar A, Lyons TJ. Phylogenetic and 
preliminary phenotypic analysis of yeast PAQR receptors: potential antifungal 
targets. J Mol Evol. 2011 Oct;73(3-4):134–52.  
66.  Mattiazzi Ušaj M, Prelec M, Brložnik M, Primo C, Curk T, Ščančar J, et al. Yeast 
Saccharomyces cerevisiae adiponectin receptor homolog Izh2 is involved in the 
regulation of zinc, phospholipid and pH homeostasis. Metallomics. 2015 DOI: 
10.1039/c5mt00095e 
67.  Dibello, Julia R, Baylin, Ana, Viali, Satupaitea, Tuitele, John Bausserman, Linda 
McGarvey, Stephen T. Adiponectin and type 2 diabetes in Samoan adults. Am J 
Hum Biol. 2009;Jan;21(3):389–91.  
68.  Zhu Y, Bond J, Thomas P. Identification, classification, and partial 
characterization of genes in humans and other vertebrates homologous to a fish 




69.  Aouida M, Kim K, Shaikh AR, Pardo JM, Eppinger J, Yun D-J, et al. A 
Saccharomyces cerevisiae assay system to investigate ligand/AdipoR1 
interactions that lead to cellular signaling. PLoS One. 2013 Jan;8(6):e65454. 
70.  Moonah S, Sanders NG, Persichetti JK, Sullivan DJ. Erythrocyte lysis and 
Xenopus laevis oocyte rupture by recombinant Plasmodium falciparum hemolysin 
III. Eukaryot Cell. 2014 Oct;13(10):1337–45.  
71.  Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing 
phylogenetic trees. Mol Biol Evol. 1987 Jul;4(4):406–25.  
72.  Efron B, Halloran E, Holmes S. Bootstrap confidence levels for phylogenetic 
trees. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13429–34. 
73.  Zuckerkandl E, Pauling L. Molecules as documents of evolutionary history. J 
Theor Biol [Internet]. 1965 Mar [cited 2015 Jun 16];8(2):357–66.  
74.  Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular 
Evolutionary Genetics Analysis version 6.0. Mol Biol. 2013 Dec;30(12):2725–9.  
75.  Maier AG, Braks J a M, Waters AP, Cowman AF. Negative selection using yeast 
cytosine deaminase/uracil phosphoribosyl transferase in Plasmodium falciparum 
for targeted gene deletion by double crossover recombination. Mol Biochem 
Parasitol. 2006;150(1):118–21.  
76.  Janse CJ, Franke-Fayard B, Mair GR, Ramesar J, Thiel C, Engelmann S, et al. 
High efficiency transfection of Plasmodium berghei facilitates novel selection 
procedures. Mol Biochem Parasitol. 2006;145(1):60–70.  
77.  Preston G, Carroll T, Guggino W, Agre P. Appearance of water channels in 
Xenopus oocytes expressing red cell CHIP28 protein. Science (80). 1992;2–4.  
121 
 
78.  Aurrecoechea C et al. PlasmoDB: a functional genomic database for malaria 
parasites. [Internet] Nucleic Acids Res. Available from: 
http://plasmodb.org/plasmo/ 
79.  Thermo Fisher Scientific Inc. Custom Mouse Monoclonal Antibody Development 
Protocols [Internet]. 2015. Available from: http://www.pierce-
antibodies.com/custom-antibodies/mouse-monoclonal-antibody-development-
protocols.cfm 
80.  Koh YT, Higgins SA, Weber JS, Kast WM. Immunological consequences of 
using three different clinical/laboratory techniques of emulsifying peptide-based 
vaccines in incomplete Freund’s adjuvant. J Transl Med. 2006 Jan;4:42. 
81.  Pilon M, Svensk E. PAQR-2 may be a regulator of membrane fluidity during cold 

















Supplementary Figure 2.1. pGEXT vector from Prigge Lab, used for GST-fusion 
protein production of GSTF80AA and GSTB80AA proteins with unique restriction 








Supplementary Figure 2.2. MBP-tev pRSF from Bosch Lab, used for MBP-fusion 







Supplementary Figure 2.3. pCC1D plasmid from Prigge Lab used for P. falciparum 






Supplementary Figure 2.4. pCC1S plasmid from Prigge Lab used for P. falciparum 











Supplementary Figure 2.5. pL0001 plasmid from Jacobs-Lorena Lab used for P. 
berghei hemolysin III knockout construct with unique restriction enzyme sites and 




CHAPTER 3: ANTIMALARIAL EFFICACY OF 
































Adapted from previously published manuscript:  
Sanders NG, Meyers DJ, Sullivan DJ. Antimalarial efficacy of hydroxyethylapoquinine 
(SN-119) and its derivatives. Antimicrob Agents Chemother. 2014 ;58(2):820-7.  





 Hydroxethylapoquinine (HEAQ), once called hydroxyethylapocupreine, is a 
quinine derivative that was first synthesized in the early 1930’s and proven to be effective 
as an antimalarial agent against bird malaria, as well as an antibacterial agent against 
human pneumococcal pneumonia. Strikingly, HEAQ was dosed at approximately eight 
grams per day in human pneumonia patients, with no toxic side effects reported due to 
the drug, suggesting that HEAQ is much less toxic than quinine. The advent of 
chloroquine and penicillin in the 1940’s resulted in this drug being tabled in favor of 
cheaper, and in the case of penicillin, more effective compounds at the time. Later the 
artemisinins replaced chloroquine as the most effective antimalarial, and artemisinin-
based combination therapies (ACTs) have been the standard treatment for malaria for 
over a decade. Unfortunately our current antimalarial arsenal has been crippled by the 
development of drug resistance to every major antimalarial drug class. Even the 
artemisinins are threatened due to the development of a delayed parasite clearance 
phenotype, even though there is no significant increase in the inhibitory dose that can kill 
50% of the parasites (IC50) reported for these compounds. 
While novel antimalarial targets and new chemical classes are being explored to 
combat drug resistant parasites, compounds such as quinine are still relevant as they have 
proven efficacy against a genetically immutable target (hemozoin), and little sustained 
resistance in the field. The narrow therapeutic index associated with quinine and its 
diastereomer quinidine makes these compounds challenging for safety reasons, and less 
toxic derivatives would be valuable candidates for partner drugs for the artemisinins to 
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delay resistance and increase the longevity of the ACTs as effective antimalarials for as 
long as possible.  
We found the historical use of HEAQ compelling, with proven efficacy against 
bird malaria and significantly greater tolerance at large doses in human patients than 
quinine. There is even one reference of Veterans returning from Korea being successfully 
treated with HEAQ for malaria. Here we report a novel synthesis of HEAQ from quinine, 
as well as three other new derivatives, the latter two based on the quinidine parent 
structure: hydroxyethylquinine (HEQ), hydroxyethylquinidine (HEQD), and 
hydroxyethylapoquinidine (HEAQD). 
For my thesis we developed the following aims in order to determine whether 
HEAQ and derivatives would be good candidates for further antimalarial drug 
development: (1) Test whether the derivatives are able to inhibit heme crystallization 
similarly to the parent compounds which may suggest a similar mechanism of action 
against the malaria parasite, (2) Determine the antimalarial efficacy of all derivatives 
against P. falciparum in vitro and against P. berghei ANKA in a murine malaria model, 
and (3) Determine whether HEAQ and derivatives are less toxic than quinine and 
quinidine. 
Quinoline compounds have been proven to inhibit heme crystallization in the 
parasite, and we demonstrated dose dependent inhibition of heme crystallization by all 
four derivatives, similar to quinine and quinidine, with HEQD having the greatest 
potency in the heme crystallization assay, with activity most similar to the parent 
compounds. We also found that the chemical property of fluorescence was maintained in 
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all derivatives, similar to quinine and quinidine, despite the modifications made to the 
side chains of the quinoline scaffold.  
We tested all compounds against three strains of P. falciparum and found that all 
four derivatives inhibited the 3D7 strain with IC50s less than 300 nM, about four times 
that of the parent drugs, while only the quinidine derivatives inhibited the chloroquine 
resistant (Dd2) or quinine tolerant strains (Dd2 and INDO) at appreciable levels, with 
IC50s less than 1 M. Similar results were seen when the compounds were tested in vivo, 
dosed orally in C57Bl/6 mice in a suppression test against P. berghei ANKA. HEAQ, 
HEQD, and HEAQD all demonstrated comparable efficacy, if less potency than parent 
compounds in vivo. Of note, the quinidine derivatives HEQD and HEAQD were 
equipotent with quinine and when combined with low doses of artesunate were able to 
cure mice and improve mouse survival better than quinidine plus artesunate.  
Finally we used two measures to test the toxicity of the derivatives compared to 
quinine and quinidine: (1) Effect of drug exposure on mammalian cell culture viability, 
and (2) Human ether-à-go-go related gene (hERG) channel inhibition as a proxy for 
potential cardiotoxicity. In our cell culture assay we found that all derivatives showed no 
toxicity against human foreskin fibroblasts at 100 M after 48 hours of incubation, and 
that HEQD and HEAQD were less toxic than both quinine and quinidine, with no toxicity 
up to 200 M. As a perhaps more relevant measure of toxicity for the quinoline 
compounds, we determined the IC50s of all compounds against hERG channels, 
suggestive of the propensity of the compounds to inhibit heart potassium channels, 
resulting in arrhythmias as a result of prolonged QRS/QT intervals. We found that HEQ, 
HEAQ and HEQD inhibited hERG channels at a much lower level than quinine (42 M) 
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or quinidine (4 M) with IC50s of approximately 100 M. HEAQD was about seven 
times less inhibitory than quinidine with an IC50 of 27 M. 
Overall we found that HEQD, one of the quinidine derivatives, was the most 
effective, least toxic compound we tested. This drug showed comparable antimalarial 
efficacy and potency to quinine, with no inhibition against hERG channels even at 100 
M, suggesting that the hydroxyethyl modification significantly decreased the likelihood 
of this compound to contribute to QT prolongation, while slightly decreasing the 
antimalarial potency of the drug. Further studies should be done to derivatize HEQD to 
improve the antimalarial potency particularly against drug resistant strains of the parasite, 
while maintaining the decreased toxicity. Further development of this compound is 
warranted and could result in a safer and more effective alternative to quinine for use in 























Quinine: Discovery and Use 
 
Cinchona bark, the source of quinine and other alkaloids, was used as early as the 
17
th
 century for treating fevers or ‘ague’ (1). However, it was not until 1820 that French 
physicians Pierre Joseph Pelletier and Joseph Caventou isolated quinine (Figure 3.1) and 
cinchonine from the bark, making these compounds available in a purified form (1). 
Following successful identification of quinine as an effective treatment for intermittent 
fevers, quinine became a valuable commodity and was used more often than the other 
alkaloids quinidine, cinchonine and cinchonidine due to the majority of obtainable 







Figure 3.1 Chemical structure of diastereomers quinine (left) and quinidine (right). 
 
Quinine was thus the first purified antimalarial drug and was the gold standard for 
treatment and prevention of malaria until the discovery of chloroquine in the 1940’s. 
After chloroquine resistance developed in the late 1950’s, quinine was again used as a 
key antimalarial until the introduction of the artemisinins in the 1980’s and continues to 
be used to treat uncomplicated malaria in pregnant women during the first trimester, as 
well as severe malaria when intravenous artesunate or artemether are unavailable (2–4). 
Periodic reports of drug resistance to quinine do exist, mainly in Southeast Asia and 
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South America, but the development of resistance is slow and not sustained, classified as 
‘low grade’, with no ‘high grade’ resistance noted for severe malaria cases, with 
treatment failures more often due to non-compliance to a treatment regimen rather than 
an actual increase in IC50 (2,3,5). Economically feasible drugs that can rapidly kill the 
parasite are especially crucial in light of the fact that definitive drug resistance or delayed 
parasite clearance has been reported for all classes of antimalarials available, including 
artemisinin-based combined therapies (6–9). 
Though quinine and its diastereomer quinidine have proven to be effective 
antimalarial drugs, both compounds have narrow therapeutic indices, that is, the effective 
dose is very close to doses associated with toxicity. In particular, higher doses of quinine 
and quinidine may result in cardiotoxicity associated with delayed ventricular 
depolarization and in the case of quinidine, repolarization, leading to a prolonged QRS or 
QT interval respectively (10). Blindness is another severe adverse event associated with 
quinine overdose, while other side effects include tinnitus, hearing loss, headache and 
loss of taste sensation (3). In light of these quinine-associated toxicities, a novel 
compound, similar to quinine but less toxic would be ideal as either a partner drug with 
artemisinin-related compounds or as a replacement for other antimalarial drugs that have 








The Search for an Antimalarial ‘As Good As or Better Than Quinine’ 
 Many efforts have been devoted to derivitizing the cinchona alkaloid series in 
hopes of discovering more effective and less toxic alternatives to quinine and include the 
discoveries of the 4-amino and 8-amino quinolines such as chloroquine and mefloquine. 
The levarotatory alkaloids including cupreine, quinine and cinchonine (Figure 3.2) as 
well as their diastereomers (not shown) have been modified at R and R’ with varied 
results in their antimalarial activity, none of which were particularly promising beyond a 






Figure 3.2 Cupreine (R=OH, R’= CH=CH2) 
 
 
 Dr. Robert Hegner, a dedicated scientist in the Department of Protozoology of 
the Johns Hopkins School of Hygiene and Public Health spent many years in the pursuit 
of a drug ‘as good as or better than quinine’, resulting in valuable insights regarding 
solubility and pharmacokinetic properties of various quinoline derivations (12,13). In 
1939 Hegner announced in his published work that such a drug had been found, namely 
hydroxyethylapocupreine, or HEAQ (Figure 3.3, (13)). Hegner reported the efficacy of 
HEAQ in the treatment of three strains of bird malaria: Plasmodium lophurae (ducks), P. 
relictum (pigeons), and P. cathemerium (canaries). HEAQ was found to have similar 
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efficacy to quinine against all three strains when used at four times the dose of the parent 







Figure 3.3 Hydroxyethylapoquinine (HEAQ), a derivative of quinine, with an 
isomerization of the R’ group and a hydroxyethyl substitution at the R group 
 
 At the same time the bird antimalarial studies were being completed for HEAQ by 
Hegner’s group, Dr. W. W. G. Maclachlan was treating human pneumococcal pneumonia 
patients with HEAQ in Pittsburg, Pennsylvania. Specifically HEAQ was used at doses of 
eight grams per day as an effective antibacterial compound from 1936-1939 in the 
treatment of over five hundred pneumonia cases, resulting in a fifty percent reduction in 
mortality with no visual disturbances or severe adverse effects, including atrial 
fibrillation, noted for the drug (15–17). At such large doses, the lack of side effects 
reported suggests that HEAQ is much less toxic than quinine in humans. Most intriguing 
is a report by Dr. Maclachlan in 1963 in which he states, “We were aware of the fact that 
in malaria hydroxyethylapocupreine [HEAQ] was as effective as quinine as observed in 
some clinical cases in Veterans from Korea and also in Venezuela, in addition to 
experimental studies recorded by Hegner et al” (18).  
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 Because no formal human trials have been conducted for the use of HEAQ 
against P. falciparum, we sought to examine activity in vitro with human P. falciparum 
and in vivo with the mouse malaria model as well as the important chemical property of 
quinolines to inhibit hERG channels. Here we resynthesized and tested HEAQ, in 
addition to three novel compounds, hydroxyethylquinine (HEQ) and the diastereomers 
hydroxyethylquinidine (HEQD) and hydroxyethylapoquinidine (HEAQD), against P. 
falciparum in vitro as well as in a murine malaria model to determine the efficacy of 
these drugs compared to the parent compounds quinine and quinidine. Further 
characterization in regards to the mechanism of action and chemical properties of these 
derivatives was also conducted, along with cytotoxicity studies using human fibroblasts 















MATERIALS AND METHODS 
General Information: 
All reagents and solvents were used as supplied by commercial sources without 
further purification. All dry solvents were purchased from Aldrich as Sure Seal bottles. 
Reactions involving air and/or moisture sensitive reagents were carried out under an 
argon atmosphere using glassware that was dried under vacuum with a heat gun. The 
evacuated flask was then filled with argon. The reactions were monitored by thin layer 
chromatography using Analtech chromatography plates (silica gel GHLF, 250 microns). 
Visualization was performed by UV light (254 and 365 nm) and/or by staining with 
potassium permanganate. Flash chromatography was performed using a Grace Reveleris 





C (125 MHz) NMR spectra of compounds were obtained using a Varian 
Mercury spectrometer. 
1
H NMR spectra recorded in CD3OD were referenced to 3.310 
ppm. 
13
C NMR spectra recorded in CD3OD were referenced to 39.15 ppm. Accurate mass 
determinations were recorded by the Mass Spectrometry Facility located at the University 
of California, Riverside. 
Synthesis and Analysis of HEAQ and Derivatives 
Preparation of demethyl quinine (cupreine): 
Modified procedure adapted from Xu, F.; et al (19) and Furuya, T.; et al (20) 
A 500 ml three-necked flask equipped with an argon inlet, a reflux condenser and a large 
magnetic stir bar (38 x 16 mm) was charged with DMF (100 ml) and 95% sodium 
hydride (5.92 g, 247 mmol, 8 equiv.). Ethanethiol (Stench! 18.3 ml, 247 mmol, 8 equiv.) 
was added drop-wise while cooling with an ice water bath. Note that after the addition of 
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approximately 10 ml of ethanethiol, stirring became difficult. The reaction was allowed 
to warm to room temperature and quinine (10.0 g, 30.8 mmol, 1 equiv.) was added in one 
portion. Once the reaction could be efficiently stirred, the remainder of the ethanethiol 
was added drop-wise at room temperature. Once the addition of ethanethiol was 
complete, the reaction was stirred at 100 ºC for 24 hours. The reaction mixture was 
cooled to ambient temperature, quenched with sat. aq. NH4Cl and water, and the aqueous 
layer extracted with ethyl acetate (3 x 200 ml). The organic phase was dried with 
anhydrous MgSO4, and approximately 300 ml of volatiles were removed by simple 
distillation in a well-ventilated hood (Stench!). During cooling to ambient temperature, 
an off-white crystalline solid formed in the still pot and was filtered via vacuum filtration 





H NMR (500 MHz, METHANOL-d4) δ 8.60 (d, J = 4.56 Hz, 
1H), 7.91 (d, J = 9.12 Hz, 1H), 7.63 (d, J = 4.56 Hz, 1H), 7.34 (dd, J = 2.52, 9.12 Hz, 
1H), 7.30 (d, J = 2.52 Hz, 1H), 5.76 (ddd, J = 7.47, 10.14, 17.29 Hz, 1H), 5.54 (d, J = 
3.14 Hz, 1H), 4.99 (td, J = 1.49, 17.13 Hz, 1H), 4.92 (td, J = 1.34, 10.38 Hz, 1H), 3.68 - 
3.80 (m, 1H), 3.08 - 3.20 (m, 2H), 2.68 - 2.82 (m, 2H), 2.40 (br. s., 1H), 1.85 - 1.97 (m, 
2H), 1.79 - 1.85 (m, 1H), 1.56 - 1.68 (m, 1H), 1.46 (tdd, J = 3.30, 10.06, 13.20 Hz, 1H). 
13
C NMR (126 MHz, METHANOL-d4) δ 158.1, 149.6, 147.6, 144.1, 142.4, 131.6, 128.5, 
123.5, 120.0, 115.3, 105.3, 72.0, 61.1, 57.5, 44.5, 40.8, 29.2, 28.0, 21.7 
Preparation of demethyl quinidine: 
The same procedure for the conversion of quinine to dimethyl quinine was used 
for the conversion of quinidine (5.00 g, 15.4 mmol) to demethyl quinidine, but product 
did not crystallize. Oil was purified via flash chromatography (gradient 99% CHCl3 plus 
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1% Et3N to 10% MeOH/89% CHCl3 plus 1% Et3N) to obtain 3.47 g of a yellow glass. 
This material contained approximately 10% quinidine and was carried on to the next step 
without further purification. 
Preparation of hydroxyethylquinine (HEAQ) and hydroxylethylquinidine (HEAQD) was 
carried out as described by Carlson, W.W.; et al (21). 
Preparation of HEAQ 
To a single-necked 50 ml RBF equipped with a reflux condenser was added 
ethylene carbonate (5.25 g, 59.6 mmol, 20.0 equiv.), potassium carbonate (824 mg, 5.96 
mmol, 2.00 equiv.), demethyl quinine 2 (926 mg, 2.98 mmol, 1.00 equiv.) and 5 ml 
anhydrous tert-butanol. The reaction was placed in a preheated oil bath (95 ºC) for 1 h. 
The reaction was then poured while still hot onto ice and approximately 10-20 ml of 5 M 
aq. NaOH. The reaction was extracted with dichloromethane and volatiles removed to 
obtain a brown oil. This material was purified via flash chromatography (gradient 99% 
CHCl3 plus 1% Et3N to 10% MeOH/89% CHCl3 plus 1% Et3N) to obtain 854 mg of a 
brown glass. The brown glass was dissolved in ca. 5 ml of hot 95% EtOH, allowed to 
cool to ambient temperature, and then placed in a -20 ºC freezer. Pink-tan crystals formed 
(726 mg) and were collected by vacuum filtration. 
1
H NMR (500 MHz, METHANOL-
d4) δ 8.66 (d, J = 4.56 Hz, 1H), 7.96 (d, J = 9.12 Hz, 1H), 7.68 (d, J = 4.56 Hz, 1H), 7.42 
- 7.51 (m, 2H), 5.76 (ddd, J = 7.62, 10.14, 17.29 Hz, 1H), 5.58 (d, J = 3.14 Hz, 1H), 4.97 
(td, J = 1.49, 17.13 Hz, 1H), 4.90 (td, J = 1.34, 10.37 Hz, 1H), 4.20 - 4.29 (m, 2H), 3.93 - 
4.01 (m, 2H), 3.69 (dddd, J = 2.36, 5.03, 10.65, 13.24 Hz, 1H), 3.06 - 3.17 (m, 2H), 2.64 
- 2.78 (m, 2H), 2.36 (br. s., 1H), 1.83 - 1.96 (m, 2H), 1.76 - 1.83 (m, 1H), 1.54 - 1.65 (m, 
1H), 1.46 (tdd, J = 3.22, 9.96, 13.15 Hz, 1H). 
13
C NMR (126 MHz, METHANOL-d4) δ 
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159.1, 150.7, 148.3, 144.9, 142.8, 131.6, 128.2, 123.8, 120.2, 115.1, 103.4, 72.3, 71.4, 
61.7, 61.2, 57.7, 44.3, 41.0, 29.3, 28.3, 21.8. HRMS (m/z): [MH
+
] calculated for 
C21H27N2O3 355.2016, found 355.2012. 
Preparation of HEAQD 
 To a single-necked 100 ml RBF equipped with a reflux condenser was added 
ethylene carbonate (19.7 g, 224 mmol, 20.0 equiv.), potassium carbonate (3.09 g, 22.4 
mmol, 2.00 equiv.), crude demethyl quinidine (3.47 g, 11.2 mmol, 1.00 equiv.) and 18.6 
ml anhydrous tert-butanol. The reaction was placed in a preheated oil bath (95 ºC) for 3 
h. The reaction was then poured while still hot onto ice and 10-20 ml of 5 M aq. NaOH. 
The reaction was extracted with dichloromethane to obtain a brown oil which was 
purified via flash chromotography (gradient 99% CHCl3 plus 1% Et3N to 10% 
MeOH/89% CHCl3 plus 1% Et3N) to obtain a reddish-orange glass. This material was 
crystallized from hot ethyl acetate to obtain 1.79 g of an off-white crystalline solid. 
1
H 
NMR (500 MHz, METHANOL-d4) δ 8.66 (d, J = 4.56 Hz, 1H), 7.95 (d, J = 9.12 Hz, 
1H), 7.69 (d, J = 4.56 Hz, 1H), 7.41 - 7.48 (m, 2H), 6.14 - 6.21 (m, 1H), 5.63 (d, J = 3.14 
Hz, 1H), 5.05 - 5.14 (m, 2H), 4.20 - 4.27 (m, 2H), 3.96 (t, J = 4.72 Hz, 2H), 3.56 (ddd, J 
= 2.12, 7.78, 13.52 Hz, 1H), 3.05 (dt, J = 2.59, 9.08 Hz, 1H), 2.88 - 2.95 (m, 2H), 2.77 - 
2.86 (m, 1H), 2.20 - 2.35 (m, 2H), 1.73 (br. s., 1H), 1.53 - 1.64 (m, 2H), 1.08 (ddd, J = 
4.09, 9.43, 13.52 Hz, 1H). 
13
C NMR (126 MHz, METHANOL-d4) δ 159.0, 150.9, 148.3, 
144.9, 142.0, 131.5, 128.2, 123.7, 120.1, 115.2, 103.3, 72.6, 71.4, 61.7, 60.9, 51.0, 50.5, 
41.6, 29.9, 27.4, 21.3. HRMS (m/z): [MH
+




General procedure for the preparation of HEAQ or HEAQD was carried out as described 
by Portlock, D.E.; et al (22) (analytical scale double bond isomerization): 
HEAQ 
 To a solution of HEQ (250.0 mg, 0.705 mmol, 1.00 equiv.), 12 ml of 50% aq. 
ethanol and 0.59 ml of conc. HCl (7.05 mmol, 10.0 equiv.) was added 12.5 mg of 5 wt% 
of Rhodium catalyst on activated carbon. The mixture was heated to reflux for 24 hrs. 
After allowing the reaction to cool to ambient temperature, the reaction was vacuum 
filtered through celite, and the volatiles of the filtrate were removed in vacuo. The residue 
was taken up in water, and the pH was made basic with conc. NH4OH. The resulting 
white precipitate was vacuum filtered and dried under high vacuum to obtain 192 mg 
(76%) of a white amorphous solid. 
1
H NMR (500 MHz, METHANOL-d4) δ 8.66 (d, J = 
4.56 Hz, 1H), 7.95 (d, J = 8.80 Hz, 1H), 7.68 (d, J = 4.56 Hz, 1H), 7.36 - 7.58 (m, 2H), 
5.60 - 5.72 (m, 1H), 5.08 - 5.28 (m, 1H), 4.15 - 4.39 (m, 2H), 3.89 - 4.06 (m, 2H), 3.69 - 
3.87 (m, 1H), 3.38 - 3.59 (m, 2H), 3.02 - 3.15 (m, 1H), 2.68 - 2.87 (m, 1H), 2.35 (br. s., 
1H), 2.07 - 2.19 (m, 1H), 1.83 - 1.98 (m, 1H), 1.56 - 1.71 (m, 1H), 1.53 (d, J = 6.76 Hz, 
1H), 1.47 (d, J = 6.76 Hz, 2H), 1.16 - 1.38 (m, 1H). 
13
C NMR (126 MHz, METHANOL-
d4) δ 159.1, 150.8, 148.3, 144.9, 141.5, 140.4, 131.5, 128.1, 123.7, 120.1, 115.9, 115.7, 
103.4, 103.4, 72.3, 71.4, 71.4, 62.0, 61.7, 61.7, 59.9, 57.6, 45.0, 45.0, 34.7, 28.6, 28.4, 
27.5, 27.3, 27.2, 12.9, 12.6. HRMS (m/z): [MH
+
] calculated for C21H27N2O3 355.2016, 
found 355.2017.  
HEAQD:  
The same procedure was used for HEQD to obtain 264 mg (88%) of a white 
amorphous solid. 
1
H NMR (500 MHz, METHANOL-d4) δ 8.65 (d, J = 4.56 Hz, 1H), 
142 
 
7.95 (d, J = 9.59 Hz, 1H), 7.59 - 7.73 (m, 1H), 7.39 - 7.53 (m, 2H), 5.52 - 5.72 (m, 1H), 
5.09 - 5.32 (m, 1H), 4.17 - 4.40 (m, 3H), 3.36 (d, J = 17.13 Hz, 1H), 3.14 - 3.28 (m, 1H), 
2.88 - 3.04 (m, 1H), 2.70 - 2.88 (m, 1H), 2.35 (br. s., 1H), 1.98 - 2.13 (m, 1H), 1.58 - 1.71 
(m, 3H), 1.55 (d, J = 6.76 Hz, 3H), 1.32 - 1.50 (m, 1H). 
13
C NMR (126 MHz, 
METHANOL-d4) δ 159.0, 159.0, 150.7, 150.7, 148.3, 144.9, 144.9, 142.5, 141.4, 131.5, 
128.2, 128.2, 123.8, 123.7, 120.2, 120.1, 114.3, 114.0, 103.4, 103.3, 72.6, 72.5, 71.4, 
71.4, 61.7, 60.7, 60.7, 53.3, 52.2, 51.8, 51.0, 34.9, 28.2, 28.0, 27.4, 27.4, 27.0, 12.9, 12.6. 
HRMS (m/z): [MH
+
] calculated for C21H27N2O3 355.2016, found 355.2029. 
Heme Crystallization Inhibition Assay 
The heme extension assay was designed to mimic hemozoin crystal formation in 
the parasite digestive vacuole, using acidic pH and lipids to initiate crystallization of 
monomeric heme. Drug dilutions were made from DMSO or water 10 mM stocks with 
100 mM sodium acetate, pH 4.8 and aliquotted in a 96 well plate (costar 3595) in 
triplicate, with five serial, two-fold dilutions per drug. Heme stock (10 mM) was made in 
DMSO and was diluted to 50 µM with 100 mM sodium acetate, pH 4.8. 10 mM 1-
Monooleoyl-rac-glycerol (MOG) stock was made in ethanol and sonicated before 
addition to 50 µM heme stock to make 25 µM MOG, 50 µM heme in 100 mM sodium 
acetate, pH 4.8. The 25 µM MOG/50 µM heme solution was sonicated and added to the 
assay plate, 100 µL/well. The plates were incubated at 37°C for two hours to allow 
crystallization, followed by addition of 100 µL 100 mM sodium bicarbonate pH 9.1 to 
solubilize any remaining monomeric heme. After an incubation of one hour at room 
temperature, the amount of solubilized monomeric heme was determined by measuring 
absorbance at 405 nm and calculating the nanomoles of heme based on a previously 
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determined standard curve. Finally, 20 µL of 1 M sodium hydroxide was added to the 
plates to dissolve any crystals that formed, and absorbance was read at 405nm to 
determine the total amount of heme present in each well. Data was exported to Microsoft 
Excel and inhibition of heme crystallization was determined as a function of the total 
nanomoles of monomeric heme minus the unincorporated heme, divided by the total 
nanomoles of heme crystal formed in the no drug control. 
Fluorescence Determination 
To verify that the four quinoline derivatives retained fluorescent chemical 
properties similar to quinine and quinidine, 1 M drug stocks of quinine, quinidine, HEAQ 
and HEAQD were made in 1 M sulfuric acid. The solutions were diluted 1:100 in 
distilled water and five dilutions of these stocks were made using 0.05 M sulfuric acid. 
The fluorescence of these compounds was determined at 350 and 450 nm. 
72-hour SYBR Green I Parasite Inhibition Assay 
A 72-hour SYBR Green I assay was used to determine the sensitivity of three 
strains of P. falciparum (3D7, INDO, Dd2 obtained from Malaria Research Reference 
Reagent Resource) to quinine, quinidine, ART, CQ, and derivatives HEQ, HEAQ, HEQD 
and HEAQD. Drug stocks were prepared at 10 mM concentrations in DMSO or water, 
filter-sterilized, and stored at -20°C. Dilutions were made in RPMI 1640 medium to the 
appropriate starting concentration, followed by serial two-fold dilutions to generate 5-10 
concentrations for each drug. Drugs (10 µL) were aliquotted in triplicate into 96-well 
plates (Costar #3595) at ten times the final concentration. P. falciparum cultures were 
synchronized and diluted to 2% ring stage and adjusted to1% hematocrit with uninfected 
erythrocytes. The cultures (90 µL) were then added to the assay plates and the plates 
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were incubated in a gassed chamber at 37°C for 72-hours until no drug control 
parasitemia reached between 10-15% (late trophozoite or schizont stages). Assay plates 
were frozen at -80°C for at least one hour or overnight, followed by thawing at 37°C for 
1-2 hours. Immediately after the freeze-thaw, 100 µL of 2X SYBR Green I in lysis buffer 
(Tris 20 mM, pH 7.5, EDTA 5 mM, Saponin .008% wt/vol, Triton X-100 .08% vol/vol) 
was added to each well for a total volume of 200 µl/well and mixed by pipetting up and 
down. The plates were allowed to incubate, protected from light, for at least one hour. 
Fluorescence was measured at 485 and 535 nm using an HTS 7000 Plus BioAssay reader, 
adjusting the gain between 80-90 for optimal reads. Data was exported to Microsoft 
Excel, where background fluorescence from the positive controls (1 mM chloroquine) 
was subtracted from each sample and percent inhibitions were calculated by dividing the 
sample fluorescence by the no drug controls and multiplying by one hundred. IC50’s were 
calculated as the concentration of drug required to inhibit 50% of the parasite growth in 
the no drug control. At least three replicates were completed for each strain of P. 
falciparum and each drug unless otherwise noted. 
Murine Malaria Model 
We obtained fifty-five C57/Bl6 mice, 5 weeks old, and weighing between 15-23 g 
from Jackson Labs for our experiment (n=5 mice per group, 12 groups; 4 mice were used 
in the artesunate alone group). Mice were kept in Johns Hopkins Bloomberg School of 
Public Health mouse facility according to the ACUC animal protocol number 
MO09H401. Mice were infected intraperitoneally with Plasmodium berghei ANKA 
(1x10
7
 infected erythrocytes) and drugs were administered orally twice a day using sterile 
plastic feeding tubes (Instech Solomon Scientific FTP 2038) for five days beginning 
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twenty-four hours post infection. All quinoline salts were dissolved in distilled water (8 
mg/ml or 2 mg/ml) and artesunate was dissolved in 100% ethanol (100 mg/ml) and 
diluted 1:100 in distilled water. The effects of compounds on parasite levels and mouse 
survival were determined by measuring weekly parasitemia levels by Giemsa-stained 
blood smears and checking mouse survival daily for up to thirty days. 
Human Ether-a-go-go (hERG) channel inhibition Ionworks patch clamp assay 
hERG channels were stably expressed in Chinese hamster ovary (CHO) cells 
which were held at -70 mV and hERG currents were evoked by two voltage pulses. 
During the first pulse, cells were depolarized to +40 mV for 2 s and hyperpolarized to -30 
mV for 2 s. This was repeated after a 3 s holding at -70 mV. The difference of tail 
currents at the second pulse between pre-compound and post-compound addition was 
used to measure compound activity, with dofetilide and buffer as positive and negative 
controls respectively. Compounds were dissolved in DMSO and diluted 1:3 in an 8-point 
gradient with the maximum concentration at 100 μM. In order to be classified as a hERG 
inhibitor, the compounds caused more than three standard deviations of reduction in 
hERG currents. Dofetilide was used as a control 
48-hour Alamar Blue Assay with Human Foreskin Fibroblasts  
Human Foreskin Fibroblasts (ATCC CRL-1635) were grown and harvested at log 
phase (Day 3 after passage). Cells were plated at 10,000 cells per well in 200 µL of MEM 
supplemented with 10% FBS, 1% penicillin/streptomycin, and 1% L-glutamine in a 96 
well plate (costar 3595) and allowed to incubate for one day at 37°C, 5% CO2 until cells 
again reached log phase. After 24 hrs, 100 µL MEM was removed and replaced with 
fresh media. After another 24 hr-incubation, 150 µL medium was removed from wells, 
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and 150 µL drug dilutions made in MEM from 10 mM stocks were added to the assay 
plate in triplicate, with four two-fold serial dilutions of drug. Plates were incubated for 
two days at 37°C, 5% CO2. After 48 hrs, 20 µL of Alamar blue was added to each well, 
including a no drug control as well as a blank well with media only. Sample fluorescence 
was read on an HTS 700 Plus Bio Assay Reader at 550 and 595 nm and data was 
exported to Microsoft Excel. Cytotoxicity of drugs was calculated as the percentage of 




















Synthesis and Analysis of HEAQ and Derivatives 
We modified the original synthetic approach of Butler and Cretcher in 1937 and 
1938 to prepare HEAQ from quinine and HEAQD from quinidine (Figure 3.4 (23,24)). 
Per Xu, F et al., 2010 and Furuya, T et al., 2009, quinine (QN) underwent demethylation 
in the presence of sodium ethanethiolate to form cupreine (19,20). Formation of the 
hydroxyethyl ether was accomplished by reacting cupreine with ethylene carbonate and 
potassium carbonate, yielding HEQ according to Carlson, W.W. et al., 1947 (21). Finally, 
rhodium catalyzed positional isomerization of the terminal alkene of HEQ resulted in the 
final product, HEAQ (E, Z) as a mixture of E and Z geometric isomers. A similar 
approach was used to produce HEQD and HEAQD (E, Z), using quinidine (QND) as the 
parent compound. The crystalline alkaloids of HEAQ, HEQD and HEAQD were initially 
obtained from solution as free bases and later converted to hydrochloride salts for use in 
animal studies.  
 
Figure 3.4 Scheme for synthesis of derivatives HEQ, HEAQ, HEQD, and HEAQD 
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Heme Crystal Inhibition and Fluorescence 
Antimalarial quinolines accumulate in the parasite digestive vacuole and are 
thought to inhibit Plasmodium growth by forming an intermolecular hydrogen bond with 
heme, disrupting formation of the hemozoin crystals resulting in the buildup of free heme 
which can become oxidized and then is toxic to the parasite (25–27). All derivatives were 
found to inhibit heme crystallization in the presence of lipid at pH 4.6 similarly to quinine 
and quinidine (Figure 3.5), but only HEQD appreciably inhibited heme to the same extent 










Figure 3.5 Quinine, quinidine and derivatives in inhibit heme crystallization after 16 
hours. Two to five independent experiments were completed for each compound with 
each concentration in triplicate, reported with corresponding standard error of the mean. 
Mean IC50 values calculated for all compounds in the order listed above were 16.3, 16.0, 
208, 59.3, 24.0, and 155 µM respectively. 
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Quinine’s inherent fluorescent properties have been well-described, and in fact 
quinine is often used as a fluorescent standard (28,29). We wanted to determine whether 
our modifications in any way altered the fluorescent properties of our four quinoline 
derivatives. We found all four derivatives to fluoresce in a dose-dependent manner 





















In vitro Antimalarial Efficacy against P. falciparum 
Quinoline derivatives were evaluated for antimalarial efficacy against three 
strains of Plasmodium falciparum in a standard 72-hour SYBR green assay with results 
shown in Table 1. All derivatives were effective at inhibiting a quinine-sensitive strain, 
3D7, at less than 300 nM, with an IC50 approximately three to four times higher than the 
parent compound, quinine or quinidine. Of note, the quinidine derivatives, HEQD and 
HEAQD were the most active against P. falciparum, with HEQD (111 nM) comparable 
with quinine (56 nM). Against the quinine-tolerant strains INDO and Dd2, all quinoline 
derivatives exhibited elevated IC50s, with HEAQ and HEAQD exhibiting IC50s five to 
nine times higher than quinine and quinidine. Importantly, the quinidine derivatives 
HEQD and HEAQD demonstrated efficacy against quinine these strains around 500 nM 
with the exception of HEQD against INDO, within the acceptable range of drug 
sensitivity for quinine and quinidine. Artemisinin was used as a control and consistently 


















Table 3.1: The average IC50 (nM) of quinine and quinidine derivatives against three 
strains of P. falciparum were determined using a 72-hour SYBR green assay. 
 Mean IC50 (nM, SEM) 
Compound 3D7 INDO Dd2 
Quinine 56 (6) 263 (25) 92 (10) 
HEQ 258 (33) 7100 (276) 2800 (363) 
HEAQ 255 (29) 3470 (429) 1133 (133) 
HEAQ HCl salt 240 (77) -- 1250 (189) 
Quinidine 24 (2 153 (279) 43 (1) 
HEQD 111 (22) 1875 (427) 313 (13)* 
HEAQD 168 (25) 725 (170) 333 (44) 
HEAQD HCl Salt 148 (55) -- 233 (17) 
Artemisinin 8.3 (1) 5.1 (1) 5.5 (1) 
Three or more biological replicates were completed for all compounds unless 
otherwise noted, with each compound in triplicate per experiment, reported with 
corresponding standard error of the mean (SEM). * Two independent experiments 
were completed for this compound. -- No data for these compounds.  
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In vivo Antimalarial Efficacy against P. berghei ANKA 
In order to see how the derivatives would perform in vivo, we next evaluated the 
antimalarial efficacies of HEAQ, HEQD, and HEAQD in a murine malaria model. Fifty-
five C57/Bl6 mice were infected intraperitoneally with Plasmodium berghei ANKA 
(1x10
7
 infected erythrocytes) and compounds were administered orally twice a day for 
five days beginning twenty-four hours post infection. Parasitemia was reduced by all 
derivatives except HEAQ 20 mg/kg at 3 days post drug administration (Figure 3.7). 
Quinine, compound HEAQ, and HEAQ in combination with artesunate all improved 
mouse survival, but were unable to cure the mice after five days of dosing (Figure 3.8, A 
and C). However, HEAQ at 80 mg/kg alone or with artesunate did significantly decrease 
parasitemia compared to the no drug control and was comparable to quinine at 20 mg/kg 
(Figure 3.7). Quinidine, HEQD, HEAQD, HEQD plus artesunate and HEAQD plus 
artesunate all significantly decreased parasitemia by day three post infection (Figure 
3.7A), but only 80 mg/kg HEAQD plus artesunate and 20 mg/kg HEQD plus artesunate 
were able to successfully clear parasitemia through day six (3.7B) and successfully cured 
three mice (Figure 3.8C). Artesunate alone at 10 mg/kg was unable to cure mice or allow 







Figure 3.7 Dose dependent clearance of P. berghei ANKA by compounds quinine (QN), 
HEAQ, quinidine (QND), HEQD and HEAQD, alone and in combination with artesunate 
(AS 10 mg/kg) in C57/Bl6 mice. Percent parasitemia was calculated as the percent of 
infected RBCS out of 500 for ≥1% parasitemia, and out of 10,000 for <1% parasitemia, 
graphed with standard error of the mean. Compounds listed first, dosages following (e.g. 
QN 20 mg/kg). (A) Day 3 parasitemia, after 2 days of dosing. (B) Day 6 parasitemia, one 
day after the final dose was administered. (C) Day 13 parasitemia, one week after the 












Figure 3.8 Dose dependent survival of C57/Bl6 mice infected with P. berghei ANKA 
after treatment with QN, HEAQ, QND, HEQD and HEAQD, alone or in combination 
with AS (10 mg/kg). (A) HEAQ at either 20 mg/kg or at 80 mg/kg was comparable to 
quinine in survival with all mice dying between day 20 and 25 (B) HEAQD and HEQD 
were comparable to quinidine with mice surviving to day 20-25 as with quinine and 
HEAQ. Despite 80 mg/kg of HEAQD having a lower parasitemia on day 16 these mice 
had a surge in parasitemia and died quickly compared to the lower dose of 20 mg/kg 
HEAQD. (C In combination with AS, 20 mg/kg of HEQD was comparable to 80 mg/kg 
of HEAQD clearing 3 of 5 mice completely parasites, as well as 3 (HEQD) or 4 
(HEAQD) of 5 mice survive until Day 30. Quinidine at 20 mg/kg allowed only 1 of 5 










Toxicity Studies: hERG Channel Inhibition and Cell Viability 
The most compelling evidence reported for HEAQ, besides its antimalarial 
efficacy, is the decreased toxicity associated with its historic human use compared to 
other quinine derivatives. An important clinical adverse drug reaction of the quinoline 
class is prolongation of the QRS heart interval associated with inhibition of the hERG 
channel. hERG inhibition studies were conducted using Chinese hamster ovary (CHO) 
cells expressing hERG channels and Ionworks automatic patch clamp to determine hERG 
IC50s for HEQ, HEAQ, HEQD and HEAQD compared to the parent compounds (Table 2, 
Figure 3.9). Strikingly, compounds HEQ, HEAQ, and HEAQD demonstrated IC50s of 
approximately 100 uM compared to 42.2 µM for quinine, while compound HEAQD was 
seven times less inhibitory than the parent, inhibiting 50% of the CHO hERG channels at 
27 µM compared to 4 µM quinidine. 
Table 3.2: hERG channel inhibition by quinine, quinidine and derivatives. hERG 
channels were expressed in Chinese hamster ovary (CHO) cells using the Ionworks patch 
clamp assay. Reported IC50 values (10,30). 
Compound IC50 (M) SD 
Reported 
IC50 (M) Hill SD 
% at max 
conc hERG Inhibitor? 
Dofetilide 0.05 0.01 0.1  2.27 0.79 -100 Yes 
Quinine 42.2 7.41 57.0 1.30 0.30 -83.4 Yes 
HEQ >100 -- - -- -- -35.2 No 
HEAQ 109 20.9 - 1.80 0.83 -49.4 Yes 
Quinidine 3.95 0.75 4.60 0.96 0.18 -95.8 Yes 
HEQD 94.3 8.12 - 4.00 0.00 -70.1 Yes 




Figure 3.9 IC50 concentrations were determined for parent compounds and derivatives 
against hERG channels expressed in CHO cells as measured by the Ionworks patch 
clamp assay. Representative graphs of quinine (A), HEAQ (B), quinidine (C) HEAQD 
(D) and (E) HEQD are pictured above. Compounds were tested in quadruplicate in a 8-









In vitro cell toxicity studies were also completed by observing the effects of 
different concentrations of quinine, quinidine, HEAQ, HEQD or HEAQD on human 
foreskin fibroblasts using a 48-hour Alamar blue assay to determine cell viability. While 
all compounds showed no toxicity at 100 µM, quinine had an LD50 of ~200 µM, with 





Figure 3.10 Dose dependent cytotoxicity of (A) HEAQ and (B) HEQD and HEAQD 
compared to quinine and quinidine against human foreskin fibroblasts, using Alamar blue 
fluorescence as a measure of cell viability and metabolic activity. Results are recorded as 






DISCUSSION AND CONCLUSIONS 
 Antimalarial drug resistance continues to threaten global public health measures 
to treat, contain and eventually eliminate malaria. HEAQ and derivatives HEQ, HEQD, 
and HEAQD may provide less toxic alternatives to quinine or quinidine, which continue 
to be effective malaria drugs, but have toxicity due to narrow therapeutic indices. 
Building on research that began in the 1930’s but was not pursued due to the discovery of 
chloroquine and other effective antimalarials, we sought to determine whether HEAQ and 
three derivatives would be effective against P. falciparum in an era of increasing 
antimalarial drug resistance and also to investigate inhibition of hERG which has been 
associated with prolongation of the Q-T interval. We were successful in synthesizing 
HEAQ as well as the novel diastereomer HEAQD, and also produced intermediates 
without the isomerized vinyl group, HEQ and HEQD. We demonstrated all compounds 
inhibit heme crystallization and retain fluorescent properties similar to the parent 
compounds, supporting the inhibition of hemozoin formation as a likely mechanism of 
action of the derivatives.  
Our in vitro and in vivo antimalarial results correspond with the data previously 
reported by Hegner et al (1941) for the activity of HEAQ against three strains of bird 
malaria, with the quinine and quinidine derivatives displaying decreased activity per 
mg/kg but at higher doses comparable action to the parent compounds (14). Specifically, 
here all derivatives showed decreased activity in vitro against clones 3D7, Indo and Dd2, 
but were equally effective at controlling parasitemia in the in vivo model at the higher 
dose of 80 mg/kg. Overall, compound HEQD and to a lesser extent HEAQD showed the 
greatest activity in the in vivo model when combined with artesunate with no adverse side 
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effects observable in the mice, making it a potential alternative to quinine or quinidine as 
an antimalarial drug. 
The reported hERG channel inhibition data suggests that all four derivatives are 
less prone to QT prolongation than the parent compounds quinine or quinidine, with 
HEQ, HEAQ, and HEQD inhibiting 50% of hERG channels at approximately 100 µM, 
twice the IC50 of quinine (42 µM). Interestingly, the intermediates HEQ and HEQD 
exhibited less hERG channel inhibition than the final products HEAQ and HEAQD. 
Cretcher and Renfrew (1941) previously commented on the effect of the resulting 
modifications on anti-pneumococcal activity, stating that “greater antipneumococcic 
action appears to be associated with the ethylidene group” (31). While we did not observe 
increased malaria activity with the ethylidene or isomerized vinyl group group, we did 
observe a decrease in hERG channel inhibition associated with the hydroxyethyl 
substitution, suggesting that this modification and not isomerization of the vinyl group 
can be credited for the great reduction in potassium channel inhibition. Our HFF cell line 
cytotoxicity data also agrees with previous studies on cell lines conducted by Kominos 
and Machlachlan (1963), with HEAQ and HEAQD showing overall less toxicity 
compared to quinine and quinidine (18). In addition, the quinidine derivatives HEQD and 
HEAQD showed no toxicity against HFFs at up to 200 µM for 48 hours. It is possible 
that metabolism of HEAQ and other derivatives is different from the parent compounds 
and that the lack of a toxic metabolite such as quinone species is the reason for the 
decreased toxicity of the hydroethyl substituted quinolines.  
Our data suggests that modifications of the methoxy side chain (R, Figure 3.2) 
with hydroxylated alkyl groups may be effective at decreasing cardiotoxic events 
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associated with quinine and quinidine in addition to the decrease in quinine-associated 
toxicities such as eye damage in dogs which decreased with hydroxylalkylation of R as 
mentioned in other studies (24,31). Interestingly, avian antimalarial potency increased 
with increasing lengths of the alkylated side chain up to four to five carbons, but beyond 
five carbons decreased potency (32). In recent studies on P. falciparum, substitutions at 
the R’ group with aromatic groups resulted in increased sensitivity against quinine-
resistant strains in some cases, while most resulted in decreased potency compared to 
parent compounds including quinine, cinchonine, quinidine and cinchonidine (33). When 
the R’ group was reduced to the dihydro group (optochin and others) a slight decrease in 
potency was noted. Compound SN-8707 has the dihydro R’ group as well as a 
hydroxyethyl R group with a reported quinine ratio of 0.6 in P. lophurae, which is more 
potent than our reported derivatives (~0.2-0.25, see Supplementary Table 1). Toxicity 
studies of SN-8707 and the quinidine derivative may provide more insight into the role of 
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Supplementary Table 3.1. List of quinoline compounds with associated quinine ratios and P. falciparum inhibition in literature 
and collaborative drug discovery database with ≥ 70% similarity to cupreine, quinine and HEAQ (32). Compounds with a 
quinine ratio greater than one are more potent than quinine. See Figure 3.2 in manuscript for R and R’ designations on quinoline 
structure. 
Compound   R R' Quinine ratio, strain 





Levarotatory           W2 3D7 Dd2 3D7 
Cinchonine,  CDD-
10723,  CDD-1522,   
SN-1030  8S, 9R H CH-CH=CH2 
2.5, 
1, 2 P. gallinaceum 100 100   183 
Cupreine,   CDD-
1007918 8S, 9R OH CH-CH=CH2           404 




1002726 8S, 9R OH C=CH-CH3       99,98 
11, -
2 490 
Quinine,   CDD-
993709, CDD-
14859,  CDD-
10961 8S, 9R OCH3 CH-CH=CH2       100 99 
100, 
150 
Dihydroquinine   












CDD-10887,   
SN-3094,    
CDD-1006404, 
CDD-1013193 
CDD-995897 8S, 9? OCH3 CH2-CH3       100 98 140 
Optochin 
   ethyl 
CDD-993708 8S, 9R O-CH2-CH3 CH2-CH3 1.05 P. inconstans   98 99 110 
   propyl,  CDD-
995898 8S, 9R 
O-CH2-CH2-
CH3 CH2-CH3 1.49 
P. inconstans  
  100 57 430 
n-Butyl 8S, 9R 
O-CH2-
(CH2)2-CH3 CH2-CH3 1.87 
P. inconstans  
        
n-Hexyl 8S, 9R 
O-CH2-
(CH2)4-CH3 CH2-CH3 1.5 
P. inconstans  
        
n-Octyl 8S, 9R 
O-CH2-
(CH2)6-CH3 CH2-CH3 1.43 
P. inconstans  
        
n-Decyl 8S, 9R 
O-CH2-
(CH2)8-CH3 CH2-CH3 1.6 
P. inconstans  
        
Apoquinine,  
isoquinine,    CDD-
1002719,   CDD-
1002729 8S, 9R OCH3 C=CH-CH3 0.98 









ethyl 8S, 9R O-CH2-CH3 C=CH-CH3 1.18 
P. inconstans  
        
169 
 
propyl 8S, 9R 
O-CH2-CH2-
CH3 C=CH-CH3 1.23 
P. inconstans  
        
n-Butyl 8S, 9R 
O-CH2-
(CH2)2-CH3 C=CH-CH3 1.1 
P. inconstans  
        
n-Hexyl 8S, 9R 
O-CH2-
(CH2)4-CH3 C=CH-CH3 1.72 
P. inconstans  
        
n-Octyl 8S, 9R 
O-CH2-
(CH2)6-CH3 C=CH-CH3 1.6 
P. inconstans  
        
n-Decyl 8S, 9R 
O-CH2-
(CH2)8-CH3 C=CH-CH3 1.18 
P. inconstans  
        




quinine, 3 8S, 9R 
O-CH2-CH2-




apoquinine 4,  
SN-119 8S, 9R 
O-CH2-CH2-




cathemerium    100   250 
Hydroxyethyl- 
dihydroquinine,     
CDD-10919,   
SN-8707 8S, 9R 
O-CH2-CH2-
OH CH2-CH3 0.6 P. lophurae         
CDD-10937,  
 SN-3133 8S, 9R 
O-CH2-CH2-
S-CH2-CH3 C=CH-CH3 0.3 P. lophurae         
CDD-10923,  8S, 9R O-CH2-CH2- C=CH-CH3 0.4 P. lophurae         
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 SN-3134 O-CH2-CH3 
CDD-10872,   
SN-7723 8S, 9R OCH3 H 0.8 P. lophurae         
CDD-11251,   
 SN-3135 8S, 9R 
NH-CH2-CH2-
OH C=CH-CH3 0.4 P. lophurae         
CDD-10922,   
SN-7325 8S, 9R 
CH2-CH2-O-
CH3 C=CH-CH3 0.2 P. lophurae         
CDD-10921,   
SN-7326 8S, 9R 
O-CH2 (OH)-
CH2-OH C=CH-CH3 0.2 P. lophurae         
CDD-10920,   
SN-8706 8S, 9R 
CH (CH2-
OH)2 C=CH-CH3 0.08 P. lophurae         
CDD-1012800,      
CDD-1002688 8S, 9R C≡N CH2-CH3       100 55 150 
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          Dextrarotatory                
Cinchonidine      
CDD-10724,      
CDD-994062 8R, 9S H CH-CH=CH2 
1, 
0.6, 






e,   
SN-3704,       CDD-
10725,     CDD-
995699 8R, 9S H CH2-CH3 2 P. lophurae   98 20   
CDD-14079 8R, 9R H CH-CH=CH2     100 100     
Dihydrocupreidine,    
SN-15293,      
CDD-10853 8R, 9S OH CH2-CH3 0.68 P. inconstans         
Dihydroepicupreidi
ne  
 CDD-996493,     
CDD-1012492 8R, 9R OH CH2-CH3       94 -4 1000 
Apocupreidine 8R, 9S OH C=CH-CH3       98 -1 250 
Quinidine,        
CDD-10884,        
CDD-14859,       
CDD-1010673 8R, 9S OCH3 CH-CH=CH2 
1.5, 
1 P. gallinaceum 
68 
(W2) 60, 98 95 9.5 
Dihydroquinidine 
methyl,    CDD- 8R, 9S OCH3 CH2-CH3 0.81 P. inconstans 
100 





14080,       CDD-
1008089,      CDD-
995421 
ethyl  8R, 9S O-CH2-CH3 CH2-CH3 0.98 P. inconstans         
Apoquinidine 8R, 9S OCH3 C=CH-CH3 1 P. inconstans         
Epiquinidine,        
CDD-10886,        









(W2) 100     
Hydroxyethyl-
quinidine, 7 8R, 9S 
O-CH2-CH2-
OH CH-CH=CH2       100   110 
Hydroxethyl-
apoquinidine, 8 8R, 9S 
O-CH2-CH2-
OH C=CH-CH3       100   170 
CDD-1008629,      
CDD-1013570 8R, 9S OCH3 
OH, CH-
CH=CH2           105 
CDD-1009849 8R, 9S OCH3 CH2-CH3           32 
CDD-10873, 
 SN-5860 8R, 9S OCH3 H 0.4 P. lophurae         
QN - 1-16 
CN - 1-4 
QD - 1-4 
















CHAPTER 4: DEVELOPING A GAMETOCYTOCIDAL ASSAY AND 
DISCOVERY OF NOVEL 














Adapted from previously published manuscript:  
 
Sanders NG, Sullivan DJ, Mlambo G, Dimopoulos G, Tripathi AK
. 
Gametocytocidal 
screen identifies novel chemical classes with Plasmodium falciparum transmission 




 The goal of malaria elimination is only going to be possible if there are sufficient 
tools to block the transmission cycle between the mosquito vector and human host. While 
vector control has been shown to be effective and essential for elimination of malaria in a 
variety of geographical regions, drugs that can kill gametocytes and block transmission 
are essential to destroy the gametocyte reservoir present in asymptomatic individuals that 
continues to go unchallenged in many endemic settings. However, screening for such 
compounds has proven challenging as current assays for transmission blocking drugs 
have limitations including a requirement for transgenic parasites, multiple or lengthy 
incubation steps making them not amenable for high throughput settings, or requirement 
for very high parasitemia gametocyte cultures for sufficient signal to noise ratio. 
 We set out to develop a high-throughput assay that would address some of these 
challenges, with a goal to use affordable reagents and instrumentation, minimal 
incubation steps and facilitate the use of any strain of P. falciparum, including field 
strains. We made use of the SYBR Green I nucleic acid dye that preferentially binds to 
double-stranded DNA and found that in combination with a background suppressor 
obtained from CyQUANT, we were able to detect only live gametocytes with intact 
membranes as the background suppressor quenched the fluorescence of any dead or 
permeabilized cells. By adding exflagellation media to drug-treated gametocyte cultures 
we were able to increase the DNA content of the male gametes to further boost the signal 
in our assay. Using this unique combination of reagents, we developed a live-dead assay 
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for P. falciparum gametocytes that we adapted for high throughput screening for 
discovery of novel transmission blocking drugs.  
 For this project my aims included: (1) Optimizing and validating the assay, 
comparing results with Giemsa stained blood films, the gold standard for determining 
gametocyte viability, (2) Screening large compound libraries for discovery of novel 
transmission blocking compounds, and (3) IC50 determination for top hits and validation 
for transmission blocking activity using membrane feeding assays. 
 After optimizing conditions for the assay we were able to demonstrate a strong 
correlation between gametocyte number and SYBR Green I fluorescence with a strong 
signal to noise ratio using between 5-10% gametocyte cultures with exflagellation media 
and addition of the background suppressor. 
 Using our optimized assay we first screened the Johns Hopkins Clinical 
Compound Library version 1.3 of approximately 1,500 FDA approved drugs and 
obtained 25 hits with IC50 values less than 20 M. We further validated these compounds 
with Giemsa-stained blood films to confirm gametocyte killing, and also performed 
membrane feeding assays with some of the top hits to validate their transmission 
blocking activity. Pyrvinium pamoate was our most effective compound, with 100% 
gametocyte killing at 4 M and 100% inhibition of oocyst development in mosquito 
midguts at 5 M. In addition we discovered a novel class of compounds, quaternary 
ammonium compounds, all of which had gametocytocidal activity and IC50s less than 10 




 We were also interested in testing compounds with known activity against asexual 
stages of the parasite, so we requested the Medicines for Malaria Venture malaria box of 
400 compounds with a combination of drug-like and probe-like molecules. Using our 
assay we identified eighteen compounds with high efficacy against gametocytes with 
IC50s less than 10 M. The majority of these compounds shared a similar pharmacophore, 
an acridine-like structure with three fused benzene rings and a central nitrogen, with 
varied side chains, one similar to chloroquine. We validated our hits by comparing our 
results with several other gametocytocidal assays that were developed around the same 
time as ours and screened the malaria box, and found that all of our hits were shared 
among at least one of the other three assays with three distinctive reporters/targets 
including alamar blue, confocal microscopy based on gametocyte specific proteins, and 
luciferase.  
 Overall we were able to develop a robust gametocytocidal assay and identify 
several new classes of potential transmission-blocking compounds. Future directions 
include target validation and determining the mechanism of action of some of the novel 









Malaria Elimination Requires Drugs to Block Transmission 
Malaria is a historically relentless public health problem and continues in the 
present day to contribute to severe morbidity and mortality worldwide, impeding 
development in many of the world’s poorest countries. Plasmodium falciparum malaria is 
associated with the highest fatality rates, resulting in an estimated 200 million cases and 
more than one million deaths in 2012 (1). Efforts to control, eliminate, and ultimately 
eradicate this disease have only been partially successful, with failure due in large part to 
the development of compound resistance in both the Anopheles mosquito vector, as well 
as the parasite (2,3). Sustainable interventions and control measures have also posed a 
challenge, and a multi-faceted strategy targeting both transmission and disease is 
necessary if there is any hope of controlling this devastating disease (2–4). 
Of particular interest is the discovery of new chemical entities and classes 
targeting the sexual stage of the parasite, gametocytes, which are responsible for 
transmission back to the mosquito vector. To this end, a variety of assays have been 
developed, each utilizing different measures of parasite viability including alamar blue to 
detect metabolic activity, detection of parasite proteins such as lactate dehydrogenase, or 
bioluminescence of viable transgenic parasites (5–11). While the reported assays are 
more high-throughput than the gold standard of counting Giemsa-stained blood films, 
they still have limitations including the requirement for transgenic parasites or multiple 
incubation and transfer steps. 
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Here we describe a simple assay using the SYBR-green I DNA probe along with a 
background suppressor to assay for live gametocytes. To achieve robust signal to noise 
ratio we use a combination of exflagellation, to increase DNA content from viable male 
gametocytes, and background suppressor to mask the signals from drug killed 
gametocytes. Incubation time after drug treatment is minimal with no transfer or 
centrifugation steps and can be easily adapted to higher throughput formats such as 384 
or 1536-well plates. In addition, this assay does not require transgenic parasites and thus 
could be used to screen field isolates. After validating the assay, we screened an FDA-
approved library of 1584 compounds as well as the MMV malaria box of 400 confirmed 
antimalarials that are active against asexual blood stages in P. falciparum. We report the 
results of both drug screens, with particular emphasis on the novel classes of active 











MATERIALS AND METHODS 
Ethics Statement 
This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. Mice 
were only used for mosquito rearing as a blood source according to approved protocol. 
The protocol was approved by the Animal Care and Use Committee of the Johns Hopkins 
University (ACUC MO14H114).  
P. falciparum gametocyte cultivation: 
 The P. falciparum NF54 strain was cultured according to the method described by 
Trager and Jenson with minor modifications. Briefly parasites were cultured using 
O
+
 human erythrocytes at 4% hematocrit in parasite culture medium (RPMI 1640 
supplemented with 25 mM HEPES, 10 mM Glutamine, 0.074 mM hypoxanthine and 
10% O
+
 human serum). Cultures were maintained under standard conditions of 37°C in a 
candle jar made of glass desiccators. Gametocyte cultures were initiated at 0.5% mixed 
stage parasitemia from low passage stock and cultures were maintained up to day 15 with 
daily media changes. To achieve greater level of asexual parasitemia before 
gametocytogenesis, hematocrit was reduced to 2% between days 3 to 6. After day 6 
hematocrit was brought back to approximately 4%. To block reinvasion of remaining 
asexual parasites and obtain pure and near synchronous gametocytes, cultures were 





Development and optimization of gametocytocidal assay: 
To determine the effect of drugs on mature gametocytes we developed a SYBR 
Green I based DNA quantification assay. Because gametocytes do not multiply, our assay 
utilizes increase in DNA content after exflagellation and Cyquant background suppressor 
dye (Life Technologies, Grand Island, NY, USA) which blocks DNA fluorescence from 
dead gametocytes to achieve a robust signal to noise ratio. For assay optimization mature 
gametocytes were enriched using Percoll density gradient centrifugation. Enriched 
gametocytes were plated in 96 well plates and serially diluted with uninfected 1% 
hematocrit erythrocytes or media alone to obtain serial gametocytemia values or 
gametocyte numbers respectively. Triplicate wells of each parasite dilution were either 
treated with 10 µM pyrvinium pamoate or 0.1% DMSO (vehicle control) for 48 hrs at 
37
o
C in candle jar as described above. After drug exposure, 11 µl of 10x exflagellation 
medium (RPMI 1640 with 200 mM HEPES, 40 mM sodium bicarbonate, 100 mM 
glucose pH 8.0) was added and plates were incubated at room temperature for 30 min.  
Next 11 µl of 10x Cyquant direct background suppressor and SYBR Green I in 
PBS was added per well and plate was incubated at room temperature for 2 hrs. After 
addition of detection reagents plates were protected from light. Fluorescence was then 
measured at excitation and emission wavelengths of 485 and 535 in a plate reader 
(HTS7000 Perkin Elmer). To achieve consistent reads, special care was taken to not 
disturb the settled layer of gametocyte infected erythrocytes for consistent readings, 




Screening of JHU FDA approved compound library:  
The Johns Hopkins University Clinical Compound Library version 1.3 is 
comprised of more than 1500 drugs, which are approved by the FDA for treatments of 
different diseases or medical conditions. The JHU drug library is stocked in 96 well 
plates at 10 mM in 100% DMSO. In order to achieve dispensable concentration we 
diluted compounds in incomplete RPMI to new master plates at 400 µM. We dispensed 5 
µl of Compound library to the 96-well plates, to a final compound concentration of 20 
µM and DMSO concentration of 0.1%. Each compound was dispensed in duplicate plates 
to get two replicates of inhibition data. Columns 1 and 12 of each plate were used as in-
plate controls and contained 0.1% DMSO (negative control, 0% inhibition) and 20 μM 
clotrimazole (positive control, ~70% inhibition), respectively. Ninety-five l per well of 
day 15 pure gametocyte cultures at approximately 3-5% gametocytemia were then added 
to the compound containing plates at 1% hematocrit. Plates were incubated for up to 48 
hrs at 37C in microaerophilic conditions of a candle jar. After 48 hrs of drug treatment, 
gametogenesis was induced by adding 11 µl per well of 10x exflagellation media and 
incubation for 30min at room temperature. Next 11 µl per well of 10x Cyquant direct 
background suppressor and SYBR Green I (Life Technologies, Grand Island, NY, USA) 
in PBS was added to the plates and further incubated at room temperature for 2 hrs in the 
dark. Plates were then read at excitation and emission wavelengths of 485 and 535 nm 
respectively and raw data was transferred to Microsoft Excel. Fluorescence signals from 
both negative (0.1% DMSO) and positive (clotrimazole) wells were used for quality 
control of the assay and to determine percent inhibition by each compound. Compounds 
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which showed values between positive and negative controls and where duplicate data 
were in concert, was considered a hit. All the hits from the primary screen were retested 
at 10 M in 24 well plates for 48 hrs and smears were prepared for microscopic 
examination after Geimsa staining. Compounds which showed activity by the gold 
standard of microscopic examination were tested at multiple concentrations for IC50 
determinations.  
Screening of the MMV Malaria Box: 
 
The Medicines for Malaria Venture (MMV) kindly provided the Malaria Box 
which was comprised of 200 drug like and 200 probe like inhibitors of P. 
falciparum asexual stage. The MMV Box was supplied in 96-well plates at 10 mM stocks 
in 100% DMSO. We diluted compound library by 50 fold to make master plates at 200 
µM and 5 µl of each compound was dispensed into the duplicate assay plates, to achieve 
final concentration of 10 μM. The first and last columns on each plate were used for the 
negative (0.1% DMSO) and positive (10 µM pyrvinium pamoate) controls. Plate set up 
and detection of fluorescence was performed as described above in method section for 
FDA approved compound library. Compounds showing >50% inhibition in both 
replicates were considered primary hits. All the primary hits were then retested at 
multiple doses and IC50 values were determined.  
Z factor determinations 
Z factors were calculated using this equation described previously for validating 













Mosquito rearing and membrane feeding assay 
Anopheles gambiae  Keele strain mosquitoes were maintained on a 10% sugar 
solution at 27
o 
C and 80% humidity with a 12-h light/dark cycle according to standard 
rearing methods. Day 15 gametocytes were treated with gametocytocidal compounds or 
0.1% DMSO for 48 hr and then were centrifuged and diluted to 0.3% final 
gametocytemia in a mixture of erythrocytes supplemented with human serum for 
mosquito membrane feeding assays. Unfed mosquitoes were removed after feeding, and 
midguts were dissected 7 days later and stained with 0.1% mercurochrome. The number 
of oocysts per midgut was determined with a phase-contrast microscope, and the median 













SYBR Green I: CyQUANT Suppressor Assay Development and Validation 
Using SYBR Green I as a live-cell permeable fluorescent probe, we were able to detect 
gametocytes based on DNA content, with exflagellation as a means to increase DNA 
content in viable male gametes. In addition we used a background suppressor from the 
CyQUANT Direct Cell Proliferation Assay kit which works specifically by entering 
permeabilized cells or cells with compromised membranes and masking green 
fluorescence. By using SYBR Green I in conjunction with the background suppressor, we 
were able to mask the signal from dead or damaged gametocytes and only read SYBR 
Green I fluorescence from live or intact cells. The assay was optimized to determine 
sensitivity comparing drug treated and untreated parasites. SYBR Green I fluorescent 
signal from total and killed (10 µM pyrvinium pamoate treated, Figure 4.1) gametocytes 
was shown to increase linearly with increasing number of gametocytes (Figure 4.2A) and 
after subtracting out signal from killed gametocytes, retained fluorescent signal with a 
coefficient of determination of 0.96, indicating strong predictive value of gametocyte 
number on fluorescent signal.  
 
 





Figure 4.2 (A) SYBR Green I fluorescence of total (diamond), killed (triangle) and live 
gametocytes after drug treatment (total minus killed, square) with decreasing number of 
gametocytes per uninfected cell, diluted with 2% hematocrit erythrocytes in media in 
presence of CyQUANT background suppressor. (B) Z factors for each dilution were 
calculated using the equation shown, described previously for validating high throughput 
assays (= standard deviation, =mean, s=sample, c=control or in this case zero 
gametocytes) (12). 
To determine the limit of detection and sensitivity of the assay, a Z-factor was 
calculated for decreasing number of gametocytes, with 5,000-10,000 gametocytes per 
well providing a Z-factor above 0.5 which is indicative of a good assay (Figure 4.2B). 
Addition of the CyQUANT background suppressor dye greatly increased the sensitivity 
of the assay compared to exflagellation, which marginally enhanced the signal of live 
gametocytes (Figure 4.3). Specifically, beginning with an average ratio of 4:1 female to 
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male mature gametocytes, exflagellation increased live gametocyte signal from 7000 to 
8000 fluorescent units, suggesting a contribution of 10-20% of exflagellation to overall 
fluorescent signal (Figure 4.3).  
 
Figure 4.3 SYBR Green I fluorescence of live or pyrvinium pamoate-killed gametocytes 
in the presence of CyQUANT background suppressor, with and without exflagellation 







Figure 4.4 Example of assay plate SYBR green I fluorescence in the presence of 
background suppressor and calculations for % inhibition. Green indicates a positive hit 
with high inhibition attributable to gametocyte killing and red indicates an intermediate 
hit, potentially attributable to inhibition of exflagellation and/or moderate gametocyte 
killing. Percent inhibition was calculated using the above equation (= standard 
deviation, =mean, s=sample, c=control or in this 100% killed gametocytes with 10 µM 
pyrvinium pamoate). One drug was plated per well using duplicate plates.  
 
Drugs inhibiting exflagellation but not killing the parasites would result in low to 
intermediate inhibition in this assay (red highlighted value, Figure 4.4), with anything 
greater than 20% inhibition indicative of some gametocyte killing (green highlighted 
value, Figure 4.4). Making blood films of positive hits can further differentiate whether 
parasites are being killed or damaged or whether exflagellation inhibition is occurring.  
For our assay, we set a cutoff value of greater than 70% inhibition (equal to or 
better than clotrimazole) for the FDA drug library screen and greater than 50% inhibition 
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(using pyrvinium pamoate as a positive control) for the MMV box screen to capture 
gametocytocidal compounds rather than solely exflagellation inhibitors. The final assay  




Figure 4.5 Overall assay setup with five steps: 1) Culture and enrich gametocytes. 
2) Incubate with drug for 48 hr. 3) Add exflagellation media and incubate 30 min. 4) Add 
SYBR Green I and background suppressor and incubate 2 hr. 5) Read SYBR Green I 
fluorescence at excitation 485 nm and emission 535 nm. 
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Screening of JHU Clinical Compound Library  
The Johns Hopkins University Clinical Compound Library version 1.3 of FDA-
approved drugs was screened using the assay described above to identify compounds that 
had gametocytocidal activity, confirmed with Giemsa stained smears of drug treated 
cultures for the top hits. During the initial screening, clotrimazole was identified as a 
moderately active gametocytocidal compound, showing 70% inhibition at 20 µM and 
was then used as a lower cutoff control for identification of screening hits, in order to 
screen for compounds that were gametocytocidal and did not only inhibit exflagellation. 
Uninfected erythrocytes were used as baseline for the initial screening.  
The FDA approved drug library was screened at 20 µM (Figure 4.6) and we 
initially selected the top 70 compounds showing more than 50% inhibition for evaluation 
using microscopic examination and at multiple concentrations IC50 determinations 
(Figure 4.7). As expected most hits showing more than 70% inhibition during initial 
screening were confirmed to be gametocytocidal by microscopic examination and they 
showed a clear dose dependent response. Overall we identified 25 compounds with IC50 
values less than 20 µM, with most less than 10 µM (Table 4.1, Figure 4.7). Most of the 
compounds with intermediate activity were determined to inhibit exflagellation (data not 
shown) but were not gametocytocidal as indicated by Giemsa smears of drug-treated 
gametocytes. The mean Z-factor calculated from the FDA approved drug library screen 





Figure 4.6 SYBR Green I assay results for the Johns Hopkins Clinical Compound 
Library version 1.3 of FDA approved drugs screened at 20µM. Plot of percentage of 
gametocytocidal activity of 1,584 compounds compared to clotrimazole control. 







Figure 4.7 IC50 values less than or equal to 20 µM of 25 hits from FDA approved 
drug library screen. Primaquine (open) had an IC50 value equal to 20 µM. An IC50 for 










Table 4.1. Gametocytocidal compounds identified in JHU FDA-approved drug library screen with 
greater than 70% inhibition at 20 μM. 
  Gametocyte Asexual 
Compound Indication 











Anthelmintic 108.8 (4.7) 0.38 99.3 (0.0) 0.1 
Melphalan Antineoplastic 98.9 (14.9) 4.0 22.9 (2.3) 20.0 
Pyrvinium pamoate Anthelmintic 91.9 (20.0) 4.0 99.6 0.6 
Thonzonium bromide Antiseptic 90.8 (10.6) 6.0 98.1 (0.0) 6.3 
Ifosfamide Antineoplastic 90.6 (15.7) 2.0 0.0 (0.0) NA 
Antimony potassium 
tartrate 
Anthelmintic 88.4 (16.4) 3.5 97.7 (0.0) NA 
Cetalkonium chloride Antiseptic 88.1 (6.2) 6.0 93.9 (0.1) 12.6 
Benzododecinium 
chloride 





Benzethonium chloride Antiseptic 85.9 (10.3) 6.0 98.6 (0.0) 4.0 
Gentian violet Antiseptic 84.7 (30.5) 8.5 99.2 (0.6) 0.6 
Cetylpyridinium 
chloride 
Antiseptic 82.9 (14.2) 7.0 66.4 (8.8) - 
Benzalkonium chloride Antiseptic 81.4 (7.5) 7.0 98.5 (0.0) 5.0 
Tilorone Antiviral 81.0 (3.0) 5.5 99.2 (0.0) 0.2
‡
 
Dithiazanine iodide Anthelminthic 80.5 (12.0) 7.0 92.9 (0.28) 3.2 
Pyrithione zinc Antiseptic 80.4 (13.7) 0.6 98.6 (0.9) - 
Cetylpyridinium 
bromide 
Antiseptic 78.2 (4.2) 9.0 86.4 6.3 
Anastrozole Antineoplastic 75.7 (22.7) 0.6 - NA 
Methylbenzethonium 
chloride 
Antiseptic 75.2 (5.9) 10.0 98.3 (1.4) - 
Maprotiline Antidepressant 73.9 (8.1) 0.9 37.4 (0.9) 20 
Clotrimazole Antifungal 70 (-) - - 1.3 
Acetomenaphthone Pharmaceutic aid 69.0 (16.4) 8.5 - 12.6 
1-Pentanol Dermatologic 63.8 (18.9) 0.7 5.2 (12.5) - 
Megestrol acetate Progestogen 62.4 (17.3) 3.5 -0.7 (5.7) NA 
Pentamidine Antiprotozoal 53.5 (59.5) 0.7 97.7 (0.0) 1.0 
Primaquine Antimalarial 47.8 (15.7) 20 84.2 (10.0) 1.3 
Anazolene sodium Diagnostic aid 34.7 (36.1) 0.6 -6.3 (8.9) 20.0 
Asexual stage 10 µM inhibition data was obtained from the Collaborative Drug Discovery Database 
(CDDD), 10 microM drug 3D7 48hr, 
3
H hypoxanthine assay for parasite inhibition protocol, and 
asexual IC50 data was obtained from from Eastman et al. or from the CDDD WRAIR IC50 nM D6 
protocol as noted [43-44]. Gametocytocidal IC50 values were calculated from one experiment with 
three replicates for top compounds. 
† 
Data only available for 96 hr assay, 
‡ 
WRAIR D6 data, – 
Unavailable, NA not active 
193 
 
Major Drug Classes with Gametocytocidal Activity 
As a result of the FDA drug library screen, several drug classes were identified that 
showed activity against gametocytes, including a known antimalarial, primaquine, as well 
as other classes including antiseptics, antineoplastics, antihelminthics, antivirals, 
antiprotozoals, antidepressants, and pharmaceutical aids (Figure 4.8). Eight of the twenty-
five positive hits were identified as a single class of drugs, quaternary ammonium 
compounds (QACs) which were classified as antiseptics. Pyrvinium pamoate, an 
anthelminthic, demonstrated 100% inhibition at 10 µM and was used for further assays as 
a positive control. By using a positive control of killed parasites in conjunction with the 
background suppressor rather than uninfected red blood cells, we were able to prevent 
artificially high inhibition values and screen for live gametocytes, not total gametocytes. 
 
Figure 4.8 Drug class representation of active molecules, IC50< 20 µM. Structures shown 
correspond to italicized compounds. 
194 
 
Validation of Gametocytocidal Compounds with Membrane Feeding Assay 
In order to validate the transmission blocking activity of compounds exhibiting 
the most potent gametocytocidal activity, mosquito infections through feeding on treated 
and untreated gametocyte cultures were performed. Gametocyte cultures were treated 
with methylene blue, a known gametocytocidal compound and clotrimazole, pyrvinium 
pamoate, and one of the quaternary ammonium compounds cetalkonium chloride for 48 
hrs prior to ingestion by mosquitoes through a membrane feeder, and mosquito infections 
were determined 7 days later as a measure of oocyst stage parasite on the mosquito 
midgut tissue (Figure 4.9). All compounds demonstrated dose dependent transmission 
blocking activity, with pyrvinium pamoate showing the highest potency with 100% 
efficacy at 500 nM.  
 
Figure 4.9 Inhibition of oocyst development in mosquito midguts by top 
compounds from JHU FDA-approved clinical compound library including clotrimazole 
(CLTZ), pyrvinium pamoate (PP), methylene blue (MB) and cetalkonium chloride (CCl). 
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MMV Malaria Box Screen 
Medicines for Malaria Venture (MMV) has generously put together a ‘malaria 
box’ of four hundred compounds with proven antimalarial activity against asexual blood 
stage parasites and made them freely available for use in the development of effective 
antimalarial compound screens, particularly those designed to identify liver stage and 
transmission blocking drugs. We screened these four hundred compounds using our 
gametocytocidal assay, this time using pyrvinium pamoate as a positive control due to 
increased efficacy compared to clotrimazole (Figure 4.10). Our initial screen of the MMV 
box identified eighteen compounds with greater than 80% inhibition at 10 µM which we 
further screened to determine their IC50s (Table 4.2). Seventeen of the compounds were 
confirmed as having greater than 50% inhibition at 10 µM and IC50s less than 10 µM, 
with one compound MMV019918 showing a submicromolar IC50. Of these seventeen 
compounds with gametocytocidal activity, seven were drug-like, while ten were probe-
like, as described by MMV (13). In addition, compounds with the greatest activity against 
gametocytes also showed nanomolar IC50s against the asexual stage parasite as reported 
with the compound information by MMV. The mean Z-factor calculated from the MMV 
malaria box screen was 0.57 (SEM = 0.04). 
Furthermore, we compared our MMV box hits with hits from four other assays 
using different reporters, including luciferase expressing parasites, alamar blue, or 
confocal fluorescence microscopy (10,14–16). We found that all of our eighteen hits 
overlapped between different assays (Figure 4.11, see supplementary data available with 




Figure 4.10 SYBR Green I assay results for the MMV box screened at 10 µM. Plot of 
percentage of gametocytocidal activity of 400 compounds compared to pyrvinium 
pamoate control. 
 
Figure 4.11 Overlap of recent screening assays for MMV Malaria Box. SYBR Green I 
assay (green) MMV box hits compared with hits from four other assays: Confocal 
fluorescence microscopy (red), Alamar blue early (dark blue) and late (light blue) and  
Luciferase (yellow) (10,14–16).  
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Table 4.2. Gametocidal compounds identified from MMV box with greater than 50% inhibition at 10 
µM and available corresponding data on asexual stage inhibition and structure from MMV. 
  Gametocyte Asexual 
MMV # 










MMV665941 122 1.8 (0.2) 96 255 0.62 
MMV000448 110 5.4 (1.4) 95 235 0.03, 1.04, 0.53 
MMV006172 104 2.6 (0.3) 97 142 0.057, 0.64 
MMV396797 100 8.8 (1.2) - 477 NA 
MMV665878 100 1.1 (0.6) 99 139 0.27 
MMV667491 99 4.5 (1.5) - 1230 NA 
MMV665830 98 3.3 (0.6) 98 1005 0.25 
MMV019780 98 3.8 (0.7) 98 697 0.84 
MMV019555 97 3.4 (0.5) 100 376 0.20 
MMV019881 96 5.5 (0.9) 98 646 1.04 
MMV019918 92 0.9 (0.3) 96 801 1.51 
MMV019690 90 >10 97 935 0.78 
MMV000445 86 10.00 98 1135 1.97 
MMV007591 85 5.4 (1.0) 85 ND 1.12 
MMV000848 85 3.6 (3.2) 97 660 1.08 
MMV020505 83 6.6 (1.1) 96 876 0.80 
MMV006303 82 2.1 (0.6) - 391 0.03 












DISCUSSION AND CONCLUSIONS 
To realize the goal of malaria elimination and eradication we need to add new and 
potent weapons active against multiple life stages of the parasite. Because most of the 
currently licensed antimalarials target only the asexual intra-erythrocytic stage, which is 
responsible for the pathology of disease, we urgently need to expand our antimalarial 
arsenal. Drugs that can effectively eliminate sexual gametocyte stages responsible for 
transmission to the mosquito vector will be required to move forward towards eventual 
goal a of malaria free world. In order to find new tools we have established a simple and 
robust HTS gametocytocidal assay based on DNA content of live gametocytes.  
Because gametocytes do not multiply we have utilized male gametocyte 
exflagellation and a background suppressor to subtract the DNA fluorescence signals 
from dead cells to achieve robust signal to noise ratio. As emphasized earlier in our 
description of assay optimization, we carefully took into consideration the contribution of 
exflagellation to fluorescent signal, and set cutoff values for our assay which allowed us 
to screen for compounds with gametocytocidal activity and not merely exflagellation 
inhibition. However, it should be noted that our assay does not allow us to distinguish 
between male and female gametocyte killing, but instead looks at overall intact 
gametocytes, and at lower inhibition levels, male gametocyte viability. Linearity of the 
assay was determined both as function of % gametocytes at 1% HCT (data not shown) as 
well as actual number of gametocytes per well, which showed a linear relationship with 
an R
2
 value of > 0.95. While many gametocytocidal assays have been developed, many 
of these assays have features that make them difficult to adapt to high-throughput 
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screening such as multiple incubations steps or requirement for high gametocytemia, or 
require transgenic parasites, making it impossible to use field isolates without further 
genetic manipulation. Our assay is simple enough to be used in any laboratory with 
access to malaria culture and a fluorescence plate reader, while also maintaining the 
sensitivity and robustness required for a high-throughput screening assay. We utilized our 
assay to screen an FDA-approved drug library of 1500 compounds as well as the MMVs 
Malaria box of 400 compounds to identify new pharmacophores with gametocytocidal 
activity. 
The FDA approved drug library was tested at a concentration of 20 µM in 
duplicate which led to the identification of several classes of compounds with 
gametocytocidal activity. Most of the hits from FDA approved library were antiseptic, 
anthelminthic, and antineoplastic as well as some antimicrobials and an antidepressant 
drug. Clotrimazole, an antifungal, was identified as having 70% inhibition against 
gametocytes with an asexual IC50 of 1.3 µM, and was recently reported as a hit in another 
gametocytocidal screen (11).  
Pyrithione zinc is an antiseptic which showed activity in our assay with high 
efficacy against both sexual and asexual stages of the parasite and was also recently 
reported in the screening of a different library for gametocytocidal drugs (10). As 
expected our screen identified primaquine as a gametocytocidal compound, albeit at a 
higher than reported IC50 due to lack of metabolism to the highly effective phenolic 
metabolites of primaquine required for inhibition (17). The antineoplastic compounds, 
anastrozole, ifosfamide, and melphalan, demonstrated greater than 50% inhibition at 
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0.55 to 4 µM concentrations against gametocytes (Table 4.1). The data available for 
melphalan showed 20% inhibition of 3D7 at 10 µM and an IC50 of 20 µM. compared to 
an IC50 of 4 µM against P. falciparum gametocytes, suggesting that melphalan shows 
slightly less efficacy against asexual compared to sexual parasites. Of the 
anthelminthics, homidium bromide and pyrvinium pamoate demonstrated the highest 
efficacy against gametocytes, with 100% inhibition at 20 µM and IC50 values of 0.38 µM 
and 4 µM respectively, while also effectively inhibiting 70-100% of asexual stages at 10 
µM. Homidium bromide (ethidium bromide) is a well-known fluorescent DNA-
intercalating agent used in molecular biology and is known to be mutagenic, whereas 
pyrvinium pamoate is an FDA-approved anthelminthic compound used to treat pinworm, 
with activity against Cryptosporidium parvum, and thought to inhibit mitochondrial 
NADH-fumarate reductase (18–20). A recent study demonstrates nanomolar inhibition 
of pyrvinium pamoate against both 3D7 and K1 strains of P. falciparum asexual blood 
stage parasites with further derivatization studies suggesting the quaternary amino group 
in the quinoline ring is not required for antimalarial activity (21). Removing the positive 
charge from the molecule may allow better bioavailability of pyrvinium pamoate, and 
further investigation of gametocytocidal activity of uncharged derivatives is warranted.  
The other anthelminthics antimony potassium tartrate and dithiazanine iodide 
inhibited 80-90% of gametocytes at 20 µM and 90% of asexual stages at 10 µM. 
Dithiazanine iodide has some structural similarity to pyrvinium pamoate and also 
possesses a quaternary amine, which raises the question of whether a positive charge is 
critical for gametocytocidal activity. Interestingly, maprotiline, a tetracyclic 
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antidepressant similar to the tricyclic antidepressant methylene blue, demonstrated 
nanomolar inhibition of both gametocyte and asexual stages of P. falciparum, but 
showed greater efficacy against gametocytes. Methylene blue has reported efficacy 
against gametocytes in vitro and also showed in vivo efficacy against asexual parasites in 
multiple murine models of cerebral malaria, protecting 75% of mice at 10 mg/kg for five 
days post-infection (9,22–25). Our observations suggest further exploration of tetracyclic 
and tricyclic antidepressants for gametocytocidal activity.  
The antiseptic QACs were the most highly represented class of drugs in the hits 
from the FDA approved library screen, comprising eight out of twenty five hits. Most of 
the QACs identified in the screen, including cetalkoniumchloride, thonzonium bromide, 
and benzododecinium chloride, demonstrated almost 100% efficacy against gametocytes 
at 20 µM with low micromolar IC50s. QACs with antimicrobial activities were identified 
as early as the 1930s and are among the most useful antiseptics and disinfectants, and 
have been used for a variety of clinical purposes (26–30). These drugs can function as 
choline analogs and can inhibit de novo phosphatidylcholine biosynthetic pathway of the 
malaria parasite. QACs have previously been shown to inhibit asexual blood stages of P. 
falciparum at nanomolar concentrations, with greater activity seen with long alkyl side 
chains and increased steric hindrance around the nitrogen atom (31).  
Phosphatidylcholine, the predominant phospholipid produced by malaria 
parasites, plays essential structural and regulatory roles in parasite development and 
differentiation. Previous studies in P. falciparum have demonstrated the presence of two 
pathways for phosphatidylcholine biosynthesis, the cytidine diphosphate (CDP)-choline 
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pathway, which uses host choline and fatty acids as precursors, and the serine 
decarboxylase-phosphoethanolamine methyltransferase (SDPM) pathway, which uses 
host serine and fatty acids as precursors. Recent studies have shown that QACs inhibit 
multiple steps during phospholipid biosynthesis by targeting the choline carrier as well 
as enzymes of both the SDPM and the CDP–choline pathways (32,33). A recently 
published study demonstrates the essentiality of phosphotidylcholine synthesis for 
gametocyte development and transmission by knocking out or inhibiting the key enzyme 
in this pathway, phosphoethanolamine methyl transferase, which results in inhibition of 
gametocyte maturation and also blocks transmission (34). These observations strongly 
suggest a critical role for phospholipid metabolism during P. falciparum gametocyte 
stages and may present a unique target for multistage drug development. While 
challenges with poor absorption have been associated with this group of compounds due 
to a net positive charge, improvements using a prodrug approach have shown promise 
(31). A choline analog, Albitiazolium is already in clinical trial for complicated malaria 
using intra-peritoneal or intra-muscular route and efforts are underway to develop this 
compound for uncomplicated malaria, using an oral route (35). Thus we have not only 
identified a class of compounds with efficacy against both asexual and sexual stages but 
also a shared target which can be utilized to identify new pharmacophores active against 
both asexual and transmission stages of malaria parasites. 
In regards to cytotoxicity, route of drug administration and approved drug levels 
for the aforementioned hits, many of the compounds identified, including the QACs, are 
topical agents which are not approved for oral drug use. Anthelminthic compounds such 
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as pyrvinium pamoate and dithiazanine iodide are approved for oral administration, but 
are not absorbed to appreciable levels by the GI tract and thus are not available in the 
bloodstream. Antineoplastics such as melphalan can be given orally or intravenously, but 
perhaps not surprisingly have side effects including bone marrow suppression. 
Maprotiline, however, is an orally administered antidepressant with an LD50 of 90 mg/kg 
in women, according to DrugBank, and approved prescription of 75-150 mg daily, 
depending on the severity of depression(36,37). While many of these FDA approved 
drug hits may not be immediately available or appropriate for oral antimalarial 
chemotherapy, they do provide novel pharmacophores with gametocytocidal and/or 
asexual activity, and are suggestive of new drug targets.  
The successful screening and hit identification from FDA approved library led us 
to request the 400 compound malaria box of asexual blood stage active compounds from 
MMV. We screened the malaria box at 10 µM in duplicate, this time using 10 µM 
pyrvinium pamoate as a positive control (100% inhibition) and 0.1% DMSO as a vehicle 
control. As compared to the FDA approved library, we observed a higher number of 
compounds showing inhibition, which was expected as all these compounds have potent 
activity against the asexual blood stages. In all we obtained 18 hits, 17 of which showed a 
dose dependent response against mature gametocytes. The majority of the active 
compounds were very similar in structure, with seven containing acridine-like structures, 
three fused benzene rings with a central nitrogen, with varied side chains, one similar to 
that of chloroquine (MMV665830). Quinacrine and pyronaridine are both acridine-based 
compounds which have been proven clinically effective against malaria (38). Multiple 
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mechanisms of action have been proposed and proven for the various acridine-like 
compounds, including inhibition of hemozoin crystallization (39–41), mitochondrial bc1
 
complex (42,43), DNA Topoisomerase II (44,45), and also DNA intercalation, though the 
latter has not been correlated with increased antimalarial activity (38). Of note, 
pyronaridine and other Topo II inhibitors have been shown to inhibit both asexual and 
sexual stages of P. falciparum in a previous study, suggesting that Topoisomerase II 
inhibitors may be utilized to target multiple parasite stages including gametocytes (44).  
Towards the end of our library screening and data analysis, four manuscripts 
describing results of gametocytocidal screening of the MMV malaria box were published. 
Comparing our MMV hits with these four recent assays, we found that all of our hits 
overlapped with either the early or late alamar blue or confocal microscopy assays or 
both, but no hits were shared with the early gametocyte Luciferase based assay (Figure 
4.11, see supplementary tables in published manuscript for list of compounds) 
(10,14,15,46). MMV019918 was a top hit identified by three assays, including our SYBR 
Green I, the alamar blue and confocal microscopy assays, with nanomolar inhibition 
against late and early stages (IC50s ranging from 320-890 nM depending on the assay). 
Four other compounds including MMV000448, MMV006172, MMV007591 and 
MMV019555 were also identified by all three assays.  
We have successfully produced and validated a gametocytocidal drug screening 
assay that will be easily adaptable to high-throughput format using SYBR Green I and a 
background suppressor to read DNA content after exposure to drug. Using this assay we 
screened an FDA-approved drug library and the MMV Malaria box, totaling 
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approximately 2000 compounds and identified two highly represented classes of 
compounds, QACs and acridine-like compounds, which were effective against both 
sexual and asexual stages of the parasite. Further target validation is required to ascertain 
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Aim 1: Determine function and virulence of Plasmodium hemolysin III 
in order to discover a potential role in severe malaria anemia 
 Characterized stage specific P. falciparum HlyIII protein expression 
using hemolysin-specific polyclonal antiserum and Western blotting 
 Genetically modified the murine malaria parasite, knocking out the 
P. berghei HlyIII homolog and characterized virulence and growth 
rate in mice, as well as essentiality in all stages of the life cycle, 
comparing the PbHlyIII KO parasite to the wild type P. berghei 
ANKA strain 
Aim 2: Discover novel antimalarial compounds to improve current drug  
regimens in light of current drug resistance and treatment failures 
 Synthesized and tested hydroxyethylapoquinine (HEAQ) and 
derivatives for ability to inhibit heme crystallization 
 Demonstrated comparable antimalarial efficacy in vitro and in vivo 
(mouse model) and decreased hERG channel inhibition of HEAQ 
and derivatives when compared to the parent drugs quinine and 
quinidine 
 Developed a high throughput assay to screen for gametocytocidal 
drugs using a novel combination of SYBR Green I and CyQUANT 
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background suppressor for efficient and robust detection of 
gametocyte killing 
 Identified new classes of transmission blocking drugs including 
quaternary ammonium compounds and acridine-like compounds 
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 Developed a synthetic approach and successfully synthesized and 
purified Seleno-Dapsone (confirmed by NMR and elemental 
analysis) 
Aim2: Determine whether Seleno-Dapsone is an active antimicrobial 
agent with comparable efficacy to Dapsone 
 Assessed antimicrobial activity of Seleno-Dapsone against Bacillus 
subtilis and Staphylococcus aureus, showing dose dependent 
inhibition of both strains 
 
PUBLICATIONS 
1. Moonah S, Sanders NG, Persichetti J, Sullivan DJ Jr. (2014) Erythrocyte lysis and 
Xenopus laevis oocyte rupture by recombinant Plasmodium falciparum hemolysin III. 
Eukaryot Cell. pii: EC.00088-14.  
2. Sanders, NG, Sullivan, DJ, Mlambo, G, Dimopoulos, G, Tripathi, A. (2014) 
Gametocytocidal screen identifies novel chemical classes with Plasmodium falciparum 
transmission blocking activity. PlosONE 9(8) e105817. doi: 
10.1371/journal.pone.0105817. eCollection 2014.  
3. Kumar K, Schniper S, González-Sarrías A, Holder AA, Sanders N, Sullivan D, Jarrett 
WL, Davis K, Bai F, Seeram NP, Kumar V. (2014)  Highly potent anti-proliferative 
effects of a gallium(III) complex with 7-chloroquinoline thiosemicarbazone as a ligand: 
synthesis, cytotoxic and antimalarial evaluation. Eur J Med Chem. 86:81-6. doi: 
10.1016/j.ejmech.2014.08.054. Epub 2014 Aug 16. 
4. Hain AU, Bartee D, Sanders NG, Miller AS, Sullivan DJ, Levitskaya J, Meyers CF, 
Bosch J. (2014) Identification of an Atg8-Atg3 protein-protein interaction inhibitor from 
the medicines for malaria venture malaria box active in blood and liver stage Plasmodium 
falciparum parasites. J Med Chem. 12;57(11):4521-31 
5. Sanders, NG, Meyers, D., Sullivan, DJ. (2013) Antimalarial efficacy of 
hydroxyethylapoquinine (SN-119) and derivatives. published online ahead of print on 18 







1. Robinett, NG, Moonah, S, Sullivan, DJ. What is a hemolytic protein like you doing in a red 
blood cell parasite like this? or Determining the functional role of Plasmodium hemolysin III 
in the parasite. Emergent Biosolutions, Gaithersburg, MD. April 24, 2015 
2. Robinett, NG, Moonah, S, Sullivan, DJ. What is a hemolytic protein like you doing in a red 
blood cell parasite like this? Gordon Research Conference: Tropical Infectious Diseases, 




1. Robinett, NG, Moonah, S, Sullivan, DJ. What is a hemolytic protein like you doing in a red 
blood cell parasite like this? Gordon Research Conference: Tropical Infectious Diseases, 
Galveston, TX. March 2015 
2. Sanders, NG, Moonah, S, Sullivan, DJ. Characterization of P. falciparum hemolysin III in 
asexual blood stages and expression in Xenopus oocytes. 25th Annual Molecular Parasitology 
Meeting at Woods Hole, MA. September 2014 
3. Sanders, N., Meyers, D., Sullivan, D.J. Antimalarial efficacy of hydroxyethylapoquinine 
(SN-119) and derivatives. 24th Annual Molecular Parasitology Meeting at Woods Hole, MA. 
September 2013 
4. Sanders, N., Meyers, D., Sullivan, D.J. Antimalarial efficacy of hydroxyethylapoquinine 
(SN-119) and derivatives. (2012) ASTMH 61st Annual Meeting, Atlanta, GA. November 
2012 
5. Sanders, N.G. Sullivan, D.J., Tripathi, A. A high throughput drug screening assay using 
SYBR Green I identifies novel classes of gametocytocidal compounds. 23rd Annual 
Molecular Parasitology Meeting at Woods Hole, MA. September 2012 
6. Sanders, N., Guziec, L. Synthesis of Seleno-Dapsone. National ACS Meeting, Washington, 




August 2015  Guest Lecturer, Johns Hopkins School of Public Health 
Course: Introduction to the Biomedical Sciences 
Lecture: General Immunology 
Mentor: Dr. Gundula Bosch, Instructor, Johns Hopkins 
Skills to gain: experience teaching a graduate level course 
July 2015  Guest Lecturer, Johns Hopkins University 
Course: Introduction to Biological Molecules 
   Lecture: Protein Architecture and Biological Function (2 sections) 
   Lecture: Translation of RNA (2 sections) 
   Labs: DNA Isolation and Restriction Mapping of DNA 
Mentor: Dr. Richard Shingles, Professor of Biology, Johns Hopkins 
Skills gained: experience teaching an undergraduate course 
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June – Aug 2013 Mentor, Undergraduate Research, Johns Hopkins School of Public 
Health 
 Student: Promise Okeke (Augsburg College, Class of 2015) 
 Project: “Irreversible heme crystal inhibition by amodiaquine and 
pyronaridine: a means to circumvent malaria drug resistance” 
 Role: Trained in in vitro heme crystallization assay and drug dilutions, 
and data analysis, buffer composition 
 
June –Aug 2012 Mentor, Undergraduate Research, Johns Hopkins School of Public 
Health 
 Student: Laura Anzaldi (Johns Hopkins Medical Student Class of 2018) 
Project: “Malaria heme crystallization inhibition: analysis of FDA drugs, 
parasite inhibition and drug resistance” 
 Role: Trained in in vitro biochemical assay techniques, drug dilutions, 
and data analysis 
 
June – Aug 2011 Mentor, Undergraduate Research, Johns Hopkins School of Public 
Health 
 Student: Melissa Santos (University of Maryland Class of 2014) 
Project: “Heme crystallization inhibition by novel quinine derivatives” 








PROFESSIONAL TEACHING DEVELOPMENT  
(Preparing Future Faculty Teaching Academy) 
 
Jan-Mar 2015  Student, Johns Hopkins School of Public Health 
   Course: Teaching at the University Level (Instructor: Dr. Anne Riley) 
Skills gained:  
 Developed a deeper understanding of how students learn 
 Designed a course syllabus for an upper level college biology class 
 Developed active learning activities for my course 
 Gave an introductory lecture for my course and received feedback 
 Developed a personal teaching philosophy 
 
Sep- Dec 2012  Student, Johns Hopkins School of Education 
Course: Introduction to Effective Instruction (Instructor: Dr. David 
Andrews) 
Skills gained:  
 Studied basic teaching pedagogy including: science of learning, 
formative and summative assessment techniques, and 
approaches/challenges to small and large group instruction 
 Developed a short teaching philosophy and gave a mini-lecture with 




 June 2011-May 2014 Student Facilitator, Public Health Christian Fellowship Student Group 
   Johns Hopkins Bloomberg School of Public Health 
 Engaged public health students in discussions of living out faith in 
the context of public health challenges and crises  
 Organized and led weekly meetings to promote fellowship and 
growth during graduate school 
 Invited faculty and outside speakers to discuss the role of faith-based 
organizations in public health and to share their perspectives on faith 
in a public health context  
 
Aug 2012-Aug 2013 President, Molecular Microbiology and Immunology Student Group 
   Johns Hopkins Bloomberg School of Public Health 
 Created a space for students to express their ideas or concerns and 
develop better communication between students and faculty 
 Organized social events to promote fellowship and collaboration 
within the department, including organizing our first annual outdoor 
picnic. 







RESEARCH GRANTS AND AWARDS 
 
Aug 2012-May 2015 Emergent Biosolutions Fellowship 
Proposal: Characterizing the role of a putative P. falciparum hemolysin 
III in malarial anemia and as a potential antimalarial drug target 
Award: $15,000 (Covered lab supplies and travel to scientific meetings) 
 
Aug 2013-May 2014 Frederick Bang Award 
Proposal: Role of P. falciparum hemolysin III in severe malaria anemia 
Award: $3000 (Covered lab supplies and travel to scientific meetings) 
 
May 2011-May 2012 Eleanor A. Bliss Honorary Fellowship 
Departmental Award, H. Feinstone Department of Molecular 
Microbiology and Immunology 




May 2010-Present Phi Beta Kappa, Alpha Chi Scholar     
Aug 2010-Present American Society of Microbiology, Student Affiliate 
 
